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ABSTRACT 
Colin Padraic O’Banion: Cellular Optogenetics for Spatiotemporal Control of Kinase 
Signaling and Biological Trojan Horses for Light-mediated Drug Release 
(Under the direction of David Lawrence) 
 Light provides an instantaneous, orthogonal, and spatially targeted tool to control 
cellular biochemistry and perform photochemistry.  In the first three chapters of my thesis, I 
will discuss light as a tool for controlling intracellular communication.  Intracellular signaling 
via kinases is highly controlled in space and time.  While many tools exist that allow us to 
modulate signaling events on a global scale or observe signaling events with high spatial 
and temporal resolution, there are relatively few tools that are amenable to studying 
subcellular compartmentalized signaling.  To this end, I have developed two optogenetic 
proteins for investigating the localized functions of 1) protein kinase A and 2) its second 
messenger cAMP.  The optogenetic protein kinase A takes advantage of the Cry2-Cib 
photodimerizing pair.  In short, a protein kinase A catalytic subunit with low constitutive 
activity was fused to Cry2 such that, upon stimulation with light, it translocates to whatever 
subcellular region Cib is localized to and activity is restored.  In order to investigate localized 
cAMP signaling, a photoactivated adenylate cyclase was engineered to be expressed at 
specific subcellular locations.  Upon activation with light, large increases in cellular cAMP 
levels are observed resulting in down-stream signaling events.  I am still tweaking the 
photoactivated adenylate cyclase to control local cAMP signaling. 
 The second half of my thesis discusses efforts to develop cell mediated delivery of 
phototherapeutics.  Chapter 5 discusses the use of erythrocyte membranes as protective 
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pools and launching pads for peptide therapeutics.  Chapter 6 focuses on efforts to develop 
a treatment strategy for glioblastoma multiforme by loading tumor-homing neural stem cells 
with cobalamin-drug conjugates.
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CHAPTER 1: CAMP, PKA, AND OPTOGENETICS: ILLUMINATING SPATIAL AND 
TEMPORAL INTRACELLULAR SIGNALING 
Introduction 
Plants and animals are highly complex, multicellular organisms that require 
extremely precise regulation of both macro and micro-scale processes in order to survive. 
Multicellular organisms contain systems of different organs, which are composed of highly-
specialized tissues. These tissues are composed of many different types of cells, and each 
group of cells is responsible for carrying out a specific role. 
Cells communicate to each other by secreting molecules that diffuse away and bind 
to receptors on other cells. There are many types of molecules and many types of receptors. 
Each molecule has a receptor, or group of receptors, that it binds to with a high degree of 
specificity. These various molecule–receptor pairs allow information to pass from the outside 
of a cell to the inside of a cell, and vice versa, thus allowing the cell to respond to external 
stimuli. Cells also must communicate within their interior as many different biochemical 
processes are going on inside a cell at any given time. Cells contain specialized 
compartments, organelles, which function to keep the cell alive. Organelles must also 
regulate each other in order to maintain cellular equilibrium. Therefore, cells must be able to 
respond to internal stimuli, and internal cellular processes must be highly regulated in both 
space and time. In order to accomplish such a precise level of regulation, cells organize 
their internal signaling machinery into nodes that contain many elements necessary to carry 
out a given process (e.g., DNA replication, energy production, etc.). These elements can 
respond to both global and local changes in the cellular environment.   
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The cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway is involved in 
many cellular process and is highly compartmentalized and regulated in both space and 
time. cAMP (a small molecule) is generated by adenylate cyclases that respond to external 
(global) or internal (local) stimuli and, in turn, activate PKA to phosphorylate specific 
substrates and carry out cellular processes ranging from cell survival to energy production. 
PKA and associated signaling proteins are sequestered to specific subcellular 
compartments by A-kinase anchoring proteins (AKAPs) to generate distinct signaling 
microenvironments. These signaling nodes provide spatial specificity to PKA so that this 
otherwise ubiquitous signaling pathway is only activated in the right location and at the right 
time. 
There are many tools available today to both control and monitor cAMP/PKA activity 
in living cells.  Pharmacological activators and inhibitors, genetic modification of pathway 
members, and Förster resonance energy transfer (FRET) based live cell imaging tools are 
widely used to study cAMP/PKA signaling dynamics and its effect on cellular, systems, and 
organismal physiology.  While FRET sensors allow us to visualize cAMP/PKA activity with 
high spatial and temporal resolution, the vast majority of studies utilize global 
pharmacological activation or inhibition of the signaling pathway, and the studies that do 
address specific spatial regulation of PKA by AKAPs or phosphodiesterases (PDEs, cAMP 
hydrolyzing enzymes) use genetic approaches with limited temporal resolution.  Biochemical 
optogenetics is an emerging field in which plant and single celled organism photoreceptors 
that are natural or engineered regulators of fused effectors such as kinases, GTPases, and 
cytoskeletal remodeling proteins. These tools are used to probe cellular and organismal 
physiology using light as a switch.  Light is an ideal switch for spatial and temporal control of 
cellular processes.  Light can be readily turned on or off for instantaneous temporal control 
and directed to specific, subcellular locations with nanometer resolution.  Therefore, the goal 
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of this section of my dissertation is to outline two distinct projects aimed at developing 
optogenetic tools to control cAMP/PKA at multiple levels of the signaling pathway.   
First, I will describe the development of a bacterial photoactivated adenylate cyclase 
(PAC) into a tool for spatial and temporal control of intracellular cAMP in mammalian cells.  
This tool will furnish control of the initial second messenger in the pathway, and then I will 
describe an optogenetic PKA (OPKA) developed to directly control kinase activity at specific 
subcellular sites.  These tools, taken together, represent a toolbox for dissecting specific 
subcellular pools of cAMP and PKA and may be extended to investigate the roles of these 
specific signaling molecules in cellular systems. 
 
Section 1.1: cAMP the first second messenger 
cAMP was initially discovered by Sutherland and colleagues in 1957 as a soluble, 
heat resistant active factor that induced hyperglycemia, via glycogenolysis, in liver slices 
after treatment with epinephrine or glucagon[1] and the structure of cAMP was concurrently 
discovered by Cook and colleagues.[2]  cAMP is the prototypical “second messenger”, an 
intracellular signaling molecule that is classically generated in response to extracellular 
stimuli.  Second messengers act to integrate and amplify the extracellular signal such that 
cells can generate an appropriate physiological response to the changing environment.  
Sutherland’s work with cAMP paved the way to define a wide array of second messaging 
signaling pathways and culminated with him being awarded the Nobel Prize for Physiology 
and Medicine in 1971.[3]  cAMP signaling was quickly recognized to be ubiquitous in 
prokaryotic and eukaryotic cells[4] and, as of August 2016 returned over 100,000 papers on 
PubMed.   
cAMP is highly regulated.  It is formed via a cyclization reaction of adenosine 
triphosphate (ATP) catalyzed by adenylate cyclases (ACs)[5] yielding cAMP and 
pyrophosphate and can be rapidly hydrolyzed by PDEs (Figure 1.1).[6] ACs were initially 
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thought to only exist as membrane bound, G protein coupled receptor (GPCR) coupled 
enzymes[4] (transmembrane adenylate cyclases or tmACs).  However, in 1975, AC activity 
was identified in the soluble fraction of rat testis[7] and was termed “soluble adenylate 
cyclase” (sAC).  ACs are encoded by ten different genes with the symbol ADCY1-10.  
ADCY1 – 9 encode tmACs while ADCY10 encodes the sAC.  AC isoforms are differentially 
expressed in tissues with multiple splice variants.  The sAC ADCY10 is, in fact, an 
enormous gene comprised of 33 exons under the control of multiple promoters.[8]   While 
tmACs are localized to the plasma membrane (PM) or sarcoplasmic reticulum[4], in 
myocytes, sACs are localized to a variety of subcellular locations including the nucleus and 
mitochondria.[9]  tmACs are activated by Gs proteins[10] and the pharmacological activator 
forskolin[11] [12], and they are inactivated by Gi proteins.[10]  Interestingly, confounding 
evidence has been reported in which tmACs are internalized upon receptor desensitization 
and endocytosis but can either be silenced or have sustained signaling in response to the 
action of β-arrestin.[13]  sACs, on the other hand, are GPCR and forskolin insensitive and are 
activated by Ca2+, bicarbonate, and local redox status.[8]  Thus tmACs act to integrate and 
amplify extracellular signals for global regulation of intracellular cAMP signals while sACs 
function as local sensors and regulators of cellular microdomains.   
cAMP has four primary effectors in mammalian cells: the cAMP dependent protein 
kinase (PKA), cyclic nucleotide gated ion channels (CNGs and HCNs), the exchange 
proteins directly activated by cAMP (EPACs)[14] and recently, the Popeye domain containing 
proteins.[15]  CNGs are cation channels that bind cyclic nucleotides to increase their open 
probability and HCNs function in a similar manner but are primarily voltage dependent and 
Figure 1.1 cAMP is generated via reaction of ATP with adenylate cyclase and is rapidly 
hydrolyzed by intracellular phosphodiesterases. 
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only open at hyperpolarized membrane potentials.[16]  CNGs have a higher affinity for cyclic 
guanosine monophosphate (cGMP) than cAMP and HCNs preferentially bind cAMP over 
cGMP.[17]  cAMP binding results in an influx of cations that acts to depolarize the plasma 
membrane.  CNGs primarily function to regulate sensory signal transduction.  They are 
expressed in olfactory neurons and retinal epithelia.[16]  HCNs are found in neurons, retinal 
epithelial cells, and cardiac pacemaker cells[16] and are important in cardiac pacemaking and 
learning and memory.[16] EPACs are two distinct genes, EPAC1 and EPAC2, and are cAMP 
regulated guanine exchange factors (GEF).[18]  EPAC1 is ubiquitously expressed while 
EPAC2 expression is tissue dependent.  The cAMP dependent GEF activity functions to 
activate the small GTPases Rap1 and Rap2.  EPACs are involved in a myriad of cellular 
functions including adhesion[19], secretion[20], differentiation[21], proliferation, apoptosis and 
gene expression.[22] Popeye domain containing proteins have only recently been described 
as cAMP binding proteins and are an active area of study involved in cell-cell contact 
formation, vesicular transport, muscle physiology, and are implicated in cardiac arrhythmia 
and muscular dystrophy.[15]  While each of the aforementioned cAMP effectors are important 
in cellular physiology, the primary focus of this work is on PKA.  For an in depth report on 
cyclic nucleotide gated ion channels, EPACs, and Popeye domain containing proteins 
please see reviews by Biel et al.[16], Cheng et al.[22], and Schindler et al.[15] respectively. 
Section 1.2: The cAMP dependent protein kinase: a ubiquitous signaling pathway as a 
model for compartmentalized signaling 
PKA was discovered in 1968 by Krebs and colleagues[23] as a cAMP dependent 
kinase in rabbit skeletal muscle that activates phosphorylase kinase.  Since its discovery, a 
vast amount of research aimed at characterizing PKA structure and function has emerged 
and it is now considered to be the “prototypical kinase.”[24]  It is important to note that the 
discovery of PKA by Krebs and Fischer lead to their winning the Nobel Prize in Physiology 
or Medicine in 1992.[25]  PKA and its various orthologues are present in nearly all eukaryotic 
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cells from single celled protists to humans.[26]  PKA is implicated in a myriad of diseases 
including cardiac disease, cancer, neurodegenerative disorders, and metabolic disease.[27]  
While much is known about PKA signaling in terms of disease and enzymology, this review 
will focus on PKA signaling as a compartmentalized process. 
PKA is a serine/threonine kinase of the AGC kinase family and exists in its resting 
state as an inactive tetrameric holoenzyme composed of two regulatory subunits (R) and 
two catalytic subunits (C), which, upon binding of cAMP to the R subunits results in release 
of the C subunit such that it catalyzes the transfer of the γ-phosphate of ATP to a protein 
substrate (Figure 1.2).  There are seven total PKA genes (RIα, RIβ, RIIα, RIIβ, Cα, Cβ, and 
Cγ) in humans that undergo alternative splicing yielding a number of possible isozymes 
highly dependent on tissue specific expression patterns.[28]  PKA isoforms are primarily 
described by the R subunit composition due to the fact that C subunits are largely 
interchangeable and were thought to be mostly redundant.  However, recent structural 
studies are revealing that the various R2C2 holoenzyme isoforms do not share symmetry and 
thus are not structurally redundant illustrating yet another level of allosteric regulation of the 
PKA family of enzymes (see below).[29] 
Figure 1.2: cAMP binds to the R subunits on the PKA holoenzyme releasing C subunits to 
phosphorylate various substrates. 
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  Initially, RI and RII isozymes were defined by the elution conditions for purification.  
RII was found to be primarily associated with the particulate fraction in heart 
homogenates[30] and RI was primarily soluble.[31]  Differences in affinity for ATP and cAMP 
have also been reported with RI type holozymes containing a high affinity and essential Mg-
ATP binding site[32] and RI being more sensitive to cAMP than RII.[33]  The R subunits 
dimerize through an N-terminal helix bundle and bind the C subunit via inhibitor sites found 
in a flexible linker that separates the dimerization domain from the cAMP binding domains at 
the C-terminus of the R subunits.[29]  C subunit binding sites on R subunits resemble peptide 
substrates and bind the active site of the C subunit thus sequestering and inactivating the C 
subunit.  Inhibitory sites differ between RI and RII isoforms in that the RI subunit contains a 
pseudo substrate inhibitory C subunit binding site where the phospho-site is Ala or Gly and 
the RII subunit contains a Ser in that position which can be phosphorylated by the C 
subunit.[29]  The C subunit is cotranslationally phosphorylated at Ser 338 and 
posttranslationally at Thr 197.  Both of these phosphorylation events are required for C 
subunit activity and stability.[34]  In addition, the C subunit contains a myristylation site that 
appears to function as a positive allosteric regulator of catalytic activity.[35] 
PKA is ubiquitously expressed in all cells and is necessary for organismal survival.[28]  
Early studies of PKA in animal hearts revealed differential distribution of RI and RII isozymes 
(see above)[31] and work from the Mayer lab in 1979 showed that elevation of cAMP in 
Figure 1.3: Overall PKA architecture.  Top is C subunit and bottom is R subunit. 
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perfused hearts by either the β-adrenergic agonist isoproterenol or prostaglandin E1 resulted 
in differential phosphorylation of PKA substrates.[36]  Isoproterenol and prostaglandin E1 both 
act via Gs coupled GPCRs but bind to different receptors. These studies brought forth the 
concept of PKA compartmentalized signaling. The discovery that a portion of intracellular RII 
associated with the microtubule associated protein 2 (MAP2) in 1981[37] and subsequent 
characterization of the MAP2-RII complex in 1982[38] opened an entirely new field of 
compartmentalized PKA signaling by subcellular localization through AKAPs.   
There have been over 50 AKAPs identified in eukaryotes[39] and they represent a 
diverse set of scaffolding proteins that bind PKA.  AKAPs interact with the R subunit’s 
dimerization/docking domain[40] via a 14 – 18 residue binding domain to sequester pools of 
PKA to subcellular compartments in close proximity to specific pools of substrates.[41]  While 
AKAPs primarily bind RII isoforms of PKA, there are a number of bispecific AKAPs that bind 
RI and RII.[40]  Other signaling and regulatory proteins associate with AKAPs such as ACs[42], 
PDEs[43], protein phosphatases (PPs)[44], GTPases[45], kinases, receptors[44b], ion 
channels[46], the cytoskeleton[38, 47], and even RNA(Figure 1.4).[47]  By sequestering 
regulatory elements of cAMP/PKA signaling, AKAP complexes function as signaling nodes 
that can react to local or global changes in cAMP and regulate local changes in effector 
activity.[48]  AKAPs are thought to be the primary mechanism for compartmentation of 
cAMP/PKA signaling.  For example, Kapiloff’s group has demonstrated that mAKAP binds 
PKA, PDE4D3, Epac, Rap1, and several members of the mitogen activated kinase (MAPK) 
pathway.[48]  Upon constitutive elevation of cAMP levels, MAPK phosphorylates PDE4D3 
and decreases PDE activity such that cAMP levels increase. However higher levels of cAMP 
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result in Epac activation, Rap1 activation, and Rap1 mediated suppression of MAPK activity 
as well as PKA activation which then phosphorylates and activates PDE4D3.  The result is a 
decrease in local cAMP concentrations, which deactivates Epac1 and releases Rap1 
mediated repression of MAPK signaling resulting in cardiac hypertrophy.[48]   
Another example of compartmentalized signaling through AKAPs is exemplified by 
PKA anchoring of AKAP79/150 to the post-synaptic density (Figure 1.4).  Here, AC V/VI, 
PKA, protein kinase C (PKC), and protein phosphatase 2B (PP2B, calcineurin) are recruited 
to the AKAP which associates with β-adrenergic receptors (β-ARs) and the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), an inward rectifying 
glutamatergic cation channel.[41]  Localized cAMP dependent signaling events act to 
increase the amount of AMPARs in the post-synaptic density membrane and may play a 
Figure 1.4: AKAP79 associates with AMPARs and β-ARs at the post-synaptic density where it 
regulates local activity.  AKAP79 recruits AC’s, PKA, PP2B, PKC, and other molecules to close 
proximity with these receptors where it acts to regulate synaptic plasticity and receptor 
recycling. 
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role in long term potentiation (strengthening of synapses associated with learning and 
memory).[49]  Evidence for a role of AKAP79/150 and PKA regulation of proper synaptic 
function is supported by another study that showed that AKAP150 (mouse homolog) 
deletion resulted in strength and coordination deficits indicating an important role for the 
complex in the cerebellum.[50]   
The preceding examples are intended to highlight the complex, multidimensional 
regulation of PKA signaling that occurs at discrete signaling nodes inside of cells.  The vast 
majority of studies use biochemical and genetic approaches to monitor changes in cellular 
physiology.  However, these studies usually use global activators of cAMP signaling such as 
forskolin or the cell permeable cAMP analogs 8-bromo-cAMP (8BrcAMP) and 8-
chlorophenylthio-cAMP (CPTcAMP).  Genetic and biochemical experiments lack temporal 
resolution essentially capturing a snap-shot of cellular signaling in time and space.  
Therefore, it is important that the research community develop new tools to investigate PKA 
signaling with a high degree of spatial and temporal resolution.  The section that follows 
outlines the current state of the art in tools for spatial and temporal studies of cAMP/PKA 
signaling. 
Section 1.3: Tools for imaging and controlling cAMP/PKA signaling 
The advent of live cell imaging tools in the late 1990’s provided a new modality to 
monitor intracellular cAMP and PKA activity in real time.  The first cAMP/PKA live cell 
imaging reagent was developed by Tsien and Taylor and consisted of R and C subunits 
chemically modified with rhodamine and fluorescein, respectively.  The fluorescently labeled 
holoenzyme was microinjected into cells.  In low concentrations of cAMP, the fluorophores 
were in close proximity and underwent Förster resonance energy transfer (FRET) when 
fluorescein was excited resulting in emission from rhodamine.  Upon increasing intracellular 
cAMP, the C subunit dissociates from the R subunit and there is a loss of FRET, which 
results in a decrease in rhodamine emission and increase in fluorescein emission when 
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fluorescein is excited (Figure 1.5).[51]  This imaging tool served as a bi-functional sensor for 
cAMP and PKA dynamics.  First, as stated above, cAMP binding to the R subunit decreased 
intermolecular FRET signifying cAMP binding and C subunit dissociation.  Then, they 
observed the translocation of free C subunit from the cytoplasm to the nucleus indicating an 
important role for PKA signaling in the nucleus. 
While this tool revolutionized the field by providing the first live cell cAMP/PKA 
sensor and allowed investigators to begin investigating cAMP/PKA compartmentalization, it 
required microinjection, a technically challenging technique, and was therefore, replaced by 
genetically encoded imaging tools over the next ten years.   
 The first genetically encoded cAMP/PKA sensor was reported in 2000 by Tsien, 
Taylor, and Pozzan.[52] The sensor was, essentially, a genetically encoded version of Tsien 
and Taylor’s chemically modified sensor outlined above and was, undoubtedly, a product of 
the rapidly expanding field of molecular and synthetic biology.  The sensor is a green 
fluorescent protein (GFP) C subunit and a blue fluorescent protein (BFP) R subunit fusion. 
Figure 1.5: A schematic representation of the mechanism of action of the first cAMP/PKA 
live cell imaging tool.  Image reprinted with permissions from publisher. [50] 
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In the absence of cAMP, BFP undergoes intermolecular FRET with GFP. Upon increased 
intracellular cAMP, the C and R subunit dissociate and FRET is lost.[52]  The following year, 
Taylor, Tsien and Zhang published the first report of a PKA activity reporter, the A kinase 
activity reporter (AKAR) which consisted of a cyan fluorescent protein (CFP) and yellow 
fluorescent protein (YFP) tethered together by a PKA substrate peptide and the 
phosphoserine binding domain 14-3-3.  Upon phosphorylation of the PKA substrate peptide, 
14-3-3 binds phosphoserine resulting in a large conformational change in the protein, 
resulting in a spatially reoriented CFP and YFP and thereby generating a FRET emission.[53]  
Jin Zhang quickly followed up her report of the first generation of AKARs with a unimolecular 
cAMP sensor termed the “indicator of cAMP using Epac” (ICUE) which takes advantage of 
the cAMP induced conformational changes in Epac1 such that CFP and YFP fused to 
opposite ends of Epac1 undergoes a loss of FRET upon cAMP binding.[54]  Unimolecular 
FRET sensors provide multiple benefits relative to bi-molecular sensors including ease of 
expression and an increased dynamic range and have become the primary method used to 
quantify cellular and subcellular cAMP/PKA activity.[55]  CNGs have also been used as 
electrophysiological and Ca2+ dye coupled sensors of cAMP dynamics at membranes and 
have even been engineered into FRET sensors.[55]  Figure 1.6 shows schematic diagrams of 
AKAR, ICUE, and CNG cAMP and PKA sensors. 
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These tools, especially the ICUE and AKAR sensors, have been widely used to 
characterize cellular and subcellular cAMP/PKA activity and have been instrumental in 
decoding compartmentalized and temporal signaling.  However, they only allow for 
investigators to monitor activity evoked from some stimulus and do not allow for 
investigation of the activation of specific pools of PKA.   
There are many tools available to control cAMP/PKA signaling on a global scale 
including AC activators and inhibitors, GPCR agonists and antagonists, PKA inhibitors, PKA 
antagonists, peptide inhibitors of R anchoring, cell permeable cAMP analogues and more.  
However, these tools do not grant a high degree of spatial and temporal control of this 
ubiquitous signaling pathway.  There have been a number of tools generated to control 
cAMP/PKA signaling with greater spatial and temporal resolution.  Shokat and colleagues 
developed a chemical genetic method to investigate kinase specific activity.  In short, they 
Figure 1.6: Representative schematics of A) ICUE, B) CNG, and C) AKAR activity 
reporters.  Reprinted with permission from publisher. [54] 
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mutated PKA’s ATP binding site by replacing Met 120 with Ala such that it would be 
specifically inhibited by the compound 1-NM-PP1.  They generated transgenic animals 
silencing endogenous C subunit and expressing the mutant C subunit such that it would only 
be sensitive to 1-NM-PP1.  Using this approach, the group investigated the temporal effects 
of PKA inhibition in sperm motility.[56]  Zhang took a different chemical genetics approach to 
control cAMP generation in space and time by generating a truncated version of the sAC 
that is solely regulated by bicarbonate.  Therefore, adding bicarbonate to the media of cells 
expressing sAC resulted in intracellular increases in cAMP.  Through this work, Zhang and 
colleagues made a controversial argument for the presence of PKA holoenzyme in the 
nucleus based on activity changes versus diffusion rates across the nuclear membrane.[57]   
Interestingly, the majority of other tools that have been developed to control 
cAMP/PKA signaling in a spatial and temporal manner are all controlled by light.  Light 
presents itself as an ideal switch for spatial and temporal control of processes.  Light is 
instantaneous in its action and it can be delivered with extreme precision in the form of fiber 
optics and lasers.  In addition, exposing cells to light does not require media exchange, 
which removes potential interference in sensitive assays such as focal plane, pH, or 
mechanical force.  cAMP that has been inactivated by the photo-caging group 
dimethoxynitrobenzyl (DMNB) has been used in a number of studies to investigate the roles 
of cAMP in neuronal differentiation[58], ion channel electrophysiology[59], insulin secretion[60] 
and other cellular processes.  Our group used the nitrobenzyl group to generate a caged C 
subunit by covalently modifying a Cys residue near the active site with a maleimide linked to 
a fluorophore. In addition, the photolabile nitrobenzyl moiety had a fluorescent quencher and 
PKA inhibitory peptide in the leaving group position.  Therefore, upon photolysis of the 
nitrobenzyl group with UV light, the peptide inhibitor and fluorescent quencher were 
released from the complex and a functional, fluorescent C subunit remained which was able 
to induce PKA dependent cellular activity.[61]  While this approach provided a high degree of 
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innovation and temporal control of PKA activity, spatial control was limited and the caged 
enzyme needed to be microinjected into cells.  
In 2002, a PAC was reported to regulate light directed motion in the algae Euglena 
gracilis.[62]  This enzyme (euPAC) was quickly adapted as a tool and has been used to probe 
neuronal activity[63] and even to stimulate axonal regeneration in zebrafish.[64]  However, it is 
plagued by large size and significant dark activity and has, therefore, not been widely 
adopted by the cAMP community.   Another PAC from the bacterium Beggiatoa spp. (bPAC) 
was reported by two separate groups in 2011[65] and has since been used to investigate 
cAMP/PKA signaling in a number of systems and will be detailed in the following section.  
To my knowledge, there is only a single genetically encoded, light activated PKA modulator 
that has been reported as of this date.  The Hahn group constructed a light activated PKA 
inhibitor (PKI) peptide linked to a light, oxygen, voltage (LOV) domain to inhibit PKA activity 
in a spatial and temporal manner.[66] 
Section 1.4: Optogenetics: a route to spatial and temporal control of kinase signaling 
Optogenetics is a young, rapidly growing field that utilizes and develops light (opto) 
controlled proteins (genetics) for spatial and temporal control of cellular signaling.  The roots 
of the field can be traced back decades to the discovery of microbial opsins and rhodopsins, 
a group of retinal binding transmembrane proton and chloride pumps or cation channels that 
are activated by light to control ion flow across cellular membranes.[67]  An obvious use for 
light activated ion channels is as tools to specifically activate neurons, and, in 2005, the 
Deisseroth group overcame a number of technological challenges to develop engineered 
channelrhodopsins[68] that would become generally useful tools in neurobiology.  As of 
September 1st 2016, there are 447 results on PubMed for “optogenetics review” indicating 
the wide adoption of this technology in little more than ten years.   
It has long been accepted that light plays a ubiquitous role in regulating biological 
processes.  From photosynthesis to phototaxis and vision, light plays a function in many 
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bacteria and nearly all eukaryotes.  While the initial optogenetics work was exclusively 
dedicated to light regulated ion channels, a number of other light sensing proteins have 
become highly attractive targets for optogenetic development.  These natural 
photoreceptors fall into two broad categories of blue light and red / near infrared (NIR) light 
sensing domains that use flavin and bilirubin derived chromophores, respectively.[69]  The 
blue light receptors are comprised of the light, oxygen, voltage (LOV), blue light using flavin 
adenine dinucleotide (BLUF), and cryptochrome (Cry) photosensory domains while the red 
light receptors are all derived from the phytochrome photosensory (PHY) domain.  Figure 
1.7 outlines the chromophore structures and spectral regions in which these photosensors 
absorb and are activated by light.   
 
Figure 1.7: Shows the various chromophores for both fluorescent proteins and 
photosensory domains.  This figure has been modified and reprinted with the permission 
of the publisher. [69] 
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BLUF, Cry, and PHY domains all primarily function as light driven homo or 
heterodimerizing domains and the LOV domain undergoes a large conformational change 
upon excitation with light.[70]  The advent of genome scale sequencing and bioinformatics 
has revealed a rich collection of prokaryotic and eukaryotic photosensory domains fused to 
biological effectors including transcription factors, kinases, phosphodiesterases, and 
nucleotide cyclases.[70-71] In addition to natural photo-regulated proteins, light sensing 
domains have been used to engineer many different optogenetic tools for spatial and 
temporal control of cellular signaling such as GTPases[72], phosphodiesterases[73], nucleotide 
cyclases[65, 74], kinases[66], cytoskeletal proteins[75], GPCRs[76], nuclear translocation[77] and 
apoptosis.[78]  There are two primary modes of developing cellular optogenetic tools: 1) 
photo-induced dimerization for control of protein-protein interactions (PPIs) and 2) light-
driven enzyme activation.   
Photo-induced dimerization is the most widely used approach to engineering cellular 
optogenetic tools.  Indeed, photodimerization is a principle mechanism of action for many 
natural photoreceptors and the vast majority of enzymes that are activated by blue light 
require dimerization for activation.[73-74, 79]  For the remainder of this section, I will focus on 
the photodimerizing pair cryptochrome (Cry) – cryptochrome-interacting basic-helix-loop-
helix 1 (Cib) and the light activated adenylate cyclase bPAC. 
The Cry-Cib photodimerization was developed as a tool for rapid and reversible 
induction of protein interactions in living systems.[80]  Cryptochrome 2 (Cry2), from 
Arabidopsis thalania, contains an N-terminal photolyase homology region (PHR), which is a 
flavin and pterin binding domain that is responsible for light-responsive activity.[81]  Tucker 
and colleagues found that the PHR domain alone is necessary and sufficient for light 
induced interactions with Cib.[80]  Cib is a natural binding partner for Cry2.  However, wild 
type (WT) Cib is a nuclear protein[81] and was, therefore, truncated to remove its N-terminal 
nuclear localization sequence in order to make it amenable to other cellular localizations.[80] 
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mCherry-Cry2 (mC-Cry2) and GFP-Cib-CAAX (plasma membrane targeted) constructs were 
generated in order to visualize subcellular translocation in response to light.  With the 
addition of various effector domains, Cry2-Cib has been used for a variety of cellular 
applications including gene transcription[80], kinase activation[82], cytoskeletal 
reorganization[75a], and apoptosis.[78] 
Our group has taken advantage of the Cry2-Cib photodimerizing system to develop a 
generalizable method for engineering light activated proteins of interest (POIs).  The 
approach takes advantage of the Michealis-Menten equation:𝑣0 =  
𝑘𝑐𝑎𝑡[𝐸][𝑆]
𝐾𝑚+[𝑆]
.  The rate of 
catalysis is dependent on the intrinsic kcat of the enzyme and its Km for substrate as well as 
the concentrations of both the enzyme [E] and substrate [S].[83]  Therefore, an enzyme with 
reduced activity via impaired turnover or substrate binding could be restored to WT 
enzymatic activity by locally concentrating the protein near a substrate.  We essentially need 
to make an inefficient catalyst and increase its local concentration to restore apparent 
activity.  We have developed a generalized approach to developing both catalytic and non-
catalytic optogenetic proteins.  First, we mutate the POI so that it is constitutively active and 
then we add additional mutations to reduce the inherent activity of the POI.  Then, we make 
a fusion of the POI to Cry2PHR and localize Cib to our subcellular compartment of interest.  
Upon transfection into cells, we are left with a POI that is inactive when diffuse in the 
cytosol, and, upon irradiation with blue light, translocates to the subcellular compartment in 
which Cib is expressed and the increase in local concentration restores activity of the POI.  
We have published two examples using this approach to this date.  The initial study reported 
a light-activated cofilin[75a], one of the primary regulators of actin dynamics, and the second 
reported light-activated Bax for control of apoptosis.[78]   
In order to generate a light activated cofilin, our group first generated a constitutively 
active and impaired activity mutant of cofilin.  Cofilin acts to sever actin and its activity is 
19 
 
negatively regulated via phosphorylation at Ser 3 and actin severing is regulated by a 
number of residues including Asp 94, Ser 120, and Lys 96.  We found that the combination 
of Ser 3  Ala and Ser 120  Ala mutations are sufficient to produce a reduced, 
constitutively active cofilin.  Upon fusion to Cry2 and recruitment to either the actin 
cytoskeleton via a lifeact-Cib (LA-Cib) or plasma membrane (PM) via Cib-CAAX, we 
observed cytoskeletal reorganization and light directed lamellipodia formation and motion, 
respectively.[75a] 
Our optogenetic Bax was developed with the same general approach.  However, Bax 
functions by oligomerizing at the outer mitochondrial membrane (OMM) and is not catalytic.  
Therefore, the focus was on disrupting inherent OMM association and oligomerization.  
Mutational studies on Bax fused to the C-terminus of mC-Cry2 revealed that a single 
mutation (Ser 148  Glu) was sufficient to eliminate mitochondrial localization and Bax 
oligomerization in the dark.  However, when illuminated over a two h period, mC-Cry2-
BaxS148E was rapidly recruited to the OMM and cells underwent apoptosis.[78]   
In the work presented here, I report the extension of our generalized approach to 
engineering optogenetic proteins to kinases by developing a light-activated PKA C subunit 
which will be discussed in Chapter 2. 
Light activated adenylate cyclases have received attention for their potential uses in 
dissecting spatial and temporal cAMP signaling.  A number of BLUF regulated PACs and a 
single LOV regulated PAC have been reported from a number of prokaryotic and eukaryotic 
organisms.[63, 65, 84]  Each PAC has unique biochemical characteristics and are generally 
evaluated on their light:dark activity ratio.  The ideal PAC would be completely inactive in the 
dark, but there is varying dark activity in each PAC.  bPAC, from the sulfur oxidizing 
bacterium Beggiatoa spp., is the most widely used and best characterized PAC as of this 
date.  bPAC was initially reported by Stierl et al. and Ryu et al. in 2011 and was the first 
small, soluble PAC to be identified (as opposed to the large euPAC,[63] which was reported 
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in 2007).  Since its publication, bPAC has been used to probe the function of a number of 
cellular and tissue specific processes including GPCR signaling[85], renal function[86], sperm 
function[87], parasite-host interactions[88], and axonal regeneration.[89]   
bPAC is a 350 amino acid protein with an N-terminal BLUF domain and C-terminal 
type III AC domain.  Upon irradiation with blue light (λmax/dark = 441 nm) bPAC rapidly 
generates large amounts of cAMP and reverts to its off state with a half-life of 12.3 s.  In 
addition, bPAC is very sensitive to light with a KM for light of 4 µW mm-2[65a] (Figure 
1.8).Mutational analysis of bPAC has also revealed a number of amino acid substitutions 
that result in changes in enzymatic activity and is reported in Table 1. 
Figure 1.8: a) represents the dark (dotted line) and light (solid line) absorbance spectra 
for bPAC. b) Shows the decay of bPAC from the signaling state to ground state. c) shows 
cAMP generation in response to a 4 s pulse from 475 nm light in vitro.  d) Represents the 
rate of catalysis as a function of light dose illustrating that bPAC is sensitive and saturable 
to light.  Reprinted with permission from publisher. [65a] 
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 Given the fact that bPAC has a high ratio of light:dark activity, is small, expresses 
well in mammalian cells, and is well characterized, we decided to engineer bPAC into a tool 
for spatial and temporal control of subcellular pools of cAMP.  I will describe our efforts 
along these lines to date in Chapter 3. 
 The first section of my dissertation is aimed at describing my efforts to engineer an 
optogenetic PKA C subunit by taking advantage of our generalized approach to develop 
optogenetic POIs using Cry2-Cib and develop bPAC into a useful tool for studying 
intracellular cAMP.  Both of these projects were designed such that we could control cAMP 
and PKA signaling at both levels of the pathway with high spatial and temporal resolution.
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CHAPTER 2: DEVELOPING AN OPTOGENETIC PKA CATALYTIC SUBUNIT1 
Introduction 
Biochemical optogenetics is an emerging field in which proteins of interest are fused 
with naturally occurring bacterial, algae, and plant photoreceptors.[90]  The constructs are 
engineered such that they are inactive in the dark, and active in the light via changes in 
localization or direct enzymatic activation.[91]  This method has been used to generate tools 
to control gene expression, cytoskeletal dynamics[75a], kinase activity[92], and GTPase 
activity.[93] However, the vast majority of biochemical optogenetic tools that have been 
generated are highly specific to the protein of interest (POI).  Our group has developed 
optogenetic tools to control actin dynamics (via cofilin)[75a] and apoptosis[78] (via Bax) using 
an approach that takes advantage of key mutations to provide a POI fused to the PHR 
domain of cryptochrome 2 (Cry2) coexpressed with its photodimerizing partner Cib.  The 
mutations in the POI are designed to render it inactive when it is diffuse in the cytosol, and 
restore activity upon sequestration to subcellular compartments and thus increasing the 
local concentration of the POI. 
Cellular signaling is highly compartmentalized in time and space.  Individual cells 
must be able to respond to, and integrate, extracellular signals while concurrently regulating 
subcellular and organellar microenvironments in response to local cues.  Therefore, cells 
have evolved highly regulated signaling pathways to control and modulate cellular 
homeostasis.  PKA is an exemplary model for compartmentalized cellular signaling.  It is 
involved in many cellular processes and is activated by a single second messenger, cAMP. 
                                               
1 This work is in preparation to be submitted for publication in Angewandte Chemie 
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Depending on when, and where, in a cell cAMP is generated, different cellular behaviors 
occur.[94]  How is it, that a single second messenger and effector can illicit many different 
phenotypes?  PKA is sequestered to various subcellular locations by AKAPs that function as 
localized scaffolds for a number of signaling molecules including ACs, PKA, PPs, and PDEs, 
thus creating localized signaling nodes such that PKA can be regulated both by global 
cAMP signals and also changes in the local cellular microenvironment such as pH and 
calcium levels.[94a]  For example, PKA regulates mitochondrial dynamics and metabolism at 
the outer mitochondrial membrane (OMM)[95], but functions to control migration and 
membrane dynamics at the plasma membrane (PM).[96] 
There are many methods that allow us to observe what is occurring inside of cells in 
response to global stimulation, but there are relatively few that allow for control of 
intracellular biochemistry at specific subcellular locations and with high temporal resolution. 
Therefore, we set out to make an optogenetic PKA catalytic subunit (OPKA).  We have 
previously reported a strategy to develop optogenetic proteins of interest using the 
cryptochrome (Cry2) – Cib photodimerizing pair.  In order to generate constructs that are 
inactive in the dark and active in light, we made mutations that decrease activity in regions 
of the protein important in regulation of activity.  We have successfully engineered tools to 
control protein-protein interactions that resulted in light dependent control of actin dynamics 
and apoptosis via an optogenetic cofilin and Bax, respectively.  Therefore, we hypothesized 
that we could extend this strategy to PKA, and potentially other enzymes, by inserting 
mutations that would decrease the KM for the PKA substrate kemptide (LRRASLG, Table 
2.1).[97]  Thus, the mutations would result in an enzyme that, when diffuse in the cytosol, 
would be inactive, and upon recruitment to specific subcellular regions, would increase the 
local concentration of PKA relative to localized substrates and restore enzymatic activity 
(Figure 2.1).   
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Table 2.1         
PKA 
Mutant 
KM kemptide (µM) Kcat (s-1) Kcat/KM KM ATP (µM) 
WT 11 20 1.8 20 
E203A 292 20 0.068 26 
F327A 696 26 0.037 249 
Y204A 341 0.9 0.002 22 
Results and Discussion 
Section 2.1: In vitro validation of C subunit mutant activity 
The PKA catalytic subunit (PKAcs) was cloned into the pMCSG11 bacterial 
expression vector as a 6X His-tag fusion via PCR and ligation independent cloning.  We 
then generated a cAMP independent mutant of PKAcs via a W196R mutation (Table 2.2, 
Figure 2.2).  Next, we aimed to reduce PKAcs activity by generating constructs that 
contained one of three different mutations from the literature[97] that were known to decrease 
PKAcs KM for the substrate kemptide (Table 2.1: E203A, Y204A, and F327A).  These PKAcs 
variants were expressed in E. coli and purified via affinity chromatography.  Activity of the 
different PKAcs mutants was quantified by coupled assay and resulted in activities of 7.4 ± 
1.0, 0.95 ± 0.2, and 0.21 ± 0.02 s-1 for E203A, Y204A, and F327A respectively (W196R 
PKAcs activity: 17.0 ± 2.8 s-1).  
Table 2.2   
Enzyme Activity (s-1) % Activity 
WT PKA 17.0 ± 2.8 100 ± 16 
F327A PKA 0.28 ± 0.02 1.6 ± 0.1 
F327A + H87Q PKA 0.18 ± 0.02 1.1 ± 0.1 
F327A + W196R PKA 0.21 ± 0.02 1.2 ± 0.1 
F327A + H87Q + W196R PKA 0.01 ± 0.001 0.07 ± 0.01 
E203A + W196R PKA 7.4 ± 1.0 43 ± 6.0 
Y204A + W196R PKA 0.95 ± 0.2 5.6 ± 1.3 
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Figure 2.2: In vitro data showing cAMP independent C subunit activity.  All 
experiments run in triplicate expressed as mean +/- standard deviation.  
Experiments performed by Dr. Melanie Priestman. 
 
Figure 2.1: Top: schematic representation of the function of OPKA. Bottom: schematic 
representation of Cry2 and Cib constructs. 
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Section 2.2: Generation of OPKA constructs and assessment of subcellular 
recruitment 
In order to assess the activity of our PKAcs variants in cells, we cloned each mutant 
as both C-terminal and N-terminal fusions to Cry2-mCherry under the CMV promoter in the 
pmCherry N1 vector (Addgene).  The PKAcs was linked to Cry2-mCherry via a 16 amino 
acid flexible linker (see methods and materials).  First, we quantified the light driven 
association and dissociation dynamics of the Cry2-mCherry-PKA fusions (referred to as 
OPKA) in MVD7 cells (a gift from Dr. James E. Bear)[98] via live-cell fluorescent microscopy 
(Figure 2.3).  We co-expressed the OPKA constructs with either an OMM, PM, or actin-
targeted Cib [75a, 78] in MVD7 cells and imaged mCherry fluorescence every 30 s over 15 min 
after a single 100 ms pulse of blue light (GFP filter cube).  All C-terminal fusions of OPKA 
(with the architecture Cry2-mCherry-PKAcs) have similar association and dissociation times 
regardless of subcellular location (Figure 2.3).  However, the N-terminal fusions do not 
recruit well and were, therefore, not used in further studies (data not shown). 
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Figure 2.3: Top: Graphs representing association and dissociation of OPKA constructs with 
the OMM (left), cytoskeleton (middle), and PM (right).  Note that OPKAWT and OPKAE203A 
were omitted from the cytoskeletal and PM studies, as they will not be were not used due 
to high dark activity (see Figure 2.6).  Bottom: Representative images of OPKA association 
with the OMM.  The top row of images are is of mCherry fluorescence at 0, 0.5, and 15.5 
min after excitation with blue light.  The bottom row are images are of OMM-Cib-GFP (left) 
and an overlay of recruited mCherry with OMM-Cib-GFP (right). Scale bar = 50 µm. 
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Section 2.3: Development and characterization of a PKA reporter 
We then sought to determine the activity of our OPKA variants in dark and light in 
live cells.  However, current live cell PKA activity imaging tools such as the AKARs are 
spectrally incompatible with blue light sensing photoreceptors as they are constructed using 
CFP/YFP or GFP/RFP FRET pairs[54, 99] and Cry2 maximally absorbs light between 400 – 
500 nm which overlaps with the excitation spectrum of CFP and GFP (Figure 2.4).  In 
addition, we were unable to analyze PKA dependent phosphorylation of endogenous 
substrates at subcellular locations due to the fact that there is a distinct lack of antibodies 
against phosphorylated forms of localized substrates.  Therefore, we generated a fixed time 
point reporter to analyze subcellular PKA activity.  The reporter is composed of an N-
terminal subcellular targeting sequence fused to a core fluorescent protein (mTurquoise2) 
via a HA-tag linker and fused to a C-terminal PKA substrate peptide composed of amino 
acids 148 – 164 of the protein VASP (Figure 2.5).   VASP is a well characterized PKA 
substrate[100] that is phosphorylated at Ser157 and has highly specific antibodies against the 
phosphorylated form that are commercially available.  The Tom20[101], Cox VIII[102] and 
Lyn[99a] kinase N-terminal targeting domains were used for targeting the reporter to the 
OMM, mitochondrial matrix (MM) or PM respectively.  we also generated non-targeted, and 
nuclear (Nu) (via the addition of a C-terminal SV40 nuclear localization sequence[103]) 
targeted reporters.  MVD7 cells are a triple knockout cell line for all VASP family member 
proteins (Ena, Mena, and VASP)[98] and were therefore, useful for quantifying PKA 
phosphorylation of the reporter via immunofluorescence (Figure 2.6).  It is important to note, 
however, that the molecular weight of the reporter is 30.9 - 37.6 kDa.  The molecular weight 
of endogenous VASP is 46 kDa.  Therefore, the reporter can be used in any cell line if 
analysis is via Western blot.  The reporter was characterized via immunofluorescence and 
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Western blot for its ability to be phosphorylated in a PKA specific manner (Figure 2.5, 2.6).  
Therefore, we moved forward, using the reporter to quantify subcellular PKA activity.   
 
Section 2.4: Determining the relative activities of OPKA constructs 
In order to determine the relative activities of our different constructs the OPKA 
variants were coexpressed in MVD7 cells with OMM reporter and OMM-Cib.  The cells were 
then stimulated with 470 nm light for 1 min in the presence or absence of the PKA inhibitor 
H89 and subsequently analyzed by semi-quantitative immunofluorescence (Figure 2.7).  WT 
and E203A OPKA phosphorylated the reporter to the same extent in both light and dark.  
However, Y204A and F327A OPKA showed light dependent increases in reporter 
phosphorylation with Y204A OPKA activation resulting in greater reporter phosphorylation 
Figure 2.4: Left: schematic representation of ICUE and AKAR real-time cAMP and PKA 
sensors respectively.  Reprinted with permission from publisher [98b].  Right: overlay of flavin 
adenine dinucleotide (FAD) optical absorption with enhanced cyan fluorescent protein 
(ECFP) excitation/emission spectra.  Spectral data was retrieved from the University of 
Arizona Spectra Database (http://www.spectra.arizona.edu/). 
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than F327A OPKA.  H89 treatment followed by light stimulation resulted in inhibition of 
reporter indicating a PKA specific phosphorylation event. 
Section 2.5: OPKA activity is spatially selective 
Since PKA is highly regulated in time and space, we wanted to validate that our 
OPKA tool was capable of phosphorylating substrates at specific subcellular locations in a 
time and dose dependent manner while leaving other cellular locations untouched by 
enzymatic activity.  Therefore, we performed “lightration” experiments in MVD7 cells with 
OPKAY204A and OPKAF327A recruited to the PM or OMM.  We coexpressed our OPKA 
constructs with either PM-Cib or OMM-Cib and the PM-reporter or OMM-reporter and 
Figure 2.5: Top left: schematic representation of reporter architecture and assay.  
Bottom: Western blot characterization of reporters.  100 µM forskolin, 100 µM forskolin 
+ 100 µM PKA inhibitor H89, or 1 mM 8Br-cAMP were incubated with MVD7 cells 
expressing the various reporters for 30 min before lysis and analysis.  H89 treatment 
blocks forskolin dependent phosphorylation of the reporters thus indicating PKA specific 
activity.  Top right: quantitation of Western blot data in bottom. 
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stimulated the cells with 470 nm LED light from 0 – 300 s before fixing and analyzing 
reporter phosphorylation via immunofluorescence.  As expected from our initial 1 min 
reporter experiments, Y204A OPKA activation yielded faster phosphorylation of the reporter 
at both the OMM and PM than OPKAF327A (Figure 2.8).  After 300 s, both OPKA constructs 
had phosphorylated the reporters to the same extent.  In order to show spatial selectivity of 
OPKA, we coexpressed OPKAY204A or OPKAF327A with PM, OMM, or actin targeted Cib and 
varied the location of the reporter between the OMM and PM and performed a lightration 
from 0 – 300 s with 470 nm LED light.  We observed a time and location dependent increase 
in reporter phosphorylation such that, only the reporter that was localized to the same 
subcellular compartment as Cib was phosphorylated (Figure 2.8) indicating that OPKA only 
phosphorylates substrates at the desired location.   
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Figure 2.6: representative images of 
PKA dependent phosphorylation of 
the cytoplasmic (top left), PM (top 
right), Nu (middle left), OMM (middle 
right), or MM (bottom) reporters in 
response to forskolin (FSK) or 
forskolin and the PKA inhibitor H89 in 
MVD7 cells.  Scale bar = 50 µm. 
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Figure 2.7: Top: representative images of light dependent PKA phosphorylation of the 
OMM-reporter by OPKAY204A.  Bottom: relative phosphorylation of OMM-reporter in 
response to 1 min light stimulation with different OPKA constructs.  All data presented as 
mean +/- SEM, N ≥ 10 cells per bar.  Data presented as fold change relative to mCherry 
in the dark. 
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Figure 2.8: OPKAy204A and OPKAF327A both phosphorylate the reporter when it is recruited 
only to the same subcellular compartment as the reporter.  The magnitude of reporter 
phosphorylation by OPKAy204A is greater than that of OPKAF327A.  Data is presented as 
mean +/- SEM, N ≥ 10 cells per experimental group. Experiments performed by Dr. Melanie 
Priestman. 
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Section 2.6: Light-induced spatially specific phosphorylation of endogenous PKA 
substrates with OPKAY204A 
Finally, we set out to validate that OPKA was capable of phosphorylating 
endogenous PKA substrates at specific subcellular regions.  Given that there is a lack of 
phospho-specific antibodies for discreet subcellular PKA substrates, we turned to proteomic 
analysis to quantify PKA activity at the OMM and PM.  293T I17 cells were transfected with 
Y204A OPKA and either OMM or PM-Cib and stimulated with light.  For the PM-Cib 
experiment, whole cell lysates were used, and for the OMM-Cib experiment, we performed 
subcellular fractionation to isolate mitochondria.  We then probed for differences in overall 
PKA phosphorylation between the light and dark via Western blot using an antibody that 
detects phospho-PKA substrates (Cell signaling technologies).  In both cases, we found that 
there were increases in specific bands that were associated with the respective subcellular 
compartment (Figure 2.9, 2.14).   
The PM-Cib experiment, initially performed with OPKAF327A, revealed an unknown 
phospho-protein of interest upon performing Western blot analysis with the phospho-PKA 
substrate antibody (Figure 2.9).   To identify the unknown phospho-protein, lysates were run 
Figure 2.9: A) Western blot showing 
the identification of the unknown 
phosphoprotein of interest. B) 
Western blot confirming that the 
event occurs when OPKA is 
expressed. C) Quantification of B. 
Experiments performed by Dr. 
Robert Hughes. 
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on an SDS-PAGE gel and the 25 – 37 kDa region was cut for tryptic digest and phospho-
proteome analysis via liquid chromatography (LC) and tandem mass spectrometry (MS) 
(Figure 2.10).  MS analysis revealed a number of enriched phospho-proteins present in the 
region of interest (top hits listed in Figure 2.10).  Antibodies against COPE, KCTD5, 
EMERIN, and SMN1 were purchased in order to perform immunoprecipitations (IP) in order 
to identify the phospho-protein of interest identified in the initial experiment.  IP for each of 
the antibodies revealed that COPE (coatomer protein epsilon) had the same electrophoretic 
mobility shift as the unknown phospho-protein of interest and was phosphorylated in 
response to light activation of OPKA (Figure 2.11).  COPE is a protein involved in protein 
trafficking associated with cellular membranes including the PM and has been shown to 
interact with the cystic fibrosis transmembrane conductance regulator (CFTR).[104]  COPE is 
phosphorylated at Ser 99, which lies inside of a classic PKA consensus site (RRDSI).[105]   
We performed a time course light experiment in order to optimize detection of phospho-
COPE for further validation by MS.  HEK 293T cells were transfected with OPKAY204A, 
OPKAF327A, or Cry2-mC and exposed to blue light for 0, 1, 2, 4, or 8 min before lysis and 
Western blot analysis with the phospho-PKA substrate antibody.  Indeed, there was an 
increase in the phospho-PKA substrate band associated with COPE in cells expressing 
Figure 2.10: 25 – 37 kDa regions from whole cell 
lysates were cut for tryptic digest.  The bottom panel 
shows the gel and regions excised.  From left to right: 
no treatment, forskolin, OPKA dark, OPKA light.  The 
top panel is a list of the most highly enriched phospho-
proteins identified in the original proteomics 
experiment. Experiments performed by Dr. Robert 
Hughes. 
 
Figure 2.10: 25 – 37 kDa regions from whole cell 
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OPKAy204A and cells treated with forskolin (Figure 2.12).   It is interesting to note that 
OPKAF327A appears to have high basal levels of COPE phosphorylation, but is normally less 
active than OPKAY204A. It is also interesting to note that forskolin treatment does not appear 
Figure 2.11: Top) Western blot of IP’d phospho-proteins of interest identified by 
MS shows that COPE is phosphorylated by OPKA after light stimulation and has 
the same electrophoretic mobility shift as the unknown phospho-protein of interest.  
Bottom) Further validation of OPKA mediated COPE phosphorylation via IP. 
Experiments performed by Dr. Robert Hughes. 
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to induce COPE phosphorylation until 8 min, while the maximal response from OPKAY204A 
occurred after 1 min and then gradually decayed over time. 
Given that the largest light-dependent change in COPE phosphorylation appeared 
after only 1 min of light exposure, we submitted the 1 min time point to the UNC Proteomics 
Core for further validation by MS.  We are currently awaiting results. 
 
For the mitochondrial experiment, HEK 293T cells were grown on galactose for at 
least 24 hs prior to an experiment in order to decrease mitochondrial associated PKA 
signaling.  In yeast, PKA plays a central role in metabolic signaling.  When yeast cells are 
grown on glucose, high levels of PKA activity are present and almost all of the cellular ATP 
content is generated by glycolysis.  However, when yeast are grown on non-fermentable 
media, the PKA activity decreases, especially that which is associated with mitochondria, 
and ATP is generated by oxidative phosphorylation (OXPHOS).[106]  There is considerable 
evidence in the literature that PKA plays a central role in metabolic switching at the OMM[107] 
in mammalian cells.  However, to my knowledge, substrate mediated changes in PKA 
activity at mitochondria have not been investigated in higher eukaryotes.  Therefore, we 
reasoned that HEK 293T cells that were glucose starved, and therefore preferentially 
metabolizing ATP via OXPHOS, should have lower basal PKA activity and, thus, any 
Figure 2.12: Left) Western blot analysis and (right) quantitation of OPKA mediated COPE 
phosphorylation over time.  Experiments performed by Dr. Robert Hughes. 
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increase in PKA phosphorylation at the OMM would be enhanced.  Indeed, cells grown on 
galactose and subsequently treated with forskolin had a greater increase in PKA activity in 
mitochondria than those maintained in glucose when mitochondrial fractions were probed 
via Western blot with the phospho-PKA substrate antibody (Figure 2.13).  Therefore, we 
cultured HEK 293T cells on galactose containing media and subsequently transfected them 
with OPKAY204A and OMM-Cib.  Untransfected cells were treated with forskolin (10 µM for 30 
min) and OPKA transfected cells were treated with light (470 nm blue LED flood lamp for 30 
min).  Following treatment, we lysed the cells and isolated the mitochondrial fraction via 
differential centrifugation and a kit (Pierce) in the presence of phosphatase inhibitors.  We 
then probed the mitochondrial and whole cell lysates for changes in phospho-PKA 
substrates via Western blot (Figure 2.14).  We observed a marked increase in mitochondrial 
fractions expressing OPKA and treated with light (Figure 2.14).  These samples were then 
submitted to the UNC Proteomics Core for mitochondrial phosphoproteome analysis.  We 
are currently awaiting results. 
 
 
Figure 2.13: Line scans were performed on phospho-PKA substrate stained Western blots 
and the resulting values were normalized to the minimum value on the scan.  The left panel 
is a trace from HEK 293T cells grown on glucose while the right panel illustrates the 
increased dynamic range of PKA phosphorylation for cells grown on galactose. 
 
41 
 
 
Section 2.7: Discussion 
Here we report the development of OPKA, an optogenetic PKA C subunit.  We took 
advantage of the fact that reduced enzymatic turnover and binding affinity for a substrate 
could be overcome by increasing the enzyme concentration at discrete subcellular locations.  
Therefore, an enzyme with low basal activity when diffuse in the cytosol would have its 
apparent activity restored when concentrated at the OMM.  In order to accomplish this goal, 
we generated three cAMP independent mutants of the C subunit (E203A, F327A, and 
Y204A) and fused them to the C-terminus of Cry2-mC yielding OPKA.  The relative activities 
of the C subunit mutants (relative to wild type) were 15, 45 and 428 fold less active for 
E203A, F327A, and Y204A respectively.  When we expressed the various OPKA mutants in 
Figure 2.14: The left panel shows the phospho-PKA substrate Western blot for HEK 293T 
cells grown on galactose and transfected with OPKAY204A and OMM-Cib as well as cells 
treated with forskolin.  The right panels are representative traces of line scans of the 
mitochondrial fractions from this experiment. 
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conjunction with OMM-Cib and the OMM-reporter and stimulated the cells with blue light, we 
found that E203A and WT OPKA were both highly active in the dark and light as assessed 
by reporter phosphorylation.   However, the F327A and Y204A mutants showed little to no 
activity in the dark and an increase in reporter phosphorylation in light.  OPKAY204A elicited a 
larger change in reporter phosphorylation in response to light than OPKAF327A.  This was an 
interesting observation due to the fact that the F327A mutant has higher activity than Y204A 
in vitro.  Our working hypothesis for this observation is that the F327A C subunit, while it 
retains a kcat similar to that of WT (26 vs. 20 s-1 respectively), has a twofold higher KM for its 
substrate and nearly an order of magnitude higher KM for ATP relative to Y204A.  While 
Y204A does have an elevated KM for its substrate vs. WT (341 vs. 11 µM respectively) and 
similar KM for ATP, it has a drastically decreased kcat (0.9 vs. 20 s-1).  Therefore, in our 
OPKA system, substrate and cofactor binding appear to trump catalytic turnover.   
Both OPKAY204A and OPKAF327A display spatially discrete reporter phosphorylation 
when recruited to either the OMM, PM, or actin cytoskeleton that is PKA and time 
dependent.  Therefore, we sought to validate that our OPKA is capable of phosphorylating 
endogenous protein substrates.  Initially, we focused on specific PKA substrates that are 
thought to be at least partially localized to specific subcellular compartments.  Our efforts 
involved attempts to stimulate PKA dependent phosphorylation of Hsp90 at the PM, VASP 
at the PM and cytoskeleton, and Drp1 and the steroidogenic acute regulatory protein (StAR) 
at the OMM (data not shown).  While some targets (VASP and Drp1) revealed promising 
results, the data was not useful due to large increases in background phosphorylation due to 
the necessity of including phosphatase inhibitors (data not shown).  In addition, our efforts in 
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investigating StAR phosphorylation were hampered by the distinct lack of StAR phospho-
antibodies and low transfection efficiency in steroidogenic cells.  It is also important to note 
Figure 2.15: Top) axonal branching increases upon treatment with 1 mM 8Br-cAMP and 
is inhibited by the inclusion of 10 µM H89 after 24 and 48 hs.  Cells expressing OPKAY204A 
had axons with more branches after 24 hs regardless of light stimulation but a slight upward 
trend in branching was observed upon treatment with 2 s blue light every 2 min.  Bottom) 
representative images of E18 rat hippocampal neurons 24 hs after treatment.  Results 
reported as mean +/- SEM, N ≥ 10 cells per group. 
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that, especially in the case of VASP and Drp1, the proteins of interest were not discretely 
localized to the subcellular locations of interest but rather occupy both cytoplasmic and 
subcellular locations. This renders data interpretation difficult.  We also investigated whether 
we could induce axonal branching in hippocampal neurons, a PKA dependent process.[108]  
However, we were plagued by acute phototoxicity and expense of materials.  Some data 
(Figure 2.15) was promising, but we decided to pursue a phosphoproteomics approach to 
validate that our OPKA system is capable of phosphorylating endogenous substrates.  
Our proteomics approach identified COPE as a membrane associated PKA substrate 
at the PM.  Final validation of COPE phosphorylation by LC/MS and MS analysis of 
mitochondrial fractions is ongoing. 
The promise of controlling axonal morphogenesis is an enticing and promising 
application of OPKA.  While our initial results are not ideal, they show promise and, with 
minor modifications, our optogenetic constructs should behave in the desired fashion.  
These light-responsive tools offer the opportunity to investigate the role that PKA plays in 
neuronal development and synaptic plasticity.  PKA is known to participate in RhoA 
dependent axonal branching[108] via phosphorylation and deactivation of RhoA as well as in 
enhancing synaptic connectivity (long term potentiation, LTP) by promoting the insertion of 
AMPARs into the postsynaptic density of dendrites[49] and phosphorylating the presynaptic 
protein RIM1α.[109]  Therefore, it would be of great interest to use OPKA to assess the roles 
of pre and postsynaptic PKA signaling in synaptic plasticity.   
One of the challenges that we faced was not seeing an obvious change in cellular 
phenotype upon activation of OPKA.  A growing body of literature suggests that PKA 
substrate specificity is encoded via AKAP scaffolding such that the PKA holoenzyme is 
positioned in close proximity to its substrates. This enables the range of cAMP mediated 
PKA activation to be limited in time and space.[110]  Indeed, recent work from Scott and 
colleagues showed that the flexible linker region of RII yields a 16 nm geographic radius of 
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C subunit activity, suggesting that the R subunit/AKAP complex positions the C subunit in an 
ideal conformation to phosphorylate tethered substrates.[111]  Furthermore, they found that, 
by restricting the motion of the R subunit by replacing the RIIα flexible linker region between 
the docking/dimerizing domain and the cAMP binding domain with short or rigid linkers, the 
catalytic activity of tethered C subunit is less efficient in its ability to phosphorylate local 
substrates.  Therefore, we propose making an OPKA construct that more closely mimics 
endogenous PKA function.   
Currently, we are using light and the Cry2-Cib heterodimerizing pair to sequester 
OPKA to subcellular compartments.  However, the C subunit might not be properly oriented 
in space with respect to its substrates.  Therefore, we will integrate a photodimerizing 
subunit into an AKAP of interest by replacing the R subunit binding domain with one of the 
various heterodimerizing pair subunits along with the VASP reporter peptide (Figure 2.16) 
and clone it under the control of a low to moderate expression level constitutive promoter in 
a lentiviral backbone. We will incorporate a siRNA targeting our AKAP of interest under the 
control of a U6 promoter upstream of the protein coding region of the vector.  This construct 
should furnish an AKAP of interest that 1) no longer binds the R subunit, 2) will effectively 
silence and replace the endogenous AKAP, and 3) act as a self-reporting entity. The C 
subunit will then be fused to the C-terminal of the flexible linker region of RII so that it will 
have the endogenous linker that would normally tether the holoenzyme to the AKAP.  
Finally, the N-terminus of the RII linker will be fused to the other photodimerizing subunit of 
a given pair to furnish an OPKA that more closely mimics endogenous enzyme (Figure 
2.16).  Given that the endogenous stoichiometry of C subunit:AKAP is 2:1, we will also 
investigate the effects of oligomerization of the AKAP associated photodimerizing domain.  
we plan on using the Magnet heterodimerizing photoswitches for this purpose.[112]  Magnets 
are engineered heterodimerizing photoswitches.  They are based on the LOV Vivid (VVD) 
domain and are small (149 amino acids).  Magnets can also have their lifetimes tuned such 
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that their dissociation times range from a few seconds to over an hour.  Therefore, this will 
allow us to investigate spatial PKA signaling with an increased spatial resolution, as well as 
tune our temporal resolution and investigate the interplay between the two in localized PKA 
signaling. 
We want to initially apply this strategy to AKAP79.  AKAP79 is involved in targeting 
PKA to postsynaptic terminal where PKA acts to promote insertion of AMPARs into the 
postsynaptic density.[49]  In addition, the RII binding domain of AKAP79 is located at its C-
terminus[113], allowing for a potentially easy cloning strategy that has a lower chance of 
disrupting normal protein function than if it were an interior domain. We will first validate that 
1) OPKA recruitment results in reporter phosphorylation and 2) that other proteins 
associated with the AKAP can still bind to it in an easy to transfect cell line such as HEK 
293Ts. Subsequently neurons will be infected in culture and slices and we’ll investigate if 
recruiting OPKA to AKAP79 results in an increase in the number of AMPARs in the 
postsynaptic density by immunofluorescence against the extracellular domain of the 
AMPAR.  By taking this approach we eliminate the need for permeabilization before we 
apply the antibody, thus only looking at AMPARs that have already been inserted into the 
synapse and NOT those that are on the cytoplasmic side of a dendrite.  This may even work 
in real time.  Then we’d like to collaborate with a neuroscientist who works with behavioral 
models of learning and memory and utilizes electrophysiology to investigate the roles of 
AKAP79 dependent PKA signaling. 
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Section 2.8: Materials and Methods 
Plasmid Construction.  
All PCR Primer sequences and plasmid insert sequences can be found after the 
Methods Section. 
Cloning and mutagenesis of PKAcs in pMCSG11: 
 PKAcs was amplified by PCR with primers that appended nucleotides necessary for 
ligation independent cloning into pMCSG11. Briefly, the PCR-amplicon was treated with T4 
DNA Polymerase with dCTP for 30 min at 22 ºC, followed by heat inactivated for 20 min at 
75 ºC and reaction clean up by spin column. Separately, the vector pMCSG11 was digested 
with SspI, gel isolated, and then treated with T4 DNA Polymerase with dGTP for 30 min at 
22 ºC, followed by heat inactivation and spin column clean up. The resulting PCR fragment 
(4 µL) and vector (1 µL) were then annealed by incubation for 20 min at room temperature, 
followed by the addition of 2 µL of 100 mM EDTA. The resulting solution was heated to 75 
ºC for 2 min, then allowed to cool slowly to room temperature. An aliquot of the resulting 
Figure 2.16: Outlines the architecture for the proposed second generation OPKA 
constructs. 
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mixture (2 µL) was then transformed into chemically competent DH5α, and resulting clones 
were analyzed for inserts via HindIII restriction digest and sequence verified. Following 
successful isolation of PKAcs (wt) in pMCSG11, mutations (H87Q, W196R, E203A, Y204A, 
F327A) were introduced via site-directed mutagenesis.  
Cloning of Cry2-mCh-PKAcs in mCherry-N1:  
PKAcs was amplified by PCR with primers that appended both BsrgI and NotI 
restriction sites as well as a sixteen-amino acid N-terminal tether. After isolation and 
restriction digest of the PCR product, it was ligated into a plasmid containing Cry2-mCh 
(mCherry-N1) that was also cut with BsrgI and NotI enzymes. The resulting construct 
encoded the fusion protein Cry2-mCh-SAGGSAGGSAGGSAGG-PKAcs. 
Cloning of CIB-CAAX:  
A construct encoding CibN (ΔNLS)-GFP-CAAX (Addgene 268267) was modified via 
PCR-mediated site-directed mutagenesis to insert a poly-lysine sequence, CAAX box, and 
stop codon between Cib and GFP. The resulting construct encoded the fusion protein Cib-
GGSG-KKKKKKSKTKCVIM. 
The following constructs were obtained from Addgene: Cry2PHR-mCh (26866), 
CibNdNLS-GFP (26867). The plasmid encoding PKAcs (PKA-pRSET) was provided by 
Susan Taylor. The bacterial expression plasmid pMCSG11 was obtained from the Arizona 
State University plasmid repository (DNASU). Cloning methods for the constructs Tom20-
Cib and LifeAct-Cib have been previously reported.  
Site-Directed Mutagenesis  
Primers for site-directed mutagenesis were designed to have a minimum Tm of 72 ºC. 
125 ng of each primer were combined with 50 ng of template DNA, 4 µL of 2.5 mM dNTPs, 
5 µL of 10X PfuUltra buffer, 1 µL of PfuUltra Hotstart DNA Polymerase, and ddH2O added to 
50 µL. The resultant PCR products were then treated with DpnI for 1 h at 37 ˚C and 1 µL of 
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this solution transformed into 50 µL of Invitrogen MaxEff DH5α. Individual colonies were 
then isolated and sequence verified.  
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Reporter Cloning and Characterization:  
The reporter was constructed by appending nucleotides encoding the PKA 
consensus site of the VASP protein (amino acids 148-164) to the 3’ end of mTurquoise2 via 
primer elongation.  An outer mitochondrial membrane targeted reporter was cloned by 
generating a PCR fragment appending an HA-tag preceded by an in-frame KpnI site onto 
the 5’ end and the VASP peptide followed by a BamHI site onto the 3’ end of mTurquoise2.  
The PCR product was digested with KpnI and BamHI and ligated into a pEF1alpha-Tom20 
vector (modified from pEF1alpha-MCS-IRES-DsRedExpress2 from Clonetech) digested with 
KpnI and BamHI such that the insert was in-frame with the Tom20 mitochondrial localization 
sequence.  The plasma membrane reporter was generated via PCR using a 5’ primer 
containing an EcoRI site followed by the Lyn kinase N-terminal myristylation sequence and 
a gene specific region against the HA-tag, the 3’ primer was the same primer used above to 
append the VASP peptide to mTurquoise2.  The PCR product was digested with 
EcoRI/BamHI and ligated into a pEF1alpha vector digested with EcoRI/BamHI.  Positive 
clones were identified via restriction digest with EcoRI and BamHI and confirmed via 
sequencing using a set of sequencing primers (see below) generated for the specific 
pEF1alpha vector used.  The plasmids were then transfected into cells and characterized for 
1) subcellular localization via fluorescent microscopy, 2) molecular weight via Western blot, 
3) ability to be specifically phosphorylated by PKA via Western blot and 
immunofluorescence.  We detected peptide phosphorylation using a mouse anti-pVASP 
S157 antibody from abcam (ab58555) at 1:100 or 1:1000 for immunofluorescence and 
Western blotting respectively. 
Materials:  
BL21DE3 competent cells were purchased from New England Biolabs. Ni-NTA resin 
was purchased from Thermo Scientific. Bovine PKA regulatory subunit and all other 
chemical were purchased from Sigma.   
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Over-expression and Purification of PKA Mutants 
BL21DE3 E. coli cells were transformed with the pMSCG11-PKAcs plasmids and 
grown in LB media supplemented with chloramphenicol.  Cells were incubated in a shaker at 
37 ºC to an optical density of 0.5 and then induced with 500 µM IPTG. Immediately after 
induction the temperature was dropped to 18 ºC and the cells were incubated for 20 hrs. 
During purification steps a mammalian cell protease cocktail (Sigma) was used to prevent 
proteolytic cleavage. Purification of PKA mutants were carried out at 4 C via an AKTA 
FPLC. Cell lysates in PBS pH 7.4 were loaded onto a 10 ml Ni-NTA agarose column and 
unbound protein was washed off with PBS followed by stepwise elution at 10, 25, 75 and 
250 mM Imidazole in PBS pH 7.4.  Fractions were analyzed by SDS-PAGE, determined to 
be > 90 % pure, concentrated and stored at -80 C.  Protein concentrations were determined 
by using the Bradford reagent from Pierce. 
Assessment PKA activity 
The in vitro activities of PKA mutant enzymes were determined using a coupled 
enzyme assay with kemptide as the substrate. Briefly, phosphorylation of the peptide was 
coupled to pyruvate kinase and lactate dehydrogenase resulting in the oxidation of NADH. 
Formation of the latter was monitored at 340 nm. Pyruvate kinase and lactate 
dehydrogenase were maintained as non-rate limiting enzymes. The activities of the PKA 
mutant enzymes (10-500 nM) were determined in 50 mM Tris pH 7.5, 100 mM NaCl, 10 mM 
MgCl2, 10% glycerol, 1 mM peptide, 1 mM ATP, 1mM DTT, 1 mM phosphoenol pyruvate 
and 0.2 mM NADH. To determine the effect of the regulatory subunit assays were run ± 50 
nM regulatory subunit (5 times the catalytic concentration) ± 100 µM cAMP.  
Cell based PKA activity assessment and Light-titration Using VASP Reporter 
Cell culture- MVD7 cells were grown on MatTek 12-well # 1.5 glass bottom plates or 
35 mm # 1.5 glass bottom dishes. The day of the microscopy experiments the media was 
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replaced with Leibovitz’s L-15 medium without phenol red containing 10% FBS, 2 mM 
Glutamax, and 50 U/ml interferon γ. 
Association and Dissociation of Cry2-mCherry-PKA constructs 
Cells were transfected with Cry2mC, Cry2PKA-Y204A, or Cry2PKA-F327A and 
Tom20-GFP-Cib, GFP-Cib-CAAX or LA-GFP-Cib at a ratio of 1:1 with a total of 2 µg DNA 
per well.  1:2 ratio of DNA: JetPrime (mass: vol) and transfection cocktails were incubated at 
10 min at RT before adding to dishes.  Cells were incubated with DNA for 3 hs at 32C 
before media was exchanged.  On day of imaging, media was exchanged for L-15/10 % 
FBS/1X GlutaMAX / 50 UI IFNgamma for imaging.  Dishes were allowed to equilibrate in 
heated incubators (32 °C, 45 % humidity) for at least half an h before imaging.  Lifeact-GFP-
Cib and Tom20-GFP-Cib imaging was performed on an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, 60X oil immersion Plan S-Apo objective and 
FITC and TxRed filter cubes from Semrock.  Images were acquired every 30 s over 15 min.  
Light stimulation was provided via a 100 ms pulse from the FITC cube in the first frame and 
translocation of Cry2-mCherry-PKA was monitored via 500 ms exposure in the TxRed 
channel.  Image analysis was performed by defining regions of interest (ROIs) at 
mitochondria and the actin cytoskeleton.  At least 3 ROIs were analyzed per cell and 3 total 
cells were analyzed.  Background fluorescence measurements were subtracted from each 
ROI and a normalized change in fluorescence was calculated.  GFP-Cib-CAAX imaging was 
performed on an Olympus FV1000 scanning confocal microscope with IX81 base using the 
488 and 559 laser lines. Two frames of the 559 nm channel (mCherry) were recorded before 
a single stimulus of the 488 laser at 10 µs per pixel and 2% power followed by imaging with 
the 559 laser every 30 s. Image analysis was performed as described above. 
Initial Cellular activity characterization and immunofluorescence 
 Control cells were treated with 100 µM forskolin for 30 min at 32 ºC before fixation 
via the same protocol outlined below.  Cells were transfected with Cry2-mCherry-PKA and 
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Tom20-GFP-Cib and allowed to grow overnight.  The cells were then either 1) kept in the 
dark, 2) exposed to light for 1 min using a 470 nM LED flood light (PAR38; Westinghouse 
0315100; 1.7 mW power) or 3) exposed to light for 1 min in the presence of 10 µM H89.  
Immediately after removal from the light the cells were fixed by adding a 2X solution of fixing 
reagent so the final concentration was 4% paraformaldehyde (Electron Microscopy 
Sciences) in PBS. Cells were incubated for 10 min at r.t. before being washed twice with 
PBS. Cells were blocked with 5% BSA + 0.1% tritionX100 in PBS (blocking buffer) for 1 h at 
r.t.  Fixed cells were incubated with a 1:100 dilution of mouse anti-phosphoVASP157 
(abcam ab58555) in 1% BSA + 0.1% tritionX100 in PBS (antibody buffer) overnight at 4 ºC. 
Cells were then washed 3 times with PBS and incubated with 1:1,000 anti-mouse Alexa 647 
antibody (Life Technologies) at r.t. for 2 hrs.  Cells were washed 3 times with PBS and 
placed in PBS for imaging.  Image analysis was performed as outlined below.  Images for 
figures were subjected to 100 pixel radius rolling ball background subtraction and intensities 
for the phospho-reporter were normalized to positive controls. 
Light-Titrations 
Control cells were treated with 100 µM forskolin + 100 µM IBMX for 30 min at 32 ºC 
before being fixed using the same protocol outlined above. Light-titrations were carried out 
by exposing the cultured cells to 0, 30, 60, 120, or 300 s of light using a 470 nM LED flood 
light (PAR38; Westinghouse 0315100; 1.7 mW power). Cells were fixed and stained as 
outlined above. 
Fluorescent Microscopy  
All fluorescent microscopy imaging was done on an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 60X oil immersion Plan S-Apo 
objective and CFP, TxRed, and Cy5.5 filter cubes from Semrock. Images were taken at 250 
ms exposure for CFP fluorescence, 500 ms exposure for mCherry fluorescence, and 1000 
ms exposure for Alexa 647 fluorescence. An ROI surrounding the entire cell was defined for 
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cells that contain both the CFP-VASP reporter and mCherry-Cib and fluorescence of the 
entire cell was measured. The minimum background fluorescence for each image was 
subtracted from each cell and then the ratio of the VASP reporter fluorescence / pVASP 
fluorescence was calculated. Values were normalized to the ratio from cells that were never 
exposed to light. All imaging analysis was done using Image J software and reported as the 
mean ± standard error of 10-25 cells per experiment. 
Phospho-PKA substrate identification and Characterization: 
Initial Survey of Phospho-Proteins Using Cry2.mCh.PKA.W196R.F327A and PKA 
substrate-specific Antibody  
HEK293T cells were plated in six well tissue culture plates at a density of 130,000 
cells per well. The next day, cells were transfected with 1 μg of total DNA per well (500 ng 
Cib.GFP.CAAX; 500 ng Cry2.mCh.PKA.W196R or Cry2.mCh.PKA.W196R.F327A or 
Cry2.mCh) using the JetPrime transfection reagent (2 μL JetPrime Polyplus reagent: 200 μL 
JetPrime buffer), following the recommended protocol. Four hours post-transfection, cell 
media was changed and the cells were stored overnight, protected from light, in a humidified 
tissue culture incubator (37 ºC; 5% CO2). The next day, cells were serum starved in PBS for 
15 min in a humidified tissue culture incubator (37 ºC; 5% CO2), and exposed to light (2 min; 
blue LED flood lamp; continuous illumination) or kept in the dark (2 min). Forskolin treated 
cells were exposed to 20 μM forskolin for 2 min. Post-light exposure or forskolin treatment, 
PBS was aspirated, and cells were lysed with 400 μL M-PER (ThermoScientific) with 1X 
Halt Protease and Phosphatase Inhibitor cocktail. Cells were lysed in the dark for 4 m at 
room temperature, prior to transferring to 1.7 mL centrifuge tubes and spun 5 m at 1000 x g 
at 4 °C. 15 μL of each supernatant was then diluted 1:1 with Laemmli sample buffer plus 
BME, and boiled for 5 min at 95 °C prior to analysis by western blot. 
Western Blot: Samples were electrophoresed on a 4-12% Tris-Glycine gradient gel 
(Biorad), and transferred to PVDF membrane overnight at 20 V in a cold room. Membrane 
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was blocked (5% BSA; TBS-Tween) for 1 h prior to overnight incubation with α-phospho 
PKA substrate antibody (Cell Signaling; 9624S), diluted 1:1000 in blocking buffer. After 
overnight incubation, membrane was washed (3 x 5 m; TBS-Tween) and placed in 
secondary antibody (Cell Signaling; 7074P2), diluted 1:3000 in blocking buffer, for 2 h at 
room temperature.  After washing membrane (4 x 5 m; TBS-Tween), blot was developed 
with chemiluminescent substrate (Biorad Clarity Western ECL substrate) for 5 min prior to 
imaging. For complete analysis, blots were stripped (Thermoscientific; RESTORE buffer) 
according to package instructions, and re-probed with GAPDH (Cell Signaling; 5174S) and 
mCherry (Abcam; 167453) antibodies.  
Isolation of Band of Interest from Gradient Gel and Characterization by 
Phosphoproteomics Analysis.  
Lysates from cells transfected with Cry2.mCh.PKA.W196R (30 μL; 4 mg/mL) were 
electrophoresed on a 4-12% Tris-Glycine gradient gel. A region between the 25 and 37 kDa 
MW markers was removed for analysis at the UNC Proteomics Core Facility. Briefly, bands 
were in-gel digested with trypsin overnight. The resulting peptides were enriched for 
phosphopeptides using TiO2, and the TiO2 elution for each sample was analyzed by 
LC/MS/MS (Easy nLC 1000-Qexactive HF). Samples were eluted over a 45 min gradient 
from 5-35 %B, where mobile phase A = 0.1% formic acid and mobile phase B = acetonitrile 
with 0.1% formic acid. The top 15 most intense ions were chosen for HCD fragmentation, 
and data were processed using Proteome Discoverer 1.4. Finally, data were searched 
against a reviewed Human Uniprot database using Sequest (10 ppm precursor ion mass 
tolerance; 0.02 Da product ion mass tolerance; up to two missed trypsin cleavage sites; 
carbamidomethylation of Cys was set as a fixed modification; oxidation of M, deamidation of 
N,Q, and phospho of S,T,Y were set as variable modifications). Peptide false discovery 
rates of 5% was used to filter all results. 
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Protein ID %abundance 
(Relative 
Peak Area) 
MW 
(kDa) 
Coatomer subunit epsilon OS=Homo sapiens GN=COPE 
PE=1 SV=3 - [COPE_HUMAN] 
100.00 34482 
Mitochondrial import receptor subunit TOM34 OS=Homo 
sapiens GN=TOMM34 PE=1 SV=2 - [TOM34_HUMAN] 
88.69 34559 
Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - 
[EMD_HUMAN] 
48.06 28,994 
Ubiquitin-conjugating enzyme E2 J1 OS=Homo sapiens 
GN=UBE2J1 PE=1 SV=2 - [UB2J1_HUMAN] 
39.26 35199 
RING finger and CHY zinc finger domain-containing 
protein 1 OS=Homo sapiens GN=RCHY1 PE=1 SV=1 - 
[ZN363_HUMAN] 
38.26 30,110 
BTB/POZ domain-containing protein KCTD5 OS=Homo 
sapiens GN=KCTD5 PE=1 SV=1 - [KCTD5_HUMAN] 
8.78 26,093 
Survival motor neuron protein OS=Homo sapiens 
GN=SMN1 PE=1 SV=1 - [SMN_HUMAN] 
5.77 31,849 
Antibodies for the top scoring PKA-substrate phospho-protein, in addition to other 
high-scoring PKA-substrate phosphoproteins with molecular weights near 30 kDa, were 
purchased, and the lysates re-probed by western blot (COPE; Abcam; ab180946. Emerin; 
Cell Signaling; 5430S. KCTD5; Abcam; ab118145. SMN1; Cell Signaling; 12976S; RING 
finger; Cell Signaling; 5754S). Only the band reveled by the Abcam COPE antibody 
matched the electrophoretic mobility of the unknown phospho-protein of interest. 
Immunoprecipitation of COPE 
100 mm tissue-culture dishes at 80% confluency were transfected with 10 μg of total 
DNA per plate(5 μg Cib.GFP.CAAX; 5 μg Cry2.mCh.PKA.W196R.F327A or Cry2.mCh) 
using Lipofectamine 2000 transfection reagent (32 μL Lipofectamine reagent: 1 mL Opti-
MEM), following the recommended protocol, in Opti-MEM with 10% FBS. 4 h post-
transfection, cell media was changed to DMEM + 10% FBS, and the cells were stored 
overnight, protected from light, in a humidified tissue culture incubator (37 ºC; 5% CO2). The 
next day, cells were serum starved in PBS for 15 min in a humidified tissue culture incubator 
(37 ºC; 5% CO2), and exposed to light (4 min; blue LED flood lamp; continuous illumination) 
or kept in the dark (4 min). Cells were then lysed using 2 mL of M-PER + 1x HALT protease 
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and phosphatase inhibitor per plate. Lysates were cleared by centrifugation (5 min; 1000 x 
g; 4 °C), and concentrations determined via the Bradford assay. For immunoprecipitation, 15 
μL of mouse anti-COPE antibody (Santa Cruz; sc-133195) was added to each sample (400 
μL; 4 mg/mL), and the samples incubated overnight on a rotator at 4 °C. The next day, 50 
μL of an M-PER washed suspension of Protein A-Sepharose 4B beads was added to each 
sample, and the samples returned to the rotator for 1 h at 4 °C. The samples were then 
centrifuged (1 min at 1000 x g), and the supernatants removed. The resulting bead pellet 
was washed (3 x 200 μL M-PER), and then eluted by boiling in 100 μL of Laemmli sample 
buffer with BME (3 min at 95 °C). The resulting eluents were subsequently analyzed by 
western blot. 
Western Blot: Samples were electrophoresed on a 4-12% Tris-Glycine gradient gel 
(Biorad), and transferred to PVDF membrane overnight at 20 V in a cold room. Membrane 
was blocked (5% BSA; TBS-Tween) for 1 h prior to overnight incubation with α-phospho 
PKA substrate antibody (Cell Signaling; 9624S), diluted 1:1000 in blocking buffer. After 
overnight incubation, membrane was washed (3 x 5 m; TBS-Tween) and placed in 
secondary antibody (Cell Signaling; 7074P2), diluted 1:3000 in blocking buffer, for 2 h at 
room temperature.  After washing the membrane (4 x 5 m; TBS-Tween), the blot was 
developed with chemiluminescent substrate (Biorad Clarity Western ECL substrate) for 5 
min prior to imaging. 
Optimization of Plasma Membrane Recruitment Using COPE as a Reporter  
HEK293T cells were plated in six well tissue culture plates were grown to 80% 
confluency, and subsequently transfected with 1 μg of total DNA per well (330 ng 
Cib.GFP.CAAX; 660 ng Cry2.mCh.PKA.W196R.Y204A or Cry2.mCh.PKA.W196R.F327A or 
Cry2.mCh) using the JetPrime transfection reagent (2 μL JetPrime Polyplus reagent: 200 μL 
JetPrime buffer), following the recommended protocol. Three hs post-transfection, cell 
media was changed and the cells were stored overnight, protected from light, in a humidified 
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tissue culture incubator (37 ºC; 5% CO2). The next day, cells were serum starved in PBS for 
15 min in a humidified tissue culture incubator (37 ºC; 5% CO2), and exposed to light (1, 2, 
4, or 8 min; blue LED flood lamp; continuous illumination) or kept in the dark. Forskolin 
treated cells were exposed to 10 μM forskolin for 1, 2, 4, or 8 min. Post-light exposure or 
forskolin treatment, PBS was aspirated, and cells were lysed with 200 μL M-PER 
(ThermoScientific) with 1X Halt Protease and Phosphatase Inhibitor cocktail. Cells were 
lysed in the dark for 4 m at room temperature, prior to transferring to 1.7 mL centrifuge tubes 
and spun 3 m at 1000 x g at 4 °C. 100 μL of each supernatant was then diluted 1:1 with 
Laemmli sample buffer plus BME, and boiled for 5 min at 95 °C prior to analysis by western 
blot. 
Western Blot: Samples (3.6 μg total protein per well) were electrophoresed on a 4-
12% Tris-Glycine gradient gel (Biorad), and transferred to PVDF membrane overnight at 20 
V in a cold room. Membrane was blocked (5% BSA; TBS-Tween) for 1 h prior to overnight 
incubation with α-phospho PKA substrate antibody (Cell Signaling; 9624S), diluted 1:1000 in 
blocking buffer. After overnight incubation, membrane was washed (3 x 5 m; TBS-Tween) 
and placed in secondary antibody (Cell Signaling; 7074P2), diluted 1:3000 in blocking 
buffer, for 2 h at room temperature.  After washing membrane (4 x 5 m; TBS-Tween), blot 
was developed with chemiluminescent substrate (Biorad Clarity Western ECL substrate) for 
5 min prior to imaging. For complete analysis, blots were stripped (Thermoscientific; 
RESTORE buffer) according to package instructions, and re-probed with GAPDH (Cell 
Signaling; 5174S) and mCherry (Abcam; 167453) antibodies. 
Scale-Up of Plasma Membrane Recruitment Using COPE as a Reporter for Proteomics 
Submission 
100 mm tissue-culture dishes at 80-90% confluency were transfected with 5 μg of 
total DNA per plate (1.7 μg Cib.GFP.CAAX; 3.4 μg Cry2.mCh.PKA.W196R.Y204A or 
Cry2.mCh) using JetPrime transfection reagent (10 μL JetPrime Polyplus reagent: 500 μL 
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JetPrime buffer per dish), following the recommended protocol. Four hs post-transfection, 
cell media was changed to DMEM + 10% FBS, and the cells were stored overnight, 
protected from light, in a humidified tissue culture incubator (37 ºC; 5% CO2). The next day, 
cells were serum starved in PBS for 15 min in a humidified tissue culture incubator (37 ºC; 
5% CO2), and then exposed to light (1 min; blue LED flood lamp; continuous illumination) or 
kept in the dark (1 min). Cells were then lysed using 2 mL of M-PER + 1x HALT protease 
and phosphatase inhibitor per plate. Lysates were cleared by centrifugation (5 min; 1000 x 
g; 4 °C), and concentrations determined via Nanodrop. 500 μL of each sample (8 mg/mL 
total protein; in triplicate) was submitted for global phospho-proteomics analysis at the UNC 
Proteomics Core Facility. 
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CHAPTER 3: AN OPTOGENETIC ADENYLATE CYCLASE FOR SPATIAL AND 
TEMPORAL CONTROL OF CAMP MICRODOMAINS 
Introduction 
Studying and understanding the roles of specific, subcellular and suborganellar 
signaling microdomains is important in order to achieve a greater understanding of basic 
biology and disease pathology. For example, several mitochondrial proteins including 
oxidative phosphorylation machinery (nuclear encoded subunits of complex I, II, III, V, and 
others) as well as mitochondrial import machinery such as subunits of the translocase of the 
outer membrane (TOM) complex contain phosphorylation sites in their presequence.[114]  
Phosphorylation of some of the preproteins of the TOM complex by PKA in a cAMP 
dependent manner were found to regulate outer mitochondrial membrane (OMM) import and 
complex assembly[115], and a complex I phosphorylation site exhibited similar function.[116]  
However, none of the functional roles of these other phosphorylation sites have been 
identified, and in one case [117] was dismissed as a “physiological mistake.”  To make 
matters more unclear, none of the specific pools of PKA responsible for the aforementioned 
phosphorylation events on mitochondrial proteins have been identified.    When and where 
do these phosphorylation events occur, and what is the functional outcome of mitochondrial 
protein phosphorylation?
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In order to answer these questions there is a need for tools to manipulate and study 
signaling pathways in a spatial and temporal manner.  Imaging tools such as genetically 
encoded FRET sensors exist and have proven very useful tools to gain an understanding of 
spatiotemporal PKA signaling.  Initially Roger Tsien and Manuela Zaccolo developed cAMP 
FRET sensors based on dissociation of a FRET pair containing PKA catalytic and regulatory 
subunit in response to cAMP.  This approach proved fruitful and a new understanding of 
cAMP microdomains was discovered.[52, 118]  Since then, Jin Zhang has had great success 
with her unimolecular sensors for cAMP (ICUE) and PKA (AKAR) and has been a major 
contributor using these tools to illustrate the spatiotemporal nature of PKA signaling.[54, 118a, 
118b, 119]  However, FRET based biosensors are not trivial to develop or use and do not 
provide localized control over specific signaling microdomains. 
Optogenetic tools provide spatiotemporal control over signaling pathways with 
extremely high resolution in both the time and space domains.  Optogenetics is a young and 
rapidly growing field.  Initially, investigators used chemical and genetic approaches to 
modulate ion channel activity in neurons with light[120] and recently the field has been 
extended to blue light activated adenylate cyclases[121] to investigate Gαs signaling.  
Recently, optogenetic tools have been engineered for spatiotemporal control of the small 
GTPase Rac1[122] and cGMP.[65b]  For a more thorough review of optogenetic technologies, 
please refer to the introductory chapter of this thesis. 
bPAC was identified as small, soluble, highly active in light AC in 2011[65] and was 
shown to be an improvement over larger tetrameric PACs that had been used up until this 
time.[63, 123]  bPAC is composed of an N-terminal Blue Light Using FAD (BLUF) domain and a 
C-terminal type III adenylate cyclase domain.[65]  It has a high ratio of activity in light vs. dark 
and can be expressed in mammalian cells. 
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Due to the need for tools to study and manipulate the cAMP / PKA pathway with 
extremely high temporal and spatial resolution we will engineer bPAC into an optogenetic 
tool which allows for the study of discreet subcellular and suborganellar microdomains of 
PKA signaling with minimally invasive techniques.  We will develop this tool so that 
biologists may use it easily and quickly for their own studies of cAMP / PKA signaling in 
concert with other technologies.  We expect that with tight control over cAMP / PKA 
signaling beyond the resolution limit of light a new level of understanding of a ubiquitous 
signaling pathway and related pathologies can be attained. 
Section 3.1: Generation of a small library of subcellular targeted PACs 
A human codon optimized bPAC gene (Genbank accession number GU461307) was 
synthesized by Genscript.  Five subcellular targeting sequences were identified to provide 
spatial localization and control over PKA activity.  The targeting sequences were designed 
to localize bPAC to the PM [124], CY [125], NU [103], OMM [101], and MM [126], which are all 
specific points of interest for PKA signaling and are outlined in Table 3.1. 
Targeted bPAC constructs were assembled using an array of molecular cloning 
techniques including PCR, site directed mutagenesis, restriction enzyme digestion, and 
ligation.  The initial constructs were developed to be highly modular. Modifying the construct 
to have different subcellular localizations, fluorescent fusion proteins, different linker regions, 
or be utilized with a different expression system would be a simple, efficient process (Figure 
4) so that our group, as well as others might easily modify the tool for a specific application. 
Part of the modular approach was to include a FLAG tag for small epitope labeling and 
Table 3.1    
Localization Source of Sequence Terminus Mode of Localization 
Plasma Membrane Kras CAAX box C Isoprenylation 
Cytoplasm HIV1 Nuclear Export Sequence C 
Export through 
Nuclear Pore 
Nucleus SV40 Nuclear Import Sequence C Import via importins 
Outer Mitochondrial 
Membrane Tom20 OMM Sequence N Transmembrane 
Mitochondrial 
Matrix 
4 X COX VIIIa Matrix 
Localization N Matrix Import Signal 
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affinity purification if necessary.  All constructs were initially cloned into mammalian 
expression vectors under the control of the human elongation factor alpha (EF-1α) promoter 
because it has been demonstrated to express exogenous proteins at more even levels and 
with higher efficiency than traditional CMV promoters.[127]  
All five constructs were cloned and their DNA sequences have been verified (data 
not shown).  Studies to validate subcellular localization were carried out in cos 7 cells and 
Hela cells and show promising results (Figure 3.1).  
 
Section 3.2: Validating light activation of PACs 
We initially used light stimulation followed by Western blot to confirm light dependent 
activity of OMM-AC in transiently transfected HeLa cells (Figure 3.2).  Drp1 and VASP are 
both known PKA substrates that are located in the CY / OMM[128] and CY / focal 
adhesions[98] respectively.  Although they are not necessarily markers of discrete subcellular 
PKA activity due to their mixed subcellular localization, good phospho-antibodies exist for 
them.  Therefore, we used them to show light dependent activation of bPACs.  Both Drp1 
Figure 3.1: Top right shows the design 
of all PAC constructs used and shows 
sources of various targeting 
sequences.  Top left represents the 
modular architecture of our cloning 
strategy such that different PACs can 
be rapidly generated.  The bottom 
panels are representative images of 
PAC constructs expressed in HeLa 
cells. 
 
Figure 3.1: Top right shows the design 
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and VASP were phosphorylated after 30 min of 440 nm light stimulation in transfected cells 
and cells kept in the dark did not exhibit any increase in basal phosphorylation status 
(Figure 3.2).  However, we found that there was a large amount of variability from 
experiment to experiment due to day to day differences in transfection efficiency (data not 
shown).  In order to reduce variability and streamline our experiments (that is, remove the 
time necessary for transfection) we decided to clone the various PAC constructs into a 
lentiviral vector for generating stable expressing PAC cell lines via lentiviral transduction.  
The lentiviral vector that we used was modified from pLL 5.5, a kind gift from Dr. Jim Bear.  
We generated a number of lentiviral transduced cell lines with OMM, PM, Nu, and MM-AC 
constructs.  We initially used rat2 FP4-mito and FP4-CAAX cell lines, gifts from Dr. Jim 
Figure 3.2: Drp1 (top right) and VASP (top left) are both phosphorylated by PKA after 30 
min of OMM-AC activation.  The bottom panel represents a Western blot of these results.  
Both Drp1 phosphorylation and VASP phosphorylation is significant relative to non-
transfected (no treat) cells and transfected cells in the dark (one way ANOVA; P < 0.01) 
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Bear, that use OMM and PM targeted VASP binding domains from Listeria to sequester 
VASP to discrete subcellular locations.[98]  After transduction, we sorted cells via FACS in 
order to generate a pure population of PAC expressing cells (Figure 3.3). We also 
transduced and purified MVD7 cells (see Section 3.5).  We reasoned that we could use the 
rat2 FP4 cells as reporters for localized PKA activity due to the fact that endogenous VASP 
was localized to the PM and OMM and that VASP not only has good antibodies against the 
PKA phosphorylation site at Ser 157, but also undergoes an electrophoretic mobility shift 
from 46  50 kDa upon phosphorylation at Ser 157 (Figure 3.4).  We reasoned that, for any 
given substrate of PKA, there would be a dose response curve for phosphorylation in 
response to increased cAMP production.  If the substrate is located proximal to the source 
of cAMP, the dose response curve should shift to the left, and if the substrate is located 
distal to the cAMP source, the dose response should be shifted to the right (Figure 3.5). 
 Therefore, we took rat2 FP4-mito (OMM-VASP) cells co-expressing either MM-AC, 
Nu-AC, or OMM-AC and subjected them to increasing numbers of 5 s pulses of blue light at 
either 100% or 50 % LED power.  Our results were promising in that after 2 pulses of light in 
the 100% LED power group, we observed a phosphorylation of OMM-VASP only when the 
OMM-AC is activated, but not MM-AC or Nu-AC.  However, with increasing light dosage, 
Nu-AC is able to induce phosphorylation of OMM-VASP.  None of the light treatments 
induces a change in VASP phosphorylation in cells expressing MM-AC, which served as a 
control because the mitochondrial matrix should not communicate with cytoplasmic 
compartments directly via cAMP.  The effect of signal segregation was enhanced when we 
decreased the LED power to 50% (Figure 3.5).  We did not, however, observe similar results 
when we attempted to reverse the experiment and look at whether or not PKA activity was 
localized using rat2 FP4-CAAX (PM-VASP) cells (data not shown).  Further investigation 
revealed that VASP sequestered to the PM existed in its basal state at around 50% 
phosphorylation, and in cells expressing AC’s, the levels of basal PM-VASP phosphorylation 
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increased to nearly 60% (Figure 3.6).  The fact that PM-VASP is highly phosphorylated in 
resting cells results in a small dynamic range for our assay that is saturated after a single 
pulse of light (Figure 3.6).  Therefore we decided to pursue another route generating and 
utilizing the VASP reporter detailed in section 2.3. 
 
Figure 3.3: rat2 FP4-mito cells transduced with lentivirus containing Nu-AC before (left) 
and after (right) FACS. 
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Figure 3.4: Dose response curve for forskolin induced VASP phosphorylation.  
VASP undergoes an electrophoretic mobility shift upon phosphorylation by PKA at 
Ser 157 (top), and is quantified (bottom).  Data is represented as mean +/- SEM. 
N = 3 
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Figure 3.5: Graphical illustration of our hypothesis that targeting PACs in close proximity 
to PKA substrates will shift the cAMP induced PKA phosphorylation of said substrates to 
the left of a non-targeted PAC and that tethering PACs distal to PKA substrates will shift 
the dose response to the right such that there is a light dose that confers site specific PKA 
activity (top).  The bottom panels illustrate a light dependent dose response (lightration) of 
PKA mediated VASP phosphorylation in rat2 FP4-mito cells at 100 % (left) and 50 % (right) 
LED power.  
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Section 3.3:  Quantifying light induced cAMP production by PACs in MVD7 cells. 
 We were aware that PACs expressed in mammalian cells are active and capable of 
inducing PKA mediated phosphorylation of substrates, but we had not quantified cellular 
activity of the PACs themselves.  Therefore, we performed a light experiment to quantify the 
amount of cAMP produced after a single, 10 s pulse of blue light.  We found, via a cAMP 
enzyme linked immuno-assay (EIA), that the OMM-AC appears to produce nearly twice as 
much cAMP in response to the 10 s pulse of light than either Nu-AC or PM-AC (Figure 3.7).  
One possible explanation is that the OMM-AC is simply more active than the Nu or PM-AC.  
The targeting sequences for the Nu and PM are C-terminal targeting sequences while the 
OMM targeting sequence is on the N-terminal of the construct.  The C-terminal domain of 
bPAC requires dimerization for activity.  Therefore, the observed reduced cAMP production 
in the Nu and PM cellular compartments is due to steric hindrance at the C-terminus of the 
protein.  A second possibility is that PDE activity in the Nu and PM is twice that of activity at 
the OMM.  Indeed, the primary PDE isoforms at the Nu and PM are part of the the PDE4 
Figure 3.6: rat2 FP4-mito cells do not show an increase in basal VASP phosphorylation in 
the presence of at the OMM, but rat2 FP4-CAAX cells do show an increase in basal VASP 
phosphorylation under the same conditions (left).  When VASP is sequestered to the PM 
(rat2 FP4-CAAX cells) it is highly phosphorylated at Ser 157 in the resting state (left) thus 
resulting in a small dynamic range for our VASP assay relative to when VASP is at the 
OMM (rat2 FP4-mito) (right). 
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family, which are regulated by PKA dependent phosphorylation and therefore activated upon 
increases in intracellular cAMP.[129]  At the OMM, the primary PDE isoform is PDE2A, a 
cyclic guanosine monophosphate (cGMP) activated cAMP hydrolyzing PDE.[129]  If cGMP 
levels are low, then PDE2A might not be particularly active, which may explain the 
difference in cAMP generation that was observed.  In order to test this hypothesis, we will 
repeat the cAMP EIA experiments in MVD7 cells with bPAC at the Nu, PM, and OMM in the 
presence of 1) specific PDE4 inhibitors such as rolipram and 2) PDE2A specific cGMP 
analogues (5,6-DM-cBIMP or 5,6-DCl-BIMP[130]).  If my hypothesis about the role of localized 
PDE isoform activity is correct, then we expect to see cAMP generation by Nu or PM-AC, in 
the presence of rolipram, approach that of the OMM-AC. In addition cAMP generation by 
Figure 3.7: We measured cAMP generation in WT MVD7 cells and cells expressing 
OMM, Nu, or PM-AC after a 10 s pulse of blue light by EIA. 
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OMM-AC should decrease to levels comparable to Nu and PM-AC upon activation of 
PDE2A.   
Section 3.4: Investigating subcellular PAC activity in MVD7 cells with the VASP 
reporter  
As mentioned in Chapter 2, MVD7 cells are a mouse embryonic fibroblast cell line 
that lacks the three VASP family member proteins Ena, Mena, and VASP.  Therefore, this is 
an ideal cell line to use in conjunction with our VASP reporter.  The reporter can be used for 
microscopy in this MVD7s as there is no background VASP for the commercially available 
phospho-VASP antibodies to bind (Figure 3.8).  In addition, the reporter transfects and 
expresses with high efficiency making it highly amenable to Western blot analysis.   
Given that we have never observed PKA activity in the MM (assayed via reporter 
phosphorylation, see figure 2.6) we focused on cAMP signaling at the OMM, PM, and Nu.  
We hypothesized that investigating the effects of a single pulse of light on PAC mediated 
cAMP production and subsequent PKA activation might provide a route to spatial 
segregation of subcellular cAMP signals and also reveal interesting subcellular PKA 
dynamics.  Our initial studies used a single 10 s pulse of 440 nm LED light followed by 
fixation with paraformaldehyde at specific intervals after the light pulse.  We used semi-
quantitative fluorescent microscopy to quantify results.  Reporter phosphorylation was 
Figure 3.8: General scheme (left) for VASP reporter experiments in MVD7 cells and an 
example of what the images look like (right). 
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quantified by determining the ratio of phospho-VASP Ser 157 antibody labeling to CFP 
fluorescence.  The results are promising (Figure 3.9) and revealed that a 10 s pulse of blue 
light is sufficient to induce PKA dependent phosphorylation of the OMM-reporter regardless 
of the location of the PAC.  However, when the reporter is in the Nu, PAC activation results 
in lower levels of reporter phosphorylation.  
Following these initial immunofluorescent studies, we tested whether we could 
monitor reporter phosphorylation by Western blot in single light pulse excitation 
experiments.  Western blot analysis allowed for higher throughput than immunofluorescence 
because, for each sample, there is a single signal that is the average of all of the cells in the 
lysate as opposed to measuring the phosphorylation level of the reporter in individual cells 
via immunofluorescence.  We transfected WT, OMM-PAC, and Nu-PAC MVD7 cells with 
OMM-reporter and exposed the cells to a single 10 s 440 nm light pulse.  Cells were lysed in 
urea lysis buffer (8 M urea, 4 % CHAPS, 1 mM DTT, 25 mM Tris pH 8) in order to denature 
and deactivate the PAC.  Western blots revealed a time dependent phosphorylation of the 
Figure 3.9: Examples of single excitation experiments in MVD7 cells.  The OMM-reporter 
is rapidly phosphorylated in response to PAC activation regardless of localization (left) 
while the Nu-reporter shows slight phosphorylation in response to OMM-AC activation 
(middle).  The experimental outline is on the right. 
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reporter that reached its maximum between 30 and 60 s and decayed to nearly basal levels 
by 300 s.  The phosphorylation event is inhibited by the PKA inhibitor H89 (Figure 3.10).  
10 s of light stimulation resulted in cross talk between all cellular compartments 
tested in PAC expressing MVD7 cells.  Therefore, we set out to do a series of “lightrations” 
to determine optimal light doses for spatial segregation of cAMP/PKA activity.  We varied 
duration, intensity, and wavelength of a single light pulse and found that the response could 
be tuned by decreasing the duration or intensity of the stimulus from 10 s or stimulating the 
PACs with longer wavelength (LEDs with peak emission at 525 nm).  However, we were 
never able to define light doses that stimulated PKA dependent reporter phosphorylation at 
a proximal location but not a distal location (ex: OMM-PAC/OMM-reporter vs. OMM-
PAC/PM-reporter) (Figure 3.11). 
We am able to observe a robust kinetic response in reporter phosphorylation in 
response to light stimulation. However, in the MVD7 cell model (unlike, the rat2 FP4-mito 
cells) cAMP signals are not sequestered to their respective subcellular compartments as 
indicated by increases in reporter phosphorylation when the reporter is at a different 
subcellular location than the PAC (e.g. OMM-reporter and PM-AC). All of the cellular 
Figure 3.10: Illustrates that we can perform single excitation experiments in MVD7 
transfected with VASP reporters via Western blot.  Ratiometric imaging of a blot is shown 
on the left (ratio = phospho-VASP signal / HA-tag signal) and quantitation on the right. 
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compartments that we are investigating are open to the cytoplasm and cAMP can 
presumably diffuse from one compartment to the other.  Phosphodiesterases (PDEs) are 
responsible for hydrolyzing free cAMP and act as negative regulators of cAMP signaling.  
Interestingly, when we plot the results from single light pulse excitation experiments 
at the OMM and PM using all possible combinations of the OMM and PM-PACs and 
reporters and a 1 s 440 nm stimulus, we see that the maximal level of OMM-reporter 
phosphorylation is halved when the PAC is at the PM vs. the OMM.  However, when we 
reverse the experiment and look at PM-reporter phosphorylation when the PAC is at the PM 
or OMM we see similar levels of reporter phosphorylation (Figure 3.12).  This may be 
evidence of unidirectional communication between cellular compartments.  That is to say, 
the OMM may communicate with the PM freely, but the PM may only communicate with the 
OMM when sufficient cAMP signal is present.  In addition, basal PKA activity at the PM is 
Figure 3.11: Representative graphs of lightration experiments.  Note that the basal levels 
of reporter phosphorylation is much higher in PM-reporter experiments than OMM-reporter 
experiments and that there is far more variability in basal levels of PM reporter 
phosphorylation. 
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significantly higher than at the OMM (Figure 3.12).  Taken together, this data suggests that 
PKA signaling might be primed at the PM by the presence of cellular “noise” and that it may 
be regulated by spatially distinct PDE isoforms (Figure 3.12).  In order to test this 
hypothesis, we reran each combination of PAC and reporter in the presence of 10 µM IBMX 
(incubated 2 min prior to light stimulation).  Indeed, regardless of PAC or reporter 
localization, an increase in reporter phosphorylation is observed, and importantly, when PM-
AC and OMM-reporter is stimulated in the presence of IBMX, the magnitude of reporter 
Figure 3.12:  Left) Outlines the experimental design and results from a 1 second pulse of 
440 nm light on MVD7 cells with PACs and reporters at indicated locations.  N = 3 
independent runs for each sample. Top right) Highlights the difference in basal 
phosphorylation status of the PM and OMM-reporter in MVD7 cells.  Bottom right) Denotes 
the current hypothesis that there is a large wall of PDE activity that blocks the “primed” 
cAMP/PKA signaling at the PM from affecting the rest of the cell during resting period.  
Therefore, only upon integration of sufficient signal would the cAMP/PKA activity at the PM 
be allowed to affect the rest of the cell. 
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phosphorylation is restored to that of OMM-AC/OMM-reporter suggesting that PDEs may 
play a role in regulating cAMP diffusion from the PM to the OMM in our experimental model 
(Figure 3.13).  The roles of PDE activity in spatial regulation of cAMP signaling in this model 
will be investigated by targeting subcellular specific PDE isoforms with commercially 
available, isoform specific, inhibitors.  We will probe the effects of PDE4 activity (widely 
distributed), PDE4D activity (nuclear), and PDE2 activity (mitochondrial) in our model using 
the isoform specific inhibitors rolipram, GEBR-7b, and EHNA respectively. 
Section 3.5: PKA dynamics in the nucleus via long term stimulation of PACs 
 In addition to single excitation experiments, we have also investigated the effects of 
long term light activation of PACs on reporter phosphorylation.  In these experiments, we 
have focused on PKA signaling in the nucleus.  A literature review of PKA spatial and 
temporal dynamics revealed that the temporal domain of the OMM, PM, and cytoplasm are 
on the order of 0.5 – 5 min whereas Nu temporal signaling requires 5 – 20 min (Table 3.1).  
Figure 3.13: pan-PDE inhibition via IBMX (orange trace) results in an increased magnitude 
of reporter phosphorylation relative to no IBMX (blue trace regardless of PAC or reporter 
location.  
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The reported values in the literature are supported by our own data indicating the 
requirement of sustained cAMP signaling and nuclear translocation of the catalytic subunit 
for nuclear activity (Figure 3.15).  Therefore, we reasoned that we should see Nu-reporter 
phosphorylation upon sustained activation of PACs.  To test this hypothesis, we stimulated 
MVD7 cells expressing Nu, OMM, and PM-AC as well as the Nu-reporter with 10 s pulses of 
light every 30 s for 0, 1, 5, 10, and 20 min.  Interestingly, the only PAC to induce an increase 
in Nu-reporter phosphorylation over time is OMM-PAC (Figure 3.14).  However, upon 
repeating the experiment in the presence of IBMX, all PACs are capable of stimulating Nu-
reporter phosphorylation (Figure 3.14), which supports the hypothesis that PDE activity is 
the primary molecular mechanism of regulating spatial cAMP activity in our model.  These 
experiments will be repeated in the presence of PDE isoform specific inhibitors in order to 
determine whether we can identify specific PDE isoforms responsible for nuclear cAMP 
signaling.   
While we are not seeing the clear spatial segregation of cAMP signaling that was 
initially anticipated, the experiments outlined above are revealing interesting roles for the 
regulatory networks that control spatial and temporal cAMP/PKA signaling.  We will continue 
to investigate the roles of PDEs in spatial cAMP signaling as outlined above and will 
investigate the roles of phosphatases in the presence of isoform specific inhibitors.  
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Section 3.6: Discussion: towards spatial segregation of subcellular cAMP and 
biological studies utilizing PACs 
 While we are not seeing the clear spatial segregation of cAMP signaling that we 
initially hoped to control, the experiments outlined above are revealing interesting roles for 
regulatory networks in controlling spatial and temporal cAMP/PKA signaling.  We will 
continue to investigate the roles of PDEs in spatial cAMP signaling as outlined above and 
will investigate the roles of phosphatases as well using isoform specific inhibitors.   
Using this approach we should be able to define what the limiting step is for 
segregation of cAMP in cellular compartments. Regardless of the mechanism, we will 
continue work to increase spatial segregation of cAMP production in order to truly control 
Figure 3.14: OMM-PAC can signal to the nuclear reporter in MVD7 cells under resting 
conditions, but pan-PDE inhibition via IBMX results in an increased magnitude of reporter 
phosphorylation regardless of PAC location in long term experiments investigating 
cAMP/PKA temporal dynamics in the nucleus. 
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subcellular cAMP localization. If the current approach does not work, there are a number of 
reported point mutations in PAC that reduce activity in vitro in different ways. We will start by 
generating the mutants T267G and A277Y, which are known to reduce PAC activity to 1/5 
and 1/3 wild type activity respectively (Table 1.1). Given that expression of PAC at 
subcellular locations is probably higher than endogenous soluble adenylate cyclases, 
reduced activity of PAC may compensate for PDE saturation and thus reveal spatial 
segregation of subcellular cAMP/PKA signaling. 
Through a combination of adjusting light dose and tuning PAC activity via single 
amino acid mutations we should be able to develop these PACs into tools that provide high 
spatial resolution in terms of cAMP generation. These optogenetic tools should prove useful 
for investigating the roles of specific intracellular pools of cAMP at the OMM, Nu, and PM.  
With these three tools, we will be able to begin decoding the roles of cAMP/PKA on 
mitochondrial function and neurodegenerative disorders. 
 cAMP/PKA signaling is known to regulate many processes at the OMM, but it is 
unclear if the cAMP signal is coming from the OMM itself or PM/cytoplasm regulated 
signaling elements such as GPCRs. Therefore, we will use the OMM-AC tool that we have 
created to investigate the roles of cAMP at the OMM.  Mitochondria are dynamic organelles 
that divide, fuse, and are transported throughout the cell.  cAMP/PKA signaling is widely 
recognized as one of the central pathways to regulate mitochondrial dynamics.[27b, 95, 131]  
PKA activity directly inhibits the pro-fission activity of the large GTPase Drp1 and has been 
reported to phosphorylate a number of proteins at the OMM and intermembrane space 
implicated in fission and fusion.[131-132]  PKA activity at the OMM is generally accepted to 
promote mitochondrial fusion.[128]  The roles of cAMP/PKA in mitochondrial trafficking are not 
well understood.  Calcium signaling is an important regulator of mitochondrial trafficking.  
The primary mitochondrial motor proteins, Miro and Milton, are negatively regulated by 
calcium.[133]  That is to say, increased levels of intracellular calcium decreases mitochondrial 
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motility via direct inhibitory activity on Miro and Milton.  In addition, PKA was recently 
reported to promote mitochondrial calcium efflux via direct phosphorylation of the NCLX 
calcium efflux channel at the OMM.[134]  Therefore, we hypothesized that PKA regulates 
mitochondrial trafficking via post-translational modification of NCLX at the OMM such that 
increased PKA activity leads to increased calcium efflux and thus decreased mitochondrial 
motion due to inhibition of mitochondrial motor proteins Miro and Milton.  In order to test this 
hypothesis, we decided to perform an exploratory experiment measuring mitochondrial 
motion in A10 rat smooth muscle cells expressing OMM-AC.  we chose to use smooth 
muscle cells as work from Sieck and colleagues has shown that environmental agents effect 
mitochondrial trafficking in airway smooth muscle cells.[135]  Images of mitochondria were 
acquired every 30 s for 30 min under non-PAC activating (559 laser only), PAC activating 
(488 + 559 nm laser), or PAC activating with PKA inhibitor H89 conditions.  Interestingly, 
mitochondrial motion decreased upon activation of OMM-PAC with 488 nm laser light, and 
the decrease in motion was mostly blocked by the inclusion of the PKA inhibitor H89 (Figure 
3.15).   
Figure 3.15: OMM-AC activation via 488 nm light decreases mitochondrial motion in A10 
smooth muscle cells in a PKA dependent manner.  The left shows the relative change over 
time in mitochondrial motion while the right panel illustrates the change in rate of motion 
via slope.  Mitochondrial motion was quantified by creating binary images of mitochondria 
and applying the function: (In - In+1)/I1 where In = binary image n.  
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 Finally, we have made an interesting observation regarding PKA signaling in the Nu.  
No combinations of PAC with Nu-reporter elicit a response in reporter phosphorylation in the 
nucleus. 8BrcAMP does not elicit phosphorylation of Nu-reporter either, but forskolin does.  
PKA signaling is known to take place in the nucleus and regulate expression of cAMP 
responsive genes.[136] There have been a number of studies in the literature that argue for 
multiple modes of regulation of nuclear cAMP/PKA signaling. For example, the catalytic 
subunit of PKA diffuses into the nucleus from the cytoplasm to phosphorylate substrates in 
response to cytoplasmic cAMP.[137] However, other studies revealed that the nucleus 
contains a pool of PKA holoenzyme.[119e] In addition, a very recent report points to 
endosomal pools of cAMP signaling and PKA acting at the nucleus after receptor 
internalization.[85] It is still unclear as to the exact mechanism of PKA signaling in the 
nucleus.  In exploratory experiments, we observed that the Nu-reporter was phosphorylated 
only by forskolin and not by 8BrcAMP or a 10 s light pulse, as noted above, and that 
forskolin treatment for 30 min resulted in a measurable increase in the nuclear: cytoplasmic 
ratio of the PKA catalytic subunit in Nu-AC expressing MVD7 cells (Figure 3.16). Although 
we now know that a single 10 s light pulse is not sufficient to induce PKA signaling in the 
Nu, the fact that one cAMP agonist (forskolin) promotes nuclear translocation of the C 
subunit while the other doesn’t (8BrcAMP) suggests that 1) there is no intranuclear pool of 
PKA holoenzyme and 2) activation of tmACs via forskolin promotes signaling to the nucleus 
but direct activation of PKA by 8BrcAMP does not.  This observation is also supported by 
some of my results from long term light experiments outlined in Figure 3.14.  Activation of 
PM or Nu-AC does not result in Nu-reporter phosphorylation.  If PKA holoenzyme is present 
in the Nu, then we would expect it to be activated upon both short, and long-time activation 
of Nu-AC given the timescales of PKA signaling in Table 3.1.  Results from the PM-AC 
experiments also suggest that there is a more complex interplay between activation of 
tmACs and subsequent Nu signaling because PM-AC activation over time results in no Nu-
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reporter phosphorylation, but direct pharmacological activation of tmACs does.  We will 
continue to investigate this conundrum in the future, perhaps be associating PACs with the 
specific AKAPs involved in known signaling pathways that induce Nu PKA activity. 
 
Section 3.7: Materials and Methods 
Cloning of PAC constructs into mammalian expression vectors 
cDNA encoding humanized bPAC was synthesized by GenScript.  bPAC was initially 
fused to the 5’ end of mCherry via a 15 amino acid GGS linker by splicing by overlap 
extension (SOE) PCR using Pfx polymerase (Life Technologies).  The 3’ primer contained 
an EcoRI restriction site and the 5’ primer contained a BamHI site.  The resulting PCR 
product was ligated between the EcoRI and BamHI sites in the pEF1α plasmid (Clontech).  
The construct included the 3’ fused mCherry and a 5’ FLAG tag (encoding the sequence: 
DYKDDDDK) epitope yielding an untargeted PAC.  The construct was modified by 
appending a Tom20 mitochondrial localization sequence (MLS) onto the 3’ end of the DNA 
by SOE PCR.  In order to generate a modular gene that was easily modified, we introduced 
Figure 3.16: Left: Images of PKA catalytic subunit, Nu-PAC, Nu-reporter, and phospho-
reporter in MVD7 cells in response to: Light (10 s 440 nm), 8BrcAMP (1 mM 30 min), 
Forskolin (100 uM 30 min).  Right: Quantitation of nuclear / cytoplasmic ratio of PKA 
catalytic subunit fluorescence in NuPAC MVD7 cells.  Data expressed as mean +/- the 
SEM N = 10 – 20 cells.  Asterix denotes significant difference as determined by one-way 
ANOVA (P < 0.05) 
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a KpnI site between the MLS and mCherry and a SpeI site between mCherry and the 
flexible linker by site directed mutagenesis (QuikChange II, Agilent Technologies).  The 
Tom20 MLS was replaced by either an AKAP1 OMM-MLS[138] or a 4X repeat of the CoxVIII 
MM-MLS to yield a different method for targeting the OMM as well as a construct localized 
to the MM.  Nu and PM associated PAC constructs were generated by appending an SV40 
nuclear localization sequence or CAAX sequence, respectively, by primer extension PCR 
using the untargeted PAC construct as a template.  All restriction enzymes were purchased 
from New England Biotechnologies and all primers were purchased from IDT.  All constructs 
were characterized by restriction digest and subsequent sequencing (Genewiz).  Expression 
protein products were characterized by Western blot using an anti-mCherry antibody 
(abcam). 
Cloning PAC into lentiviral vectors 
Lentiviral vectors containing cloning sites under the control of the MCSV 5’ long 
terminal repeat (LTR) promoter (for moderate expression levels) were obtained as a gift 
from Dr. James Bear.  The vector pLL5.5 (Figure 3.17) was modified to suite our needs by 
removing the internal ribosomal entry site (IRES).  First, the IRES and second cloning site 
(MCSII) were removed by restriction digest at the BamHI and SbfI restriction sites and blunt 
ends were created by filling in the 3’ overhang at the BamHI site and removing the 5’ 
overhang at the SbfI site with T4 DNA polymerase (New England Biotechnologies).   Finally, 
Figure 3.17: Schematic representation of pLL 5.5. 
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the blunt ended linear DNA was ligated with T4 DNA ligase (New England Biotechnologies) 
and confirmed by sequencing.  PAC constructs were cloned between the EcoRI and BamHI 
sites of the newly created lentiviral expression vector by restriction digest and ligation.   
Lentiviral packaging  
Low passage HEK 293T cells were plated in 10 cm dishes and transfected with 
plasmids encoding RSV-REV, VSVG, G/P, Citron, and the lentiviral donor plasmid at a 
1:1:1:1:1 ratio for a total of 20 µg DNA per plate using JetPrime transfection reagent 
(PolyPlus) overnight in DMEM + 10% FBS + 1X GlutaMax (Gibco) + 1X pen/strep (Gibco).  
The following day, media was exchanged for fresh media.  24 hs later, the supernatants 
were collected and viral titer was confirmed via lenti-go stix (Clontech).  Viral supernatants 
were aliquoted and stored at -80 ºC. 
Generation of stable, PAC expressing rat2 and MVD7 cell lines 
Rat2 or MVD7 cells were plated in 6 well dishes at 100,000 cells per well and 
allowed to incubate overnight.  The cells were infected with viral supernatants containing 
various PAC genes at varying ratios of supernatant to media in the presence of 4 µg/ml 
polybrene (Sigma) overnight.  The infection mixture was removed and the cells were 
trypsanized and reseeded in larger plates.  An aliquot of cells from each infection was plated 
on Mattek glass bottom dishes and monitored via fluorescent microscopy for expression of 
the mCherry-PAC gene products and subcellular localization.  For the OMM targeting PAC 
constructs we used the AKAP OMM-MLS because the Tom20 OMM-MLS did not localize to 
mitochondria in lentiviral vectors.  Once the cells in large plates (T-75s) were confluent, we 
sorted and purified them using FACS.  The resulting pure, PAC expressing cell lines were 
used in all subsequent experiments. 
Determining subcellular localization of PAC constructs 
HeLa cells were plated on 35 mm glass bottom dishes (MatTek) and transfected with 
2 µg/well OMM, PM, Nu, or MM-PAC in the pEF1α vector at a 2:1 ratio with JetPrime 
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transfection reagent.  Cells were incubated with transfection mixture for 3 hs in complete 
media before media exchange.  The following day, the cells were stained with 50 nM 
MitoTracker Deep Red (Molecular Probes) and 1 µg/ml Hoescht 33342 (Molecular Probes) 
in complete media for 30 min before being extensively washed.  Imaging media (Lebowitz L-
15, Gibco) was added to the dishes and the cells were imaged on our confocal microscope 
(see imaging in Chapter 2 methods). 
Drp1 and VASP phosphorylation experiments 
HeLa cells were plated in 6 well plates and transfected with 2 µg/well OMM-PAC in 
the pEF1α vector at a 2:1 ratio with JetPrime transfection reagent.  Cells were incubated 
with transfection mixture for 3 hs in complete media before media exchange.  24 h later, 
cells were treated with either 500 µM CPT-cAMP (Sigma) or 440 nm light for 30 min at room 
temperature.  The cells were lysed in urea lysis buffer (8 M Urea (Sigma), 4 % CHAPS 
(Sigma), 1 mM DTT (Sigma), 25 mM Tris pH 8.0 (Invitrogen)) for 10 min at room 
temperature in the presence of HALT protease and phosphatase inhibitors (Pierce).  Protein 
content of lysates was quantified with the Pierce 660 nm protein assay and prepared for 
SDS-PAGE.  10 µg of protein was run on 4 – 12% bis-tris gels (Invitrogen) in MOPS-SDS 
running buffer (Invitrogen) and subsequently transferred to PVDF membranes (BioRad) 
overnight at 4 ºC.  The membranes were blocked for 1 h in 5% dried milk in tris-buffered 
saline + 0.1% Tween20 (TBST, Fisher Scientific) at room temperature and incubated with 
primary antibodies (anti-phospho Drp1 S637 and anti-phospho VASP S157, Cell Signaling 
Technologies) at 1:1000 overnight at 4 ºC.  The following day, the blots were washed 3X 
with TBST and incubated with the appropriate horseradish peroxidase (HRP) conjugated 
secondary antibodies at 1:5000 for 1 h before imaging with chemiluminescence.  Blots were 
then stripped with stripping buffer (Pierce) and probed for Drp1 (anti-Drp1, Cell Signaling 
Technologies) or actin (anti-actin, abcam) at 1:1000 followed by secondary and 
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chemiluminescent imaging.  Quantification was performed in imageJ by determining optical 
density. 
VASP gel shift assay 
Cells were plated on dishes and either transfected as described above or treated 
with 100 µM forkolin (Fisher Scientific) for 30 min at room temperature.  The cells were lysed 
with urea lysis buffer and run on either 4 – 12% bis-tris gels in MOPS buffer or 10% tris-
glycine gels in tris-glycine-SDS buffer.  Gels were transferred to PVDF membranes 
overnight.  Blots were probed with anti-VASP antibody (Cell Signaling Technologies) at 
1:1000 overnight at 4 ºC and subsequently with HRP conjugated secondary at 1:5000 for 1 
h at room temperature.  Chemiluminescent imaging was used to image the blots.  
Quantification was perfomed by measuring the optical density of the 50 kD band 
(phosphorylated) and 46 kD band (not phosphorylated) on the blots.  we then determined 
the ratio of phophorylated to total (50 + 46 kD) VASP. 
Rat2 cell experiments 
Rat2 FP4-mito or FP4-CAAX cell lines expressing Nu, MM, or OMM-PAC were 
plated in 6 well plates and allowed to grow overnight.  The following day, cells were exposed 
to 0, 1, 2, 3, 4 or 5 5 s pulses of 440 nm LED light and lysed in urea lysis buffer.  Control 
groups were treated with 100 µM forskolin for 30 min at room tempturate before lysis.  we 
performed the VASP gel shift assay (as described above) for all samples and expressed 
data as the proportion of phosphoVASP / total VASP relative to the forskolin controls. 
cAMP EIA experiments 
WT MVD7 cells and MVD7 cells expressing OMM, Nu, or PM-PAC were plated in 96 
well plates and stimulated with a single 10 s pulse of 440 nm LED light.  The cells were 
lysed in 0.1 M HCl at indicated time points.  The lysates were clarified by centrifugation and 
used in the cAMP EIA assay (Enzo Life Sciences) according to the manufacturers protocol.  
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Protein concentration was determined by Pierce 660 nm protein assay and the results were 
expressed as pmol cAMP / mg protein. 
Immunofluorescent single excitation decay experiments in MVD7 cells 
MVD7 cells expressing OMM, Nu, or PM-PAC were transfected with OMM or Nu-
reporter at 2 µg / ml using JetPrime.  The following day, the cells were exposed to a single 
10 s pulse of 440 nm blue LED light and fixed at indicated timepoints, or treated with 100 µM 
forskolin for 30 min at room temperature as a control.  The cells were fixed in 4% PFA in 
PBS for 10 min at room temperature.  After fixing, the cells were briefly washed and blocked 
for 1 h at room temperature in blocking buffer and immediately placed in antibody buffer 
containing anti-phospho VASP S157 (mouse, abcam) at 1:100.  Primary antibody was 
incubated with cells overnight at 4 ºC.  The following day, cells were washed 3X with PBS 
and incubated for 1 h at room temperature in blocking buffer containing anti-mouse alexa 
fluor 647 (Molecular Probes) at 1:1000.  The cells were washed again and then imaged on 
the widefield microscope (see materials and methods, Chapter 2).  In order to quantify the 
images, the fluorescent intensity of alexa fluor 647 was divided by the intensity of the 
reporter (CFP) providing a ratio of phosphorylated reporter to total reporter.  10 – 20 cells 
per time point were counted and intensities were expressed relative to forskolin controls as 
mean +/- SEM. 
MVD7 single excitation decay experiments and lightration 
OMM and PM-PAC expressing MVD7 cells were plated on 6 or 12 well plates and 
grown overnight.  The following day, the cells were transfected with either OMM or PM-
reporter for 3 hs using JetPrime transfection reagent.  24 hs later, the cells were exposed to 
a single pulse of light and lysed in urea lysis buffer.  Lysates were run on 4 – 12% bis-tris 
gels in MOPS buffer and transferred to PVDF membranes as described above.  Western 
blots were then probed for reporter phosphorylation as described in Chapter 2 materials and 
methods.   
89 
 
For lightration experiments, the light sources used were: 440 nm LED at 100% power 
for 10 and 1 s, 50% for 1 s, 30% for 2 s, or 525 nm LED for 10 s or 5 s at 100% power.   
The experiments outlined in Figures 3.12 and 3.13 used a single 1 s pulse of 440 nm LED 
light at 100% power. Figure 3.13 included 10 µM IBMX. 
MVD7 long term illumination experiments 
MVD7 cells expressing Nu, OMM, or PM-PAC were plated on 12 well plates and 
transfected with Nu-reporter as outlined above.  The cells were exposed to 30 second 
pulses of 440 nm light per min for 0 – 20 min in the presence or absence of 100 µM IBMX. 
Cells were lysed in urea lysis buffer and processed for Western blotting as described above.   
Mitochondrial motion experiments 
A10 rat smooth muscle cells were plated on 35 mm glass bottom dishes as 
described above.  The cells were transfected with OMM-PAC in the pEF1α vector as 
described previously.  24 hs after transfection, media was replaced with imaging media 
(Lebowitz L-15 + 10% FBS) and placed at 37 ºC in the humidified chamber on our confocal 
microscope.  Images were captured at a rate of 1 frame / min for 15 min with the 559 nm 
laser only (to image mCherry at the OMM) and then 1 fram / min for 15 min with the 488 nm 
and 559 nm laser to activate PAC.  10 µM H89 was used as a control.  Images were taken 
at a 1024 x 1024 resolution with a dwell time of 8 µs / pixel and 5X Kalman averaging.  A 
60X oil objective was used (see materials and methods Chapter 2) and both lasers were set 
to 1% power.    After image acquisition, the images were analyzed by the following 
procedure in imageJ: 
– Background subtraction with 10 pixel rolling ball radius 
– Thresholding with manual adjustments 
– Convert thresholded images to binary masks 
– Run the “open” function on binary masks to clean up 
– Perform the following functions on each image: 
𝐼𝑛−𝐼𝑛+1
𝐼1
  to yield a measure of 
motion between frames. 
– Data was then normalized to t=0 and plotted as mean of 4 cells +/- SEM 
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– Slope was calculated by finding dy/dx for each treatment (frames 1-14 for 559 
only and 16 – 30 for 488 559. 
Nuclear translocation of the C subunit 
Nu-PAC MVD7 cells were plated on glass bottom dishes and transfected with Nu-
reporter as described previously.  Cells were treated with 100 µM forskolin or 1 mM 
8BrcAMP for 30 min at 32 ºC in the dark or exposed to 440 nm light for 10 s before being 
fixed with 4% PFA in PBS for 10 min at room temperature.  The cells were blocked in 
blocking buffer for 1 h at room temperature and incubated with primary antibodies(rabbit 
anti-PKA catalytic subunit, 1:100, abcam, mouse anti-pVASP S157, 1:100, abcam) 
overnight in antibody buffer.  The following day, the cells were washed with PBS an 
incubated for 1 h in blocking buffer containing anti-rabbit alexa fluor 488 and anti-mouse 
alexa fluor 647 (Molecular Probes) at 1:1000 and 1:500 respectively.  The cells were then 
imaged at 60X on the confocal microscope.  In order to quantify the results, a ROI within the 
nucleus was defined and measure for average fluorescent intensity.  Then, the same ROI 
was moved to the cytoplasmic region of cells and measured in a similar fashion.  The results 
are shown as a ratio between the nuclear and cytoplasmic mean fluorescent intensity.  
Results were expressed as mean +/- SEM with an N = 12 – 18 cells and statistics were 
performed using one-way ANOVA on ranks in SigmaPlot. 
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CHAPTER 4: PHOTOCHEMICAL PROTECTING GROUPS AND CELLULAR 
CARRIERS FOR DEVELOPING DRUG DELIVERY PLATFORMS 
Section 4.1: Challenges in drug delivery and the treatment of disease 
Drug discovery and disease treatment in humans is one of the primary goals in 
modern biomedical research.  Indeed, the National Institutes of Health (NIH) requires that 
any grant proposal submitted must have a direct relationship to human health highlighting 
the importance of discovering new mechanisms to treat diseases.  Given that treatment of 
human disease has been a highly active field of study from ancient times to present, why is 
it then, that we have made limited progress in treating the myriad of afflictions (such as 
cancer and neurodegeneration) that effect humans?  The answer can be divided into two 
general arenas: 1) we do not know the mechanism of action of disease or 2) an effective 
therapy has not yet been discovered.  With the advent of modern biomedical research 
including, but not limited to, molecular biology, chemical biology, bioinformatics, genomics, 
and proteomics, we are experiencing a revolution in the rate of discovery in disease 
mechanisms.  However, our ability to treat these diseases has not kept up with our 
understanding of systems, cellular, and molecular mechanisms of pathology.  
A major reason for the discrepancy described above is the fact that humans are 
comprised of an amalgam of eukaryotic cells that all contain the same genome, and thus 
similar biochemical compositions.  Therefore, treatment with a compound that is highly 
effective in vitro and in animal models of disease may not function as desired or may be 
toxic in clinical trials.  Indeed, a study that investigated drug discovery failure rates from 
1992 – 2002 found that 43% of drug discovery projects were terminated in clinical trials due 
to inefficacy and another 33% due to toxicity and adverse reactions in humans.[139]  Many 
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drugs (e.g. chemotherapeutics and steroids) make it to the market despite toxicity due to 
their efficacy.  However, their use is still limited by the extent to which a human can bear the 
adverse effects of their treatment.  A prime example of this is the use of doxorubicin (DOX) 
in the clinic.  Dox is a frontline drug for many cancers.  It has been used as an antineoplastic 
agent for over three decades and is one of the most potent approved chemotherapeutic 
agents.[140]  Unfortunately, DOX lacks specificity in terms of cellular uptake.  Dox is quickly 
absorbed by all cells and interacts with a multitude of intracellular biomolecules.[141] The 
most important of which is intercalation of DNA and subsequent inhibition of topoisomerases 
leading to double strand DNA breaks.[142]  The major dose limiting side effect of DOX 
treatment is cardiotoxicity.  Patients are limited to a lifetime dose of 400 mg/m2 and 
protection against cardiotoxicity and subsequent heart failure is not guaranteed.[143]  There 
have been extensive attempts to curb DOX’s off-target toxicity by varying formulation and 
delivery mechanisms (PEGylation and liposomal delivery respectively).[143]  These 
approaches have improved the therapeutic window for DOX treatment, but cardiomyopathy 
is still a dose limiting side effect.   
DOX is the poster child for drugs that are highly effective, but have a vast array of off 
target toxic effects.  However, there are a number of other drugs and drug like molecules 
that suffer from the same problem.  Dexamethasone (DEX), a glucocorticoid anti-
inflammatory drug, is extremely effective in rheumatoid arthritis, and other diseases, but long 
term exposure to therapeutic doses is associated with a number of adverse side effects.[144]  
Other cytotoxic molecules such as the anti-mitotic auristatins[145] and maytansine[146] 
derivatives and DNA damaging camptothecin[147] and calicheamicin[148] derivatives show 
incredible promise as chemotherapeutic agents, but are so toxic that systemic administration 
is not an option.  All of the aforementioned cytotoxic agents have been covalently linked to 
antibodies in an effort to develop tumor specific antibody-drug conjugates (ADCs), but 
traditional methods of ADC drug release by an acid labile hydrazone or hydrazine linker 
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have proven to be unstable in circulating plasma. Even with the advent of enzyme specific 
cleavable linkers and linkage via disulfide bonds, increased dosage is correlated with 
increased off site toxicity.[149]  For example, a calicheamicin ADC (Mylotarg[150], Figure 4.1) 
was approved for use by the FDA but was subsequently taken off the market when it was 
discovered that the drug increased mortality without increasing efficacy.[151] 
The examples outlined in the preceding paragraphs demonstrate a need for drug delivery 
with high spatial and temporal control.  We have a large number of effective drugs, but they 
are only effective when delivered to the right place and at the right time.  Therefore, we are 
applying our expertise in photochemical protection, sequestration, and release of biologically 
active small molecules to develop drug delivery platforms. Our end goal is to actively deliver 
inactive drugs to our targets of interest with a high degree of spatial resolution and then 
release the active drugs such that there is a high concentration at the site of interest and low 
systemic concentrations of drug. 
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Figure 4.1: Outlines the structure and mechanism of action by which Mylotarg functions.  
Reprinted with permission from publisher.[150] 
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Section 4.2: Photoprotecting groups as a route to spatial and temporal control of 
biological function 
Photochemistry has long been used as a method to induce chemical reactions in 
synthetic chemistry.  The first report of a light induced chemical transformation was by 
Trommsdorff in 1834 when he described that sunlight caused a color change and 
subsequent destruction of α-santonin crystals.[152]  A number of different chemical moieties 
that absorb light and undergo some sort of rearrangement have been used as chemical 
protecting groups since then.  However, it was not until 1978, when Hoffman and colleagues 
appended an ortho-nitrobenzyl moiety to the γ-phosphate of ATP (“caged” ATP) and used 
light to release free ATP and thus activate the Na+/K+ ATPase[153] that photoprotecting 
groups found their way into the world of biological research.   
 Since the advent of caged ATP, a wide variety of photoprotected biomolecules have 
been developed that provide an unprecedented level of spatial and temporal control over 
cellular processes (Figure 4.2).  The ideal caged compound is described as having: 1) a 
high quantum yield (φ, the number of photons required to induce the reaction), 2) high molar 
extinction coefficients (the measure of a molecule’s ability to absorb light of a given 
wavelength) above 300 nm (the lowest cutoff for minimal interaction with biomolecules), 3) 
inactive photochemical byproducts, 4) a photolytic rate faster than that of the process 
studied, 5) biological inertness prior to photolysis, and 6) aqueous solubility.[154]   
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Indeed, the majority of caged compounds fall under these guidelines.  By far, the most 
commonly used photoprotecting group is the ortho-nitrobenzyl moiety.  Cyclic 
nucleotides[155], cell permeable Ca2+ chelators that release Ca2+ upon photolysis[156], steroids 
for manipulating gene expression[157], and a myriad of neurotransmitters[158] have been 
developed and utilized to probe activation of cellular signaling.  In addition, caged 
peptides[159], proteins[159], and nucleic acids[160] have been developed to study intracellular 
signaling and gene expression respectively.  However, the nitrobenzyl photoprotecting 
group has a major drawback: it is activated by ultraviolet (UV) light.  UV light, while useful in 
vitro and in cellulo, does not penetrate tissue and can damage biomolecules such as 
DNA.[161]  As in vivo whole animal studies became more common, it was necessary to 
develop photoprotecting groups that responded to longer wavelengths of light, ideally within 
the optical window of tissue (Figure 4.3).  The optical window of tissue lies between 650 and 
Figure 4.2: A sample of different nitrobenzyl caged biomolecules. 
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1000 nm.[162]  Below 650 nm, light is significantly absorbed by biomolecules and above 1000 
nm, water begins to absorb light and is heated.  
 Some long-wavelength photoprotecting groups have been reported including the use 
of two-photon technology with nitrobenzyl derivatives at 700 nm[163] and single photon 
photolysis of boron dipyrromethene (Bodipy) at green wavelengths (500 – 550 nm).[164]  
However, two-photon imaging requires concentrating photons to the extent that a molecule 
absorbs two photons at the same time and thus, requires an incredibly high photon flux that 
can result in sample heating.  The Bodipy derivatives utilize green light which is red-shifted 
further than nitrobenzyl or coumarin photoprotecting groups, but is still outside the optical 
window of tissue.   
Figure 4.3: The optical window of tissue.  Reprinted with permission from the publisher.[162] 
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 Work by Dr. Shell and Dr. Lawrence investigating the photochemistry of vitamin B12 
(cobalamin, Figure 4.4) found that, through a yet-to-be ascertained mechanism, homolytic 
photolysis of an alkyl axial ligand of the central cobalt atom can be tuned by placing a long 
wavelength fluorophore in close proximity to the cobalamin core (Figure 4.4).[165]  The 
fluorophores act as molecular antennae to transmit the energy from light to cobalamin 
initiating photolysis.  Since the initial discovery that cobalamin photochemistry is tuneable, 
our group has developed a number of technologies including erythrocyte mediated drug 
delivery[166] and long-wavelength polymerization of hydrogels.[167]   
Figure 4.4: Green light (500 – 560 nm) photolyzes the cobalt-carbon bond in the axial 
position on cobalamin (Top).  When a long wavelength fluorophore, such as Cy5, is in close 
proximity to cobalamin (Bottom) the long wavelength energy is transferred to cobalamin 
and induces photolysis.  The red hydroxyl (OH) on the underside ribose can be modified. 
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 Cobalamin is a much larger photoprotecting group than the nitrobenzyl moiety and is 
not cell permeable.   In addition, cobalamin photochemistry at long wavelengths only occurs 
when an alkyl chain is bound to cobalt.  The result is that there is a limitation to the 
functional groups that can be photolytically released. Given that many biologically active 
functional groups are heteroatoms, masking key functionality may be difficult with 
cobalamin.  Indeed, Lawrence and Shell found that cAMP appended to cobalamin via the 8’-
amine is still capable of activating PKA before photolysis despite the steric bulk of cobalamin 
(personal communication).  This did not spell doom of cobalamin as a photoprotecting 
group.  Cobalamin is endosomally taken up into cells in a receptor mediated fashion and is 
spatially sequestered from the cytoplasm.  In addition, we have appended fatty acyl chains 
to the reactive hydroxyl group on the ribose moiety of cobalamin thus furnishing a molecule 
capable of being loaded on the outer leaflet of the PM.[166]  Thus, cobalamin functions as a 
sequestering photoprotective group, which, upon photolysis, liberates a cell permeable small 
molecule of interest.  We are using the sequestering and long-wavelength tuning 
characteristics of cobalamin to develop drug delivery platforms. 
Section 4.3: Erythrocytes and neural stem cells as drug delivery depots 
 Erythrocytes as drug carriers: The primary role of erythrocytes (RBCs) is to deliver 
oxygen to tissues and remove carbon dioxide in order to provide energy and maintain 
homeostasis respectively.  RBCs are anuclear and lack other organelles such as 
mitochondria and the endoplasmic reticulum.  They are primarily sacks of hemoglobin, in 
which hemoglobin constitutes at least 90% of the composition of RBCs.[168]  However, RBCs 
do contain a number of other membrane-bound and cytoplasmic proteins involved in signal 
transduction, glycolysis, structural regulation, and antioxidant activity.[169]  RBCs have a 120 
day life cycle and are highly elastic (average diameter RBC = 5 – 10 µm, diameter of some 
capillaries = 3 – 5 µm).[170]  The long circulation time, relatively simple composition, low 
immunogenicity, and elastic nature of RBCs make them attractive targets as drug delivery 
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vehicles when compared with liposomes or nanoparticles, which are rapidly cleared by the 
kidney and liver[171] and can be immunogenic.[172]   
 Indeed, research on RBCs as drug carriers has been an active field since the 1950s, 
and a number of RBC mediated delivery systems have been developed over the decades 
including small molecule therapeutics, proteins, and diagnostics.[173]  RBCs are amenable to 
two major types of loading of exogenous substances: 1) internal loading of RBCs by 
membrane pore formation in a hypotonic buffer or electroporation and 2) loading of the 
extracellular membrane by covalent modification, antibody recognition, and hydrophobic 
anchoring of lipids to the outer leaflet of the RBC membrane.  Both of these methods has 
resulted in promising therapies in clinical trials for treatment of inflammatory disease and 
cancer.[173]  The main focus of my work with RBCs focuses on lipid-mediated membrane 
loading and will, therefore, not focus on internal loading.  The passages below describe past 
and current efforts in membrane loading of therapeutics on RBCs. 
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 RBC membrane loading with antibody conjugates: RBC membranes are 
composed of proteins, lipids, and carbohydrates.  Proteins and lipids comprise 52% and 
40% of the membrane weight, respectively,[174] thus providing a multitude of potential 
anchors for electrostatic and covalent modification with therapeutics.  One example of RBC 
membrane loading utilized an antibody-enzyme conjugate that binds to glycophorin, a highly 
expressed RBC membrane protein, and contains urokinase, a tissue-type plasminogen 
activator.[175]  The goal of this study was to develop RBC carrier mediated delivery of the 
plasminogen activator to sites of microclots in cerebral ischemia in order to reduce the 
number of clots and restore blood flow to ischemic areas of the brain.  Delivery of bound 
urokinase reduced the number of clots and helped to reduce the effect of local ischemia 
while reducing off-target bleeding that can occur with perfusion of urokinase alone (Figure 
4.5).[175] 
Figure 4.5: A) plasminogen activators (dots) are rapidly cleared by the liver and can be 
unsafe due to dissolution of mural clots and subsequent bleeding.  B) Injection of anti-
glycophorin-urokinase restricts plasmogen activation to RBCs and enhances interactions 
with nascent clots while reducing the potential for off-target interaction with mural clots.  
Reprinted with permission from publisher.[175] 
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 RBC membrane loading by chemical covalent modification and lipids: RBC 
membranes can also be loaded by covalent modification or lipid insertion into the outer 
leaftlet of the PM.  These strategies are advantageous as they provide more permanent 
modifications to the cell and reduce the potential for off-target effects of the antibodies 
themselves.  In addition, these methods are not antigen specific and therefore, can be 
applied to any RBC (or membrane for that matter).  Covalent modification of RBC 
membranes has been achieved through the use of N-ethylmaleimide,[176] N-
hydroxysuccinimide,[177] glutaraldehyde,[178] and cyanuric chloride.[179]  Studies by Scott and 
colleagues used cyanuric chloride to covalently PEGylate RBCs and mask natural RBC 
antigens that define blood type.[179]  By masking these blood type antigens, it is possible to 
use any donor for a blood transfusion thus allowing rapid availability of blood in, for 
example, a combat setting.   
 Lipids are another route to loading RBC membranes with drugs.  RBC membranes 
are composed of 40% lipids which are primarily composed of phosphatidylserine, 
phosphatidylethanolamine, phosphatidylcholine, and sphingomyelin.[174]  The nature of a 
lipid bilayer provides a hydrophilic exterior and hydrophobic interior such that molecules of 
similar structure can freely associate with, and embed in, the membrane.  Lipid targeting of 
compounds to RBC membranes is especially appealing as it does not involve permanent 
chemical modification of any endogenous membrane species and can be applied to a wide 
variety of small molecules that are amenable to modification with lipid tails.  For example, 
our group has published two studies where RBC membranes were loaded with lipidated 
fluorophores and cobalamin-drug conjugates[166] or photolabile peptides[180] in an effort to 
utilize RBC membranes as carriers for spatial and temporal control of drug release.  Chapter 
5 will describe a recently published study using photolabile peptides loaded onto the outer 
leaflet of the RBC membrane as a proof of principle study for temporal release of peptide 
therapeutics.[180] 
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 Neural Stem Cells as homing depots for drug delivery: One of the major 
challenges in treating neural pathology, including neurodegenerative disorders and cancer, 
is the difficulty of delivering therapeutics across the blood brain barrier (BBB).[181]  A number 
of approaches to circumvent the BBB have been developed including direct intracerebral, 
intrathecal, or intranasal injection,[182] carrier mediated transport through natural import 
mechanisms[183], receptor mediated transport[183], or delivery of liposomes/nanoparticles after 
disruption of the BBB.[184]  However, none of these strategies have yet to provide an 
effective method for general delivery of therapeutic agents to sites of brain pathology. 
Aboody and colleagues discovered, in 2000, that neural stem cells (NSCs) migrated 
to established glioblastoma multiforme (GBM) tumors when injected into various regions of 
the brain (Figure 4.6) or tail vein of mice.[185]  In a follow up preclinical trial, Aboody’s group 
injected an engineered NSC line that expressed cytosine deaminase and allowed the NSCs 
to migrate to the tumor.  Then, they treated mice with the pro-drug 5-fluorocytosine, which 
was converted to its active form, 5-fluorouracil, by cytosine deaminase resulting in significant 
increases in event free survival in NSC implanted animals over three months.[186] The 
promise of this therapeutic strategy has culminated into a phase I clinical trial that is 
currently actively recruiting participants (Clinical Trial Identifier: NCT02015819). 
A number of other groups have taken advantage of the fact that NSCs migrate to 
GBM (Figure 4.7) in a chemokine/growth factor dependent manner (Figure 4.8).[187]  One 
approach focuses on delivery of tumor necrosis factor-related apoptosis-inducing ligand 
(TRAILs) which interact with death receptors expressed on the surface of GBM cells paired 
with death receptor sensitizing agents to induce apoptosis.[188]  Others use NSCs that carry 
conditionally replicative adenoviruses to tumor sites and induce adenoviral oncolytic 
activity.[189] Another approach is to load tumor homing NSCs with nanoparticles loaded with 
pH sensitive DOX[190] or gold nanorods for induction of cell death by laser induced 
hyperthermia.[191]  
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While all of the above mentioned approaches hold promise for treating GBM, none of 
them are trivial to engineer and require extensive genetic or chemical engineering efforts to 
develop.  Therefore, we are collaborating with the Hingtgen group at UNC to load our 
cobalamin-drug conjugates onto and into NSCs for targeted phototherapy of GBM.  These 
studies are described in Chapter 6 of my thesis. 
 
  
Figure 4.6: NSCs implanted into sites distal from GBM implants migrate to and interact with 
GBM tumor.  In panels A, B, G, H, I, and J NSCs are blue and GBMs are pink.  In panels C, 
D, E, and F NSCs are shown in red migrating towards the tumor (green).  Reprinted with 
permission from publisher.[185] 
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Figure 4.7: a) Representative drawing of experimental paradigm. b-
e) Real time migration towards tumor by monitoring NSC luciferase 
activity in mice. f) Interactions of NSCs (red) with GBM cells (blue) at 
a central tumor and (g) distal satellite tumors. h) Interactions of NSCs 
with blood vessel.  Reprinted with permission from publisher.[187] 
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Figure 4.8: Various mechanisms of NSC migration to GBMs.  
Reprinted with permission from publisher.[187] 
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CHAPTER 5: THE PLASMA MEMBRANE AS A RESERVOIR, PROTECTIVE 
SHIELD, AND LIGHT-TRIGGERED LAUNCH PAD FOR PEPTIDE 
THERAPEUTICS2 
Section 5.1: Overview 
Although peptide-based therapeutics are finding increasing application in the clinic, 
extensive structural modification is typically required to prevent their rapid degradation by 
proteases in the blood. We have evaluated the ability of erythrocytes to serve as reservoirs, 
protective shields (against proteases), and light-triggered launch pads for peptides. We’ve 
designed lipidated peptides that are anchored to the red blood cell surface, which furnishes 
a protease-resistant environment. A photo-cleavable moiety is inserted between the lipid 
anchor and the peptide backbone, enabling light-triggered peptide release from 
erythrocytes.  We’ve shown that a cell permeable peptide, a hormone (melanocyte 
stimulating hormone), and a blood-clotting agent, can be anchored to erythrocytes, 
protected from proteases, and photolytically launched to create the desired biological effect. 
Section 5.2: Background 
 Peptides enjoy a number of favorable attributes as drug candidates, including high 
potency, selectivity for their biochemical targets, and a modular framework, making them 
amenable to library screening and structure activity relationships (SAR).[192] However, these 
favorable traits are offset by a limited circulation lifespan due, in large part, to rapid 
                                               
2 This Chapter describes work published an Angewandte Chemie and is reprinted with permission from 
the publisher: C. P. O'Banion, L. T. Nguyen, Q. Wang, M. A. Priestman, S. P. Holly, L. V. Parise, D. S. 
Lawrence, Angew. Chem. Int. Ed. 2016, 55, 950, John Wiley and Sons 
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degradation by blood plasma proteases. Massive SAR efforts, along with newer approaches 
(stapling and cyclization),[193] have been required to address the concerns of peptide 
bioavailability and stability.[192, 194]  
 Can human cells be used as carriers of peptide therapeutics? Live cells have 
garnered intense interest as therapeutic agents, including cancer seeking/killing T cells,[195] 
erythrocytes,[196] and stem cells[197]. Patient-derived cell-based therapeutics display a number 
of potentially useful properties, including relatively long in vivo persistence, evasion from 
immune surveillance, and access to specific tissues depending upon cell type. These 
properties could potentially endow hitchhiking peptide drugs with analogous traits, but only if 
the peptide guest can be simultaneously protected from proteolytic degradation. Proteases 
are ubiquitous, inhabiting the intracellular environment of cells, the extracellular matrix of 
tissues, and the blood stream. Assuming a protease-safe zone on the cell carrier can be 
identified, once the cell has reached the intended in vivo destination, the peptide must be 
released from the carrier. We’ve previously shown that fluorescent probes can be anchored 
to intracellular biological membranes and the probes rapidly released, upon photolysis, into 
the cytoplasm.[198] In this regard, the outer leaflet of the plasma membrane offers a number 
of promising features as a reservoir for peptide therapeutics. First, since the majority of 
peptides are not cell permeable, addition to and release from the plasma membrane 
sidesteps the issue of cell permeability. Second, the cell surface is covered by a 
glycoprotein/polysaccharide coat (“glycocalyx”) that could serve as a protective shield 
against extracellular proteases for peptides moored on the cell surface. Indeed, peptide 
carriers that lack a glycoprotein sheath (e.g. liposomes), do not protect peptides from their 
enzyme targets (e.g. protein kinases).[198] We chose erythrocytes as the carrier, given their 
long circulatory lifetime (up to 4 months), their easy acquisition from and introduction into 
patients, and their circulation throughout all regions of the body.[196] The design of 
membrane anchored, photo-releasable, peptides is illustrated in Figure 5.1. Lipidation 
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should anchor the peptide to the cell surface and therefore under the protective umbrella of 
the glycocalyx, whereas insertion of a light-sensitive cleavage site between the lipid anchor 
and the peptide moiety should furnish the desired on-command release of the peptide from 
the cell carrier. 
Section 5.3: Light-triggered release of a cell permeable peptide. 
 Our initial studies focused on 5TAMRA-Aoc-GRTGRRFSY-amide (where 5TAMRA = 
5-carboxytetramethylrhodamine and Aoc = amino octanoic acid, Scheme 5.1), a fluorescent 
cell permeable peptide (Figure 5.2). Analogs of the peptide were prepared that contain an o-
Figure 5.1: A lipidated photocleavable peptide anchored to the surface of a cell carrier and 
positioned within the protective shell of the glycoprotein/polysaccharide coat. Illumination 
at the appropriate wavelength releases the peptide, which is now able to act upon its 
biological target. Image used under license from Shutterstock.com 
Scheme 5.1: Structures of the peptide (1–3) and linker/lipid anchor (4, 5) modules used in 
this study, along with the photocleavable unit dmnb. 
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nitrobenzyl light-cleavable amino acid (φ) inserted between the fluorescent peptide and a 
membrane anchoring lipid moiety. For example, the C-terminal Cys residue in peptide 1 is 
easily attached to the lipidated maleimide 4, to furnish 6 (Figure 3).  A key issue proved to 
be identifying a lipid moiety that stably anchors the peptide to the erythrocyte membrane. 
We addressed this by co-incubating erythrocytes bearing peptide-lipid conjugates with HeLa 
cells. Ideally, the fluorescent peptide should be retained on erythrocytes in the absence of 
photolytic cleavage. By contrast, peptide transfer from erythrocyte to HeLa cell membranes 
in the dark would suggest insufficient membrane retention. Indeed, although attachment of a 
C18 fatty acid to Aoc-GRTGRRFSY-amide furnishes a conjugate that readily binds to 
erythrocytes, this lipid-peptide migrates from erythrocytes to HeLa cells in the dark (Figure 
Figure 5.2: Loading of Ac-Dap(5-TAMRA)-GRTGRRFSY-amide is temperature 
dependent. HeLa cells were loaded with 5 µM peptide and imaged on a widefield 
microscope.  Left: Loading at 4° C for 2 min, imaged with 20X objective. Right: Loading 
at 37 °C for 2 min, imaged with 40X objective. The punctate image on the right implies 
endocytic loading at 37 ˚C. Scale bar is 10 µm. 
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5.3). However, the peptide-lipid conjugate 6, derived from the reaction of 1 with the 
dipalmitoyl derivative 4, is stably maintained on erythrocytes upon dark incubation with HeLa 
cells (Figure 5.4c-e).   
Figure 5.3: Dark transfer of stearoyl-dmnb-Dap(TAMRA)GRTGRRFSY-amide from 
erythrocyte to HeLa cell membranes. HeLa cells were incubated with stearoyl-dmnb-
Dap(5-TAMRA)GRTGRRFSY-amide loaded erythrocytes at 37 °C for 15 min with and 
without UV photolysis and imaged on a widefield microscope with a 40X objective Top: 
Fluorescent 5-TAMRA images. Bottom: Transmitted images. Left: No erythrocytes. Middle: 
No photolysis. Right: 5 min UV photolysis. Scale bar is 10 µm. 
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 The peptide-lipid conjugate 6 was anchored to the surface of hemoglobin-depleted 
erythrocytes via brief incubation, followed by centrifugation and washing of the erythrocyte 
pellet. Approximately 2x105 – 2x106 molecules of 6 are bound per erythrocyte (Supporting 
Information). Erythrocytes containing 6 were separately exposed to trypsin and 
Figure 5.4: Erythrocytes/6 imaged on a confocal microscope at 40X (a) 
before and (b) after photolysis and co-cultured (c-k) with HeLa cells. 
Erythrocytes/6 were co-cultured with HeLa cells in the dark (c - e) and 
exposed to 360 nm (f - h; i - e). Hoechst nuclear stain was used to 
differentiate HeLa cells from erythrocytes. Fluorescence of 6 is shown in red 
(c, f, i), Hoechst in blue (d, g, j), and overlay in purple (e, h, k). Scale bars = 
50 µm. (a) loaded erythrocytes pre-photolysis, (b) loaded erythrocytes post-
photolysis, (c - e) 1% serum HeLa no photolysis, (f - h) 1% serum HeLa 
photolysis (40X), (i - k) 1% serum HeLa photolysis (100X).  
113 
 
chymotrypsin. In both cases, erythrocytes afford nearly complete protection of the peptide 
against proteolysis (Figure 5.5). By contrast, the non-lipidated analog of 6, 5TAMRA-Aoc-
GRTGRRFSY-amide (Figure 5.5), as well as 6 in the absence of erythrocytes (Figure 5.6) 
are digested by both proteases. Erythrocytes containing 6 were also co-incubated with HeLa 
cells. Illumination at 360 nm triggers the anticipated migration of 5TAMRA fluorescence from 
erythrocytes to the adherent HeLa cells (Figure 5.4: f - h @ 40X and i - k @ 100X), which is 
consistent with the photolytic conversion of 6 to the cell permeable 5TAMRA-Aoc-
GRTGRRFSY-amide (Figure 5.7).  
 
  
Figure 5.5: Proteolytic stability of 6, and its non-lipidated counterpart.  Erythrocytes 
were loaded with 6 (,) or exposed to a non-lipidated analogue (5TAMRA-Aoc-
GRTGRRFSY-amide; ,) of 6. These mixtures were separately incubated with 5 nM 
trypsin (,) or chymotrypsin (,). 6 anchored to erythrocytes (,) is protected 
from proteolysis, but 5TAMRA-Aoc-GRTGRRFSY-amide is degraded (,) by both 
proteases. 
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Figure 5.6: Proteolysis of peptide 6 (2.5 µM) in PBS in the presence of chymotrypsin (, 
5 nM) or trypsin (, 5 nM) as a function of time. 
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Figure 5.7 Partial photolysis of peptide 6 (1 µM) in water (200 µL) as assessed by LC-
MS. LC-MS of peptide 6 (a) before and (b) after 2 min photolysis. 
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Section 5.4: Light-triggered release of a peptide hormone. 
 The melanocortins (MCs), such as α-melanocyte stimulating hormone (αMSH), elicit 
an array of biological effects, including pronounced anti-inflammatory activity.[199] Unlike 
currently employed therapeutics, the MCs do not abolish the immune response but rather 
modulate it, and thus have been described as having the “sledgehammer properties of a 
steroid, but without the side effects”.[199a] However, the half-life of αMSH is only a few 
minutes due to the action of serum proteases.[200] Given the length of αMSH (where MSH = 
SYSMEHFRWGKPV), we were concerned that a single anchor (i.e. 8; Figure 5.8) might not 
hold the entire peptide close enough to the cell surface to completely protect it from 
proteolysis. Consequently, we prepared both the double lipid anchored conjugate 7 
(fluorophore-Cys-MSH-Cys-amide 2 + lipid 5) as well as its single anchored counterpart 8 
(fluorophore-MSH-φ-Cys-amide + 4) (Figure 5.8). As a control, we synthesized a non-
lipidated MSH peptide, in which the two free Cys residues in 2 are modified with N-
ethylmaleimide [fluorophore-C(NEM)-MSH-C(NEM)-amide]. 
 
 As expected, non-lipidated fluorophore-C(NEM)-MSH-C(NEM)-amide is digested 
within minutes by both trypsin and chymotrypsin, whereas the erythrocyte-embedded double 
lipidated peptide 7 remains fully intact after 2 h of incubation with the proteases (Figures 5.9 
Figure 5.8: Peptide 7 contains lipids (5) positioned at both the N- and C-termini, which 
doubly anchors the MSH sequence to the cell membrane. Peptide 8 is singly anchored by 
a dipalmitoyl moiety and may therefore display significant vertical mobility, potentially 
exposing the 13-amino acid MSH sequence to proteases. Fl = fluorophore. 
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& 5.10). By contrast, lipid-peptide conjugate 8 displays intermediate behavior, with 
approximately half of the peptide hydrolyzed after 1 h of incubation (Figure 5.11). Although it 
is tempting to ascribe this proteolytic sensitivity of 8 to the model illustrated in Figure 5.8, 
future studies will need to fully assess the effect of peptide length on proteolytic resistance. 
However, it is reassuring that two strategically positioned anchors offer full protection from 
proteolysis in the event that a single anchor is insufficient.  
 The action of MCs is mediated through the melanocortin receptors (MCR), of which 
there are five members. We chose to work with the MC1R receptor, given its selectivity for 
αMSH.[201] The fluorescent peptide 2 stains the MC1R protein expressed on the surface of 
HEK293T cells in the expected fashion (Figure 5.12). Two control experiments were 
performed to validate the selectivity of 2 for MC1R: (a) HEK293K cells not expressing MC1R 
were exposed to peptide 2 and (b) HEK293K cells expressing MC1R were pretreated with 
non-fluorescent MSH and subsequently exposed to 2. Under both conditions, no red 
fluorescence is associated with the HEK293K cells, implying a specific interaction between 
peptide 2 and MC1R (Figure 5.13). Erythrocytes loaded with peptide 7 were subsequently 
incubated with the HEK293Ks and, in the dark, erythrocytes retained construct 7 (Figure 
5.12). By contrast, upon illumination at 360 nm, the MC1R on HEK293Ks were labeled, 
highlighting the migration of the photolyzed product (Figure 5.12 and Figure 5.14) to the 
adherent HEK293s. 
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Figure 5.9: Proteolytic stability of peptides 7 (on erythrocytes) and 2a [5-TAMRA-
C(NEM)-MSH-C(NEM)amide; non-lipid analog of peptide 7]. Peptide 7 (loaded on 
the surface of erythrocytes) remaining (% undigested) when incubated in the (a) 
absence of proteases for 0 h, (b) presence of -chymotrypsin (2.5 nM) for 2 h, (c) 
presence of trypsin (2.5 nM) for 2 h, (d) absence of proteases for 2 h. Peptide 2a 
(2.5 µM) remaining (% undigested) when incubated in the (e) presence of 
chymotrypsin (2.5 nM) for 30 min, (f) presence of trypsin (2.5 nM) for 30 min. 
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Figure 5.10: Time dependent proteolytic stability of peptide 7 anchored to the surface 
of erythrocytes and peptide 2a [5TAMRA-C(NEM)-MSH-C(NEM)amide; non-lipidated 
analog of peptide 7] in the presence of trypsin or -chymotrypsin at 37 ˚C. (a) Peptide 
7/erythrocytes + 5 nM trypsin (o); (b) peptide 7/erythrocytes + 5 nM -chymotrypsin (); 
(c) peptide 2a + 2.5 nM trypsin (); peptide 2a + 2.5 nM -chymotrypsin (). 
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Figure 5.11: Proteolytic stability of peptide 8 anchored to the surface of 
erythrocytes. Peptide 8 (loaded on the surface of erythrocytes) remaining 
(% undigested) when incubated in the (a) presence of -chymotrypsin (5 
nM) for 1 h, (b) presence of trypsin (5 nM) for 1 h, (d) absence of proteases 
for 1 h. Results were obtained by comparing the supernatant fluorescence 
to fluorescence when all the erythrocyte membrane bound peptide were 
cleaved by high concentration (50 nM) of protease. 
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Figure 5.12: Binding of MSH peptides (red) to HEK293T cells co-expressing MC1R 
and enhanced green fluorescent protein (green). (a – c) non-transfected cells 
exposed to 2; (d – f) MC1R/EGFP-transfected cells exposed to 2; (g – i) 
7/erythrocytes, no photolysis; (j – l) 7/erythrocytes, photolysis.  Left panels are 
EGFP, middle panels are fluorescent peptide, right panels are overlays of both 
images. Scale bars = 50 µm. 
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Figure 5.13: HEK293T cells were transfected with FLAG-melanocortin 1 receptor (MC1R) 
that expressed an EGFP marker downstream of an internal ribosome entry site sequence, 
which allows expression of two proteins off of one mRNA. Transfected cells were treated 
with (a – c) 200 nM 6 or (d – f) blocked with 400 nM unlabeled MSH for 30 min followed by 
200 nM 6 for 30 min. Right panels are EGFP fluorescence, middle panels are 6 fluorescence 
(5TAMRA), and right panels are overlay. Blocking with unlabeled MSH prevents binding of 
6 to cells expressing the MC1R, showing specificity of 6 for the expressed MC1R construct. 
Scale bar = 50 µm. 
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Figure 5.14: Photolysis of peptide 7 [5-TAMRA-Cys(Mal-dmnb-Stearyl)-MSH-Cys(Mal-
dmnb-Stearyl)-amide]; 20 µM] in 50% MeOH/H2O with 10 mM DTT as assessed by LC 
and HRMS. LC and MS of peptide 7 (a) before and (b) after 5 min photolysis.  
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Section 5.5: Light-triggered release of a blood-clotting factor. 
 Blood clotting is mediated by platelet adhesion and aggregation, processes triggered 
by a multitude of surface receptors including protease-activated receptors (PARs). PARs are 
activated by pro-coagulant proteases (e.g. thrombin) whose action exposes an N-terminal 
sequence on the PAR, which serves as an intramolecular ligand that activates the receptor. 
Free peptide analogues of the N-terminal PAR sequence likewise act as PAR agonists, 
triggering platelet shape change and aggregation.[202] We constructed an analogue (3a + 4  
= 9, Scheme 5.2) of a potent peptidic PAR agonist[203] to create modified erythrocytes that 
promote aggregation upon exposure to light. When 9 is anchored to erythrocytes, it is nearly 
completely protected from proteolytic attack by trypsin or chymotrypsin, even after 2 h of 
incubation. By contrast, 3b, a non-lipidated analogue of 9, is digested within minutes under 
identical conditions (Figures 5.15-5.16). 
 
 Aggregation assays were performed using platelets isolated from human volunteers 
and PAR ligand-induced platelet aggregation quantified via light transmission aggregometry 
(Figure 5.17, plot).[204] In addition, aggregation is visually apparent since, as platelets begin 
to aggregate, there are fewer (albeit larger) particles and the solution becomes less turbid 
(Figure 5.17, insert). Illuminated erythrocytes/9 (blue trace) induce the rapid (2 min) 
aggregation of platelets (67.7 ± 3.8%), an effect similar to that produced by the non-lipidated 
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Scheme 5.2: Structure of the lipidated PAR agonist analogue 9  
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PAR agonist 3b (black trace; 87.0 ± 7.0%; Figure 5.17 and Figure 5.18). The moderately 
lower final transmittance of the former is likely due to the presence of erythrocytes. Finally, 
non-illuminated (green trace) samples of erythrocytes/9 fail to induce any detectable platelet 
aggregation. The sensitivity of light-induced aggregation is notable since the erythrocyte 
hematocrit employed is 12.5%, which is one quarter of the hematocrit of human blood.[205]  
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Figure 5.15: Stability of peptides 9 (on erythrocytes) and 3b (non-lipidated analog of 9) 
against chymotrypsin and trypsin, in PBS, 2 mM DTT, 37 ˚C, 2 h.  (a) Peptide 
9/erythrocytes, (b) peptide 9/erythrocytes + 50 nM chymotrypsin, (c) peptide 9/erythrocytes 
+ 5 nM trypsin, (d) peptide 3b + 50 nM chymotrypsin, (e) peptide 3b + 5 nM trypsin, and (f) 
peptide 3b. 
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Figure 5.16: Time dependent incubation of peptides 9 (on erythrocytes) and 3b 
(non-lipidated analog of 9) with chymotrypsin and trypsin at 37 ˚C. Peptide 
9/erythrocytes + 50 nM chymotrypsin (green); peptide 9/erythrocytes + 5 nM 
trypsin (black); peptide 3b + 50 nM chymotrypsin (blue); peptide 3b + 5 nM trypsin 
(red). 
Figure 5.17: Light-mediated platelet aggregation. Plot: Representative kinetic traces of 
platelet aggregation (black = non-lipidated PAR agonist 3b; blue = illuminated 
erythrocytes/9; red = erythrocytes (not loaded with 9); green = non-illuminated 
erythrocytes/9). Insert: Platelet aggregation in the presence of 3b (a), non-illuminated 
erythrocytes/9 (b), and illuminated erythrocytes/9 (c). 
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Section 5.6: Conclusions 
 In conclusion, we’ve used erythrocytes as a reservoir for lipidated therapeutic 
peptides, which offers protection from proteolytic degradation, while serving as a light-
triggered launching pad. The photo-release of biologically potent, proteolytically sensitive, 
peptides recapitulates the endogenous behaviour of natural peptide hormones (e.g. MSH). 
Namely, the powerful biological activity of hormones is elicited where and when needed, but 
activity is rapidly curtailed by subsequent proteolysis. We are currently extending these 
studies to other cell carriers, additional therapeutically active peptides, and at longer, deeper 
tissue penetrating, wavelengths[164b, 165-166, 206]. 
  
Figure 5.18: Traces of platelet aggregation from three different blood donors. Results 
of donor 2 alone are provided in Figure 6 in the manuscript. Black = non-lipidated PAR 
agonist 3b; red = donor 1; green = donor 2; yellow = donor 3; magenta = donor 1 + 360 
nm; blue = donor 2 + 360 nm; cyan = donor 3 + 360 nm 
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Section 5.7: Materials and Methods 
I. Synthesis of Peptides and Peptide-dmnb-Lipid Conjugates. 
 
Reagents for peptide synthesis and peptide characterization.  
All reagents and solvents were purchased from Sigma-Aldrich or Fisher except for 
1H-benzotriazolium 1-[bis(dimethylamino)methylene]-5-chlorohexafluorophosphate (1-),3-
oxide (HCTU), 6-chloro-benzotriazole-1-yloxy-tris-pyrrolidinophosphonium 
hexafluorophosphate  (PyClock), amino acids, NovaSyn TGR resin and NovaPeg Rink 
Amide resin, which were obtained from NovaBiochem or AAPPTEC. Fmoc-Photo-Linker 
(Fmoc-dmnb-OH) and Fmoc-Aoc-OH was obtained from Advanced ChemTech. Amine-
reactive fluorophores were obtained ChemPep. α-Chymotrypsin (Type II) and trypsin were 
obtained from Sigma-Aldrich. NMR spectra were acquired on a Bruker 400 WB NMR 
spectrometer. HRMS data was acquired on a Thermo Scientific electrospray linear trap 
quadrupole Fourier transform mass spectrometer (LT-QFT). Purity of peptides labeled with 
fluorophores (5-TAMRA) was confirmed via Agilent 1200 series LC chromatography. 
 
Peptide Synthesis: General Methods.  
Peptides were synthesized via a standard Fmoc peptide synthesis protocol on a 
NovaPeg Rink amide resin or NovaSyn TGR resin using a Prelude automatic peptide 
synthesizer from Protein Technology (amino acids 5 eq, HCTU 5 eq, DIPEA 10 eq, in DMF). 
Fmoc deprotection was performed using 30% piperidine in DMF. Peptides were cleaved with 
trifluoroacetic acid (TFA):H2O:ethanedithiol (EDT):triisopropylsilane (TIS) in a ratio of 
94:2.5:2.5:1, and purified via HPLC using a C18 column eluted with 0.1% TFA in 
water/acetonitrile system (for non-lipidated peptides) or a C4 column eluted with 0.1% TFA 
in water/isopropanol or water/methanol system (for lipidated peptides).  Purity of 5-TAMRA 
or 5-FAM labeled peptides was confirmed with Agilent analytical LC chromatography as 
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assessed by UV-Vis (550 nm for 5-TAMRA and 440 nm for 5-FAM) absorbance and 
fluorescence (Ex/Em 550/590 nm for 5-TAMRA and 490/525 nm for 5-FAM). 
a. Synthesis of the non-lipidated analog (1a) of peptide 6. 
i. Peptide 1a (TAMRA-Aoc-GRTGRRFSY-amide). 
 After synthesis of Fmoc-Aoc-GRTGRRFSY-resin (see Peptide Synthesis: General 
Methods) and removal of N-terminal Fmoc, 5-TAMRA (1.2. eq) was coupled to the peptide 
using HCTU (1.2 eq.) and DIPEA (5 eq.) in dimethylformamide (DMF) overnight. The 
peptide was cleaved from the resin, and purified using standard procedures (see Peptide 
Synthesis: General Methods). 1a: Exact Mass Calculated for C80H110N22O17: 1650.84, 
found (ESI+) 826.7 (M+2H)2+, 551.5 (M+3H)3+. 
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LC of Purified 1a. Fluorescence Ex/Em 550/590 nm. 
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b. Synthesis of peptide 6. 
i. Peptide 1. Fmoc-Aoc-GRTGRRFSY-dmnb-C-resin was synthesized on the TGR 
resin using the standard protocol (see Peptide Synthesis: General Methods), the N-
terminal Fmoc removed (25% piperidine in DMF, 20 min), and 5-TAMRA (1.2 eq.) was 
coupled using HCTU (1.2 eq.) and DIPEA (5 eq.) in DMF overnight. The resin was washed 
by DMF and methylene chloride, dried by vacuum filtration, and the peptide cleaved and 
purified using standard procedures (see Peptide Synthesis: General Methods). Peptide 1, 
C96H133N25O23S, exact mass calculated 2036.0 (M), found (ESI+) 1018.2 (M+2H) 2+, 679.2 
(M+3H) 3+, 509.7 (M+4H) 4+. 
 
 
ii. Maleimido-lipid 4. 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine 4a (1.45 
mmol, 1 eq.) was dissolved in CH2Cl2 and DMF. 3-Maleimido-propionic acid 4b (1.2 eq.) and 
HCTU (1. 2 eq.) were dissolved in DMF in two separate glass vials. DIPEA (2 eq.) was 
added to the solution of 4a immediately followed by the addition of the 4b and HCTU 
solution. The reaction was shaken at room temperature for 30 min followed by addition of 
HCl (10 M) to pH 4. The reaction mixture was then extracted with EtOAc three times. The 
  
 
LC of Purified 1. Fluorescence Ex/Em 550/590 nm. 
 
 
  
 
LC of Purified 1. Fluorescence Ex/Em 550/590 nm. 
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organic extract was dried and purified by silica column using CH2Cl2:MeOH (MeOH with 
0.5% CH3COOH) as the solvent, gradient from 0% to 50% MeOH. Compound 4: 1H NMR 
(400 MHz, CDCl3) δ 7.53 (s, 1 H), 6.72 (s, 2 H), 5.19 (s, 1 H), 4.37 (d, J = 9.5 Hz, 1 H), 4.15-
4.11 (m, 1 H), 3.91-3.79 (m, 6 H), 3.41 (bd, 2 H), 2.54 (t, J = 7 Hz, 2 H), 2.30-2.25 (m, 4 H), 
2.01 (s, 4 H), 1.25 (s, 48 H), 0.88 (t, J = 6.8 Hz, 6 H). MS calculated for C44H79N2O11P + H+ 
(M+) m/z: 843.54937, found 843.55050. 
 
 iii. Peptide 6. Peptide 1 (3.57 µmol) was dissolved in a minimum amount of MeOH. 
Compound 4 (6.17 µmol) was dissolved in CHCl3. The two solutions were mixed, bubbled 
with Ar for 10 s, sealed, and shaken overnight. The solvent was removed with an air stream 
and subsequently via vacuum. Peptide 6 was purified on a C4 column using H2O:MeOH 
(each with 0.1% TFA) as solvent. Peptide 6, C140H211N27O34PS-, exact mass calculated 
2877.5 (M)1-, found (ESI+, m/z) 1440.1 (M+3H)2+, 906.3 (M+4H)3+, 720.5 (M+5H)4+.  
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LC of Purified 6.  Fluorescence Ex/Em 550/590 nm. 
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c. Synthesis of Peptide 7. 
i. Peptide 2 (5TAMRA-Cys-MSH-Cys where MSH = -Ser-Tyr-Ser-Met-Glu-His-Phe-
Arg-Trp-Gly-Lys-Pro-Val-). Peptide 2 was synthesized according to Peptide Synthesis: 
General Methods and 5-TAMRA attached to N-terminal using 5-TAMRA, HCTU, and DIPEA 
in DMF. ESI MS Calculated for C106H137N25O24S3+ 2H+ (M2+) m/z:  1120.97869, found 
1120.97955; C106H137N25O24S3 + 3H+ (M3+) m/z: 747.65488, found 747.65564; 
C106H137N25O24S3 + 4H+ (M4+) m/z: 560.99298, found 560.99381. 
 
 
ii. Peptide 2a. Purified peptide 2a (5TAMRA-Cys-MSH-Cys-amide) (0.35 µmol, 1.0 
eq) was reacted overnight under Ar with N-ethylmaleimide (NEM, 5 eq) in the presence of 
2,6-lutidine, 2.5 µL 2,4,6-collidine (to maintain a neutral pH) in 250 µL DMF. The product 
was purified on HPLC using a C18 column. ESI MS Calculated for C118H151N27O28S3 + 2H+ 
(M2+) m/z: 1246.02636, found 1246.02904; C118H151N27O28S3 + 3H+ (M3+) m/z: 831.02000, 
found 831.02014.   
 
 
  
LC of Purified 2. Fluorescence Ex/Em 550/590 nm. 
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iii. Photolinker 5. Octadecylamine (212 mg, 0.79 mmol) was reacted with Fmoc-
dmnb-OH (429 mg, 0.82 mmol), PyClock (653 mg, 1.18 mmol), DIPEA (388 µL, 2.35 mmol) 
in 5 mL DMF, 5 mL DCM (dichloromethane), for 1 h in the dark. 2 mL of water was added to 
stop the reaction, and then 20 mL chloroform and 3 mL pyrrolidine were added to remove 
the Fmoc group. The product was washed with 0.2 N sodium bicarbonate, followed by 
saturated sodium chloride solution, dried with sodium sulfate, and concentrated via rotary 
evaporation. The resulting crude product (5b) was reacted with maleimidopropionic acid 4b 
(200 mg, 1.18 mmol), PyClock (653 mg, 1.18 mmol), DIPEA (388 µL, 2.35 mmol) in DMF for 
1 h in the dark. Residual activated maleimidopropionic acid was quenched by adding 60 mg 
diethanolamine (0.6 mmol), then 3 mL 2N HCl to keep solution acidic. Additional water was 
added and the product extracted with ethyl acetate. Ethyl acetate was removed via rotary 
evaporation and the residue dissolved in minimum of chloroform, precipitated by adding 
methanol, and recrystallized at 4 ˚C, providing product 5 (328 mg, 59% yield). 1H NMR (400 
MHz, DMSO-d6) δ ppm 0.85 (t, J = 6.65 Hz, 3 H) 1.17 - 1.30 (m, 30 H) 1.37 (d, J = 6.65 Hz, 
3 H) 1.34 - 1.39 (m, 2 H) 1.93 (quin, J = 6.85 Hz, 2 H) 2.21 (t, J = 7.43 Hz, 2 H) 2.30 - 2.44 
(m, 2 H) 3.01 (q, J = 6.65 Hz, 2 H) 3.49 - 3.62 (m, 2 H) 3.88 (s, 3 H) 4.01 (t, J = 6.46 Hz, 2 
H) 5.30 - 5.38 (m, 1 H) 6.97 (s, 2 H) 7.12 (s, 1 H) 7.46 (s, 1 H) 7.80 (t, J = 5.67 Hz, 1 H) 8.60 
  
LC of Purified 2a.  Fluorescence Ex/Em 550/590 nm. 
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(d, J = 7.83 Hz, 1 H). ESI MS calculated for C38H60N4O8 + H+ (M+) m/z: 701.44834, found 
701.44863.  
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iii. Peptide 7. Purified peptide 2 (5TAMRA-Cys-MSH-Cys-amide) (0.33 µmol, 1.0 eq) 
was reacted with compound 5 (Mal-Ф-Stearyl) (5 eq) in the presence of 2,6-lutidine and 2.5 
µL 2,4,6-collidine in 300 µL DMF and 300 µL chloroform. Chloroform was removed via rotary 
evaporation and the peptide subsequently purified via HPLC using a C4 column with 0.1% 
TFA in water/isopropanol. ESI MS Calculated for C182H257N33O40S3 + 3H+ (M3+) m/z: 
1214.61559, found 1214.61487; C182H257N33O40S3 + 4H+ (M4+) m/z: 911.21351, found 
911.21436.  
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LC of Purified 7.  Fluorescence Ex/Em 550/590 nm. 
 
0
100
200
0 2 4 6 8 10 12 14 16 18
F
lu
o
re
s
c
e
n
c
e
0
100
200
0 2 4 6 8 10 12 14 16 18
F
lu
o
re
s
c
e
n
c
e
0
100
200
0 2 4 6 8 10 12 14 16 18
F
lu
o
re
s
c
e
n
c
e
136 
 
d. Synthesis of Peptide 8. 
i. Peptide 8a. 8a (5FAM-MSH-dmnb-Cys-amide) was synthesized on TGR resin as 
described in Peptide Synthesis: General Methods. 5-FAM (1.5 eq.) was preactivated with 
HOBt (20 eq.) and DIC (1.7 eq.) for 10 min before being added to the resin. After 5-FAM 
addition, the reaction was kept at room temperature for 2 h, and the resin washed with 
piperidine (25% in DMF) until no fluorescence was detected in DMF. The solvent was 
removed from the resin and cleaved as described in Peptide Synthesis: General Methods. 
Peptide 8a (5FAM-MSH-dmnb-Cys-amide), C112H138N24O30S2, exact mass calculated 2363.0 
(M), found (ESI+, m/z) 789.0 (M+3H)3+, 592.0 (M+4H)4+. 
 
 
  
 
 
LC of Purified  8a. Fluorescence Ex/Em 490/525nm. 
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ii. Peptide 8. Peptide 8a (5FAM-MSH-dmnb-Cys-amide) (1 eq.) was dissolved in a 
minimum amount of MeOH. Compound 4 (2 eq.) was dissolved in CHCl3. The two solutions 
were mixed, bubbled with Ar for 10 s, sealed, and shaken overnight. The solvent was 
removed with an air stream and subsequently via vacuum. Peptide 8 was purified on a C4 
column using H2O:MeOH (each with 0.1 % TFA) as solvent.  Peptide 8, C156H216N26O41PS2-, 
exact mass calculated 3204.5 (M)1-, found (ESI+, m/z) 1070.4 (M+4H)3+, 802.9 (M+5H)4+.  
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LC of Purified 8. Fluorescence Ex/Em 490/525 nm. 
0
2
4
6
0 1 2 3 4 5 6 7 8 9
F
lu
o
re
s
c
e
n
c
e
0
2
4
6
0 1 2 3 4 5 6 7 8 9
F
lu
o
re
s
c
e
n
c
e
0
2
4
6
0 1 2 3 4 5 6 7 8 9
F
lu
o
re
s
c
e
n
c
e
0
2
4
6
0 1 2 3 4 5 6 7 8 9
F
lu
o
re
s
c
e
n
c
e
139 
 
e. Synthesis of Peptide 9. 
ii. Peptide 3a [Ala-Phe(4-F)-Leu-Leu-Arg-Lys(TAMRA)-dmnb-Cys-amide]. The 
procedure for the synthesis of 2a was followed for the synthesis of Peptide 3a. ESI MS 
Calculated for peptide 3a C77H103FN16O16S + 2H+ (M2+) m/z: 780.37934, found 780.37920; 
C77H103FN16O16S + 3H+ (M3+) m/z: 520.58865, found 520.58893. 
 
 
ii. Peptide 3b [Ala-Phe(4-F)-Leu-Leu-Arg-Lys(TAMRA)-amide]. 3b was 
synthesized according to the protocol outlined in Peptide Synthesis: General Methods. 
Fmoc-Lys(ivDde)-OH was used so that the side chain amine of Lys could be selectively 
deprotected and modified. Boc-Ala was used for the N-terminal amino acid so that ivDde on 
Lys can be removed without affecting the N-terminus. After synthesis of backbone 
sequence, ivDde was removed using 2% hydrazine 3x10 min, and 5-TAMRA (5 eq) was 
coupled to the Lys side chain using HCTU (5 eq), DIPEA (10 eq) in DMF. The peptide was 
cleaved and purified as described in Peptide Synthesis: General Methods. ESI MS 
Calculated for C61H82FN13O10 + H+ (M+) m/z: 1176.63633, found 1176.63482; for 
 
 
 
 
 
LC of Purified 3a. Fluorescence Ex/Em 550/590nm. 
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C61H82FN13O10 + 2H+ (M2+) m/z: 588.82180, found 588.82163; for C61H82FN13O10 + 3H+ (M3+) 
m/z: 392.88363, found 392.88375. 
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LC of Purified 3b. Fluorescence Ex/Em 550/590nm. 
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 iii. Peptide 9 [Ala-Phe(4-F)-Leu-Leu-Arg-Lys(TAMRA)-dmnb-Cys(Mal-Dipal)-
amide].  Purified peptide 3a (0.33 µmol) in 0.3 mL DMF was reacted with 4 (0.66 µmol) in 
0.3 mL chloroform in the presence of 2.5 µL 2,6-lutidine and 2.5 µL 2,4,6-collidine. The 
reaction mixture was deoxygenated by bubbling in N2, the flask sealed, and then shaken in 
the dark overnight. Chloroform was removed via rotary evaporation, and the product was 
purified on HPLC using a C4 column with 0.1% TFA in water/isopropanol. ESI MS 
Calculated for Peptide 9: C121H182FN18O27PS + 2H+ (M2+) m/z: 1201.65038, found 
1201.65104. 
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LC of Purified 9. Fluorescence Ex/Em 550/590nm. 
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II. Photolysis of Peptide-Ф-Lipid Conjugates. Photolysis was performed using an 
Oriel 200 W Hg-arc lamp (model 66907; Power supply model 66901) with a UV bandpass 
360 ± 50 nm filter (Newport, FSQ-UG1). 
a. Photolysis of Peptide 6 (5TAMRA-Aoc-GRTGRRFSY-dmnb-Cys(Mal-Dipal)-
amide). Peptide 6 (1 µM) in water (200 µL) was photolyzed using a Hg-Arc lamp in the 
presence of a 360 nm bandpass filter. The product was analyzed by LCMS. Figure S3. 
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b. Photolysis of Peptide 7 [TAMRA-Cys(Mal-dmnb-Stearyl)-MSH-Cys(Mal-
dmnb-Stearyl)-amide]. Peptide 7 (50 µL, 20 µM) in 50% MeOH/H2O with 10 mM DTT was 
photolyzed for 6 x 5 min, the product was separated on a C4 column (5 μm, 50 x 2.1 mm) by 
LC and checked by HRMS (LT-QFT): ESI MS Calculated, for peptide 7a C120H153N29O30S3 + 
3H+ (M3+) m/z: 859.69054, found 859.68938; for C120H153N29O30S3 + 4H+ (M4+) m/z: 
645.01972, found 645.01875. ESI MS Calculated, for peptide 7a.1 + 7a.2: C151H205N31O35S3 
+ 3H+ (M3+) m/z: 1037.15305, found 1037.15266; for C151H205N31O35S3 + 4H+ (M4+) m/z: 
778.11661, found 778.11685. Figure S5. 
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c. Photolysis of Peptide 8 [(5FAM-MSH-dmnb-Cys(Mal-Dipal)-amide)]. A solution 
of Peptide 8 in H2O was irradiated with UV light (from a Hg-Arc lamp using a 360 nm 
bandpass filter) for 30 min. The solution was then dried and purified by HPLC using a C18 
column. Peptide 8a 5FAM-MSH-amide), C96H117N21O24S, exact mass calculated (M) 1979.8, 
found (ESI+, m/z) 990.9 (M+2H)2+, 661.2 (M+3H)3+, 496.2 (M+4H)4+. Figure S6. 
 
d. Photolysis of Peptide 9 [Ala-Phe(4-F)-Leu-Leu-Arg-Lys(TAMRA)-dmnb-
Cys(Mal-Dipal)-amide]. Peptide 9 (100 µL, 20 µM) in 50% MeOH/H2O with 10 mM Dtt 
(helps prevent potential formation of imine) was photolyzed for 6 x 5 min, the product was 
separated on a C4 column (5 μm, 50 x 2.1 mm) by LC and checked by HRMS (LT-QFT). 
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LC for Photolysis of 7. Fluorescence Ex/Em 550/590nm. 
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ESI MS calculated for photolysis product (same as peptide 3b): C61H82FN13O10 + 2H+ (M2+) 
m/z: 588.82180, found 588.82196; for C61H82FN13O10 + 3H+ (M3+) m/z: 392.88363, found 
392.88383. Figure S7. 
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III. Preparation of erythrocytes, loading of peptide-lipid conjugates onto erythrocytes, and 
photorelease of peptides from erythrocytes. 
 a. Hemoglobin-free erythrocyte ghost preparation. Peripheral human 
erythrocytes were washed with L-15 media upon receipt and stored in L-15 media 
containing FBS (10%) at 10% hematocrit. Hemoglobin-free erythrocyte ghosts (henceforth 
referred to as erythrocytes) were prepared fresh before all experiments. Briefly, the stored 
erythrocytes (1 mL) were washed with PBS 1 x 3 times (1 mL PBS 1X, centrifuged at 2000 g 
for 2 min), followed by washes (5x) with PBS 0.1X (1 mL PBS 0.1X, centrifuged at 14,000 g 
for 2 min). The erythrocytes were then restored and kept in PBS 1X (1 mL) for 1 h at 37 ˚C 
to reseal, followed by three additional washes with PBS 1X (1 mL PBS 1X, centrifuged at 
10,000 g for 2 min) and suspension in PBS 1X (1 mL) for peptide loading. 
 
 b. Peptide loading on erythrocytes. Lipidated peptide stock solutions were 
predissolved in ethanol (10 µL). To this solution was then added hemoglobin-free 
erythrocytes in PBS 1X (1 mL, 10% hematocrit). The final peptide concentration was 2.5 µM. 
The solution was gently shaken at room temperature (10 min), followed by centrifugation 
(10,000 g for 2.5 min). The pellet was resuspended in PBS 1X (1 mL) and transferred to a 
new tube. The suspension was washed two more times with PBS 1X (1 mL, 10,000 g for 2.5 
min) and resuspended in PBS 1X (1 mL) to furnish hemoglobin-free peptide-loaded 
erythrocytes (1 mL, 10% hematocrit). All supernatants were collected for fluorescence 
measurement to assess the presence of unbound peptide. The pellet was washed three 
more times with 1x PBS containing 2 mM DTT, 0.02% BSA and then re-suspended in 1 mL 
PBS containing 2 mM DTT, 0.02% BSA to furnish the peptide-loaded erythrocyte (lipid 
peptide concentration 2.5 µM for 1 mL suspension of 10% hematocrit generated 
erythrocyte).  
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 The loading efficiency of Peptide 6 (2.5 µM) on erythrocytes (10% hematocrit) was 
estimated as 96 ± 2% by comparing the absorbance (550 nm) of washings and the 
absorbance of peptide 6 (2.5 µM) in methanol. The number of cells in 1 mL of 10% 
hematocrit erythrocyte was estimated as 6.1x107 by an automated particle counter, and 
6.4x108 by a hemocytometer. Therefore the loading of Peptide 6 to each erythrocyte cell is 
approximately 2x106/cell - 2x107/cell. 
 c. Photorelease of peptides from erythrocytes/peptide 6, 7, and 9. The lipid-
peptide (2.5 µM) loaded erythrocyte suspension (200 µL; 10% hematocrit) in 0.5 mL 
microcentrifuge tube was photolyzed with water bath cooling. After every 5 min of UV 
irradiation, the fluorescence of the erythrocyte suspension was checked by plate reader. 
Illumination continued until there was no further increase in supernatant fluorescence. (i) 
Assessment of photo-released peptide: UV irradiated lipid peptide-erythrocyte suspension 
80 µL was centrifuged, and 60 µL supernatant was transferred to a 96-well plate well filled 
with 60 µL MeOH; (ii) Assessment of photo-released + non-photoreleased peptide: UV 
irradiated lipid peptide-erythrocyte suspension 80 µL was centrifuged, and the supernatant 
was collected. The pellet was treated with 80 µL MeOH to extract remaining that was not 
photo-released. The extract was centrifuged to remove cellular debris and combined with 
the supernatant that had been previously collected containing photo-released peptide. 120 
µL of the combined solution was transferred to a 96-well plate represent the total peptide 
amount. (iii) Assessment of peptide released in the absence of photolysis: The lipid-peptide 
loaded erythrocyte suspension (80 µL) without UV irradiation was centrifuged, and 60 µL 
supernatant was transferred to a 96-well plate well filled with 60 µL MeOH. Fluorescence 
was measured using a Molecular Devices Spectra Max Gemini EM plate reader with 
excitation at 550 nm, Emission at 590 nm. 
Peptide 6/erythrocytes; photolysis protocol: 3 x 5 min; % peptide released: 51.4 ± 0.3% 
Peptide 7/erythrocytes; photolysis protocol: 5 x 5 min; % peptide released: 61.3 ± 0.5% 
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Peptide 9/erythrocytes; photolysis protocol: 3 x 5 min; % peptide released: 59.2 ± 0.5% 
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Photolysis of 2.5 µM peptide 6/erythrocytes (10% hematocrit) in PBS buffer with 2 mM DTT, 
0.02% BSA. (a) Peptide 6/erythrocytes, UV 3x5 min, supernatant; b) Peptide 6/erythrocytes, 
UV 3x5 min, total extraction; (c) Peptide 6, no UV; (d) Peptide 1a (5TAMRA-Aoc-
GRTGRRFSY-amide) for comparison. 
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Photolysis of 2.5 µM peptide 7/erythrocytes (10% hematocrit) in PBS buffer with 2 mM DTT, 
0.02% BSA. (a) Peptide 7/erythrocytes, UV 5x5 min, supernatant; b) Peptide 7/erythrocytes, 
UV 5x5 min, total extraction;  (c) Peptide 7, no UV  
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Photolysis of 2.5 µM peptide 9/erythrocytes (10% hematocrit) in PBS buffer with 2 mM DTT, 
0.02% BSA. (a) Peptide 9/erythrocytes, UV 3x5 min, supernatant; b) peptide 9/erythrocytes, 
UV 3x5 min, total extraction;  (c) peptide 9, no UV  
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IV. Proteolytic stability of peptides and erythrocyte-bound peptides. 
 a. 5TAMRA-Aoc-GRTGRRFSY-amide (non-lipidated analog of peptide 6). 
5TAMRA-Aoc-GRTGRRFSY-amide (2.5 µM) in PBS 1X solution (500 µL) was incubated in 
the presence of an erythrocyte suspension (500 µL, 10% hematocrit). An aliquot (100 µL) 
was quenched with HCl (10 µL, 10 M). The remainder (900 µL) was preincubated at 37 ˚C 
for 5 min before adding enzyme (5 nM α-chymotrypsin or trypsin). At various time points, 
aliquots (100 µL) were quenched with HCl (10 µL, 10 M). MeOH (1 mL) was added to the 
samples, followed by centrifugation at 21000 g/10 min. Supernatants were collected, dried, 
dissolved in DMSO, and analyzed by LC-MS. Figure 2. 
 b. Erythrocyte associated peptide 6. PBS 1X (500 µL) was added to peptide 6 
loaded erythrocytes (500 µL 10% hematocrit, 2.5 µM peptide). One aliquot (100 µL) was 
quenched with HCl (10 µL, 10 M), another aliquot (100 µL) was transfer to a new vial and 
incubated at 37 ˚C for 2 h and then quenched with HCl 10 µL (10 M). The remainder (800 
µL) was preincubated at 37 ˚C for 5 min before adding the enzyme (5 nM α-chymotrypsin or 
trypsin). At various time points, aliquots (100 µL) were quenched with HCl (10 µL, 10 M). 
MeOH (1 mL) was added to all quenched samples were added followed by centrifugation at 
21000 g for 10 min. Supernatants were collected, dried, dissolved in DMSO, and analyzed 
by LC-MS. Figure 2. 
 c. Peptide 6 in the absence of erythrocytes. Peptide 6 (2.5 µM) in 100 µL 1x PBS 
was assayed against 5 nM α-chymotrypsin or Trypsin at 37 ˚C. The assay was stopped by 
adding 10 µL 2M HCl and 100 µL MeOH and analyzed via LC. Figure S5. 
 d. Peptide 3a [5TAMRA-Cys(NEM)-MSH-Cys(NEM)] (non-lipidated analog of 
peptide 7). Peptide 3a (2.5 µM) in 1X PBS was assayed against 2.5 nM α-chymotrypsin or 
trypsin as described for 5TAMRA-Aoc-GRTGRRFSY-amide. Figures S8 and S9. 
 e. Erythrocyte associated peptide 7. Peptide 7 loaded erythrocytes (10% 
hematocrit, 2.5 µM peptide) was assayed against 5 nM α-chymotrypsin or trypsin as 
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described for peptide 6. At each time point, after the assay was stopped, and supernatant 
(80 µL) was collected by centrifugation, the pellet was further extracted with 2x80 µL MeOH, 
and the supernatants were combined and analyzed via LC. Figures S8 and S9. 
 
 f. Erythrocyte associated peptide 8. Peptide 8 loaded erythrocytes (10% 
hematocrit, 2.5 µM peptide) was assayed by measuring the supernatant fluorescence. The 
peptide loaded erythrocytes suspension (1 mL) was diluted in PBS 1X to 5% hematocrit and 
divided into two sets with each set containing three vials. For each set one vial (1 mL) was 
incubated at 37 ˚C. Another vial was treated with α-chymotrypsin or trypsin (5 nM), followed 
by incubation at 37 ˚C. At t = 1 h, aliquots (500 µL) were centrifuged (14,000 g for 10 min), 
followed by supernatant fluorescence assessment (200 µL) on a Gemini EM fluorescence 
plate reader from Molecular Devices (Ex/Em: 490/525 nm). α-chymotrypsin (50 nM) was 
added to the third vial and incubated at 37 ˚C for 2 h to generate the fully cleaved peptide as 
a control. The vial was then centrifuged (14,000 g for 10 min) and supernatant fluorescence 
measured as control fluorescence (200 µL). Figure S10. 
 g. Peptide 2a [Ala-Phe(4-F)-Leu-Leu-Arg-Lys(5TAMRA)-amide] (non-lipidated 
analog of peptide 9). Peptide 2a (2.5 µM) in 1X PBS was assayed against 50 nM α-
chymotrypsin or 5 nM trypsin as described for 5TAMRA-Aoc-GRTGRRFSY-amide. Figures 
S11-S12. 
 h. Erythrocyte associated peptide 9. Peptide 9 loaded erythrocytes (10% 
hematocrit, 2.5 µM peptide) was assayed against 50 nM α-chymotrypsin or 5 nM trypsin as 
described for peptide 6. At each time point, after the sample (100 µL) was quenched and 
supernatant was removed by centrifugation, the pellet was extracted with 100 µL MeOH 
containing 2% TFA and the MeOH extract (if the aqueous supernatant was included to the 
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extract, the trypsin digested fragment which is more hydrophobic won't show up well in the 
LC analysis.) was analyzed by LC. Figures S11-S12. 
 
 V. Cell culture studies. 
 General methods. Cell culture media and solutions were from Invitrogen. HeLa cells 
were from the tissue culture facility at the University of North Carolina. HeLa cells were 
passaged by treatment with 0.5% trypsin + 0.53 mM EDTA before reaching confluence and 
maintained in DMEM containing 10% fetal bovine serum (FBS) supplemented with 
streptomycin/ penicillin at 37 ºC in a 5% CO2 incubator. One day prior to microscopy 
experiments, cells were plated into MatTek 35 mm 1.5 glass bottom dishes. On the day of 
the microscopy experiments, the media was replaced with Leibovitz’s L-15 without phenol 
red supplemented with 1% FBS. 
 a. Cell culture experiments with Ac-Dap(TAMRA)-GRTGRRFSY-amide. Dishes 
with HeLa cells were exposed to 100 µM coumarin-Aoc-GRTGRRFSYP-amide (R. S. 
Agnes, F. Jernigan, J. R. Shell, V. Sharma, and D. S. Lawrence, J. Amer. Chem. Soc. 
2010,132, 6075-6080) for 2 min at 37 °C and then washed with PBS to block adsorption of 
Ac-Dap(TAMRA)-GRTGRRFSY-amide to the plate surface. HeLa cells were then loaded 
with 5 µM Ac-Dap(TAMRA)-GRTGRRFSY-amide (N. P. Oien, L. T. Nguyen, F. E., Jernigan, 
M. A. Priestman, and D. S. Lawrence, Angew. Chem. Int. Ed. Engl., 2014, 53, 3975–3978) 
at 4 °C or at 37 °C for 2 min in L-15 media with 1% FBS. Cells were washed 3 times with 
PBS and then imaged in L-15 media with 1% FBS. All results are representative 3 - 5 
experiment 
 b. Cell culture experiments with peptide 6. HeLa cells were plated in 35 mm glass 
bottom dishes (Mattek) and incubated for 24 h prior to co-culture with peptide loaded 
erythrocytes. The latter were loaded with 2.5 µM 6 and pelleted by centrifugation for 10 min 
at 1000x g. The pelleted erythrocytes containing 6 were resuspended in L-15 media 
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containing 0 or 1% fetal bovine serum to 5% hematocrit. HeLa media was removed and 
replaced by L-15 containing 5% hematocrit and dishes containing the co-culture were 
placed on ice. Cells were photolyzed on ice for 30 min using an Oriel 200 W Hg-arc lamp 
(model 66901) equipped with a beam splitter and a UV bandpass filter (360 ± 50 nm, 
Newport, FSQ-UG1). Non-photolyzed samples were stored in the dark. After photolysis, 
erythrocytes were removed from the dishes containing HeLa cells, and the latter were 
stained for 5 min with 5 µg/mL Hoechst 33342 (Molecular Probes) nuclear dye in L-15 in 
order to differentiate HeLa cells from erythrocytes. HeLa cells were then washed 6 times 
with L-15 to remove excess dye and erythrocytes. Non-lipidated 1a was incubated on ice 
with HeLa cells at 2.5 µM in L-15 media for 30 min and washed 6 times with L-15 as a 
positive loading control. 
 c. Cell culture experiments with MSH peptides 3 and 7. The melanocortin 1 
receptor (MC1R) gene (Entrez Gene ID 4157) was obtained from the DNASU plasmid 
repository and amplified via PCR to generate an N-terminal FLAG tagged MC1R fusion 
containing EcoRI at the 5’ end and SalI at the 3’ end of the PCR product (Forward Primer: 
5’-TCA AGC TTC GAA TTC ACC GCC ATG GAC TAC AAA GAC GAC GAC GAC AAG 
GCT GTG CAG GGA TCC CAG AG-3’, Reverse Primer: 5’-TCG ACT GCA GAA TTC TCA 
CAA CCA GGA GCA CGT CAG C-3’).  The FLAG-MC1R PCR product was cloned between 
the EcoRI and SalI sites of pEF1-MCS-IRES-EGFP (Clontech) via restriction and ligation 
cloning. Positive clones were identified via restriction digest (EcoRI/SalI) and sequencing. 
The pEF1-MCS-IRES-EGFP plasmid backbone was chosen so that EGFP could act as a 
fluorescent reporter of expression. 
 HEK293T cells were transiently transfected with 2 μg of DNA per 35 mm dish in 
Mattek glass bottom dishes for 16 h for all experiments using JetPrime transfection reagent 
(Polyplus transfection). All experiments were performed after 3 h serum starvation in DMEM 
basal medium.   
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 To establish specificity of peptide 3a binding to the transfected MC1R gene product, 
transfected cells were either treated with 200 nM peptide 3a or 400 nM native MSH for 30 
min at º37 °C. Cells blocked with native MSH were then washed and treated with 200 nM 
peptide 3a for an additional 30 min at 37 ºC before wash. Cells were then fixed in 4% 
paraformaldehyde in PBS and imaged on an Olympus FV1000 scanning confocal 
microscope with IX81 base. 488 and 559 lasers were used to excite EGFP and 5TAMRA 
respectively.   
 In order to establish light dependent release of peptide 7a from erythrocytes loaded 
with peptide 7, transfected cells were incubated for 30 min at 37 ºC in the dark with peptide 
7 loaded erythrocytes at 25% hematocrit that were either photolyzed using a 365 nm UV 
LED at 100% power (Colibri) for 2 x 10 min or stored at room temperature in the dark (non-
photolyzed). Erythrocytes were washed away in PBS and the cells fixed in 4% 
paraformaldehyde in PBS prior to imaging. Cells were imaged on the Olympus FV1000 
scanning confocal microscope with an IX81 base using the same parameters noted in the 
previous paragraph. Controls included non-transfected HEK293FT cells treated with 200 nM 
peptide 3a as a negative control and transfected HEK293FT cells treated with 200 nM 
peptide 3a as a positive control.  All image analysis was performed using imageJ. 
 d. Human platelet isolation. Venous blood (50 mL) was drawn from healthy, human 
volunteers into 3.8% trisodium citrate via a protocol approved by the University of North 
Carolina’s Institutional Review Board (IRB #15-0651). Platelets were isolated as described 
previously (S. P. Holly, J. W. Chang, W. Li, S. Niessen, R. M. Phillips, R. Piatt, J. L. Black, 
M. C. Smith, Y. Boulaftali, A. S. Weyrich, W. Bergmeier, B. F. Cravatt, L. V. Parise, Chem. 
Biol. 2013, 20, 1125-34). Briefly, blood was centrifuged at 150 x g to separate erythrocytes 
from platelet-rich plasma. Plasma was treated with 50 ng/mL prostacyclin (PGI2, Cayman 
Chemical) and spun at 500 x g to yield a platelet pellet. Platelets were gently resuspended 
in modified Tyrode’s buffer (5 mM HEPES pH 6.5, 137 mM NaCl, 2.7 mM KCl, 12 mM 
157 
 
NaHCO3, 0.42 mM NaH2PO4, 5.5 mM glucose, 1 mM MgCl2 and 0.1% delipidated, 
endotoxin-free BSA from Millipore) containing 1unit/mL apyrase (Sigma). Prostacyclin (50 
ng/mL) was added, platelets were spun again at 500 x g and resuspended in the same 
buffer with 0.5 units/mL apyrase. Prostacyclin was added again and the final pellet was 
resuspended in pH 7.4 Tyrode’s buffer with no apyrase. Platelets were counted with a Z1 
Particle Counter (Beckman-Coulter) and adjusted to 3 x 108 platelets/mL in Tyrode’s buffer 
pH 7.4 plus 1 mM CaCl2. 
 e. Platelet aggregation experiments. 1.05 x 108 platelets were magnetically stirred 
in a Model 700 two-channel lumi-aggregometer in the presence of 200 µg/mL human 
fibrinogen (Sigma) prior to stimulation. Aggregation was initiated with 100 µL of various 
erythrocyte preparations loaded with and without AFLLR peptide in a final volume of 400 µL. 
Aggregation proceeded for at least 3 min at 37 ºC. Positive controls were platelets treated 
with ADP or peptide 2a. Slopes and maximum amplitudes of aggregation traces were 
calculated with Aggrolink 8 software for quantitative measures of platelet activation.   
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VI. Microscopy.  
HeLa cells were imaged to determine peptide loading using an Olympus FV1000 
scanning confocal microscope with IX81 base. Images were acquired using either a 40X or 
100X oil objective. 405 nm and 559 nm lasers were used for excitation of Hoechst 33342 
and 5-TAMRA respectively. All images were acquired at a resolution of 1024 x 1024 pixels 
and a pixel dwell time of 10 µs/pixel.  All multichannel images were acquired sequentially in 
order to minimize Hoechst 33342 bleed trough into the 5-TAMRA channel. Widefield 
fluorescent microscopy imaging was performed on an inverted Olympus IX81 widefield 
microscope equipped with a Hamamatsu C8484 camera, 20X Phase 1 LUCPlanFL N 
objective or a 40X Phase 1 LUCPlanFL N objective,  and TexasRed filter cube from 
Semrock.  All imaging analysis was performed using Image J software. Multichannel images 
were split into their respective single channels.  Hoechst 33342 images were used as is with 
no processing. 5-TAMRA images were processed to enhance contrast and remove 
background fluorescence. First, a background fluorescence image was generated via 
blurring the original image using the Gaussian Blur filter with a radius of 100 pixels. The 
background image was then subtracted from the original image via the operation i = (i1-i2), 
where i1 and i2 are the original image and background image respectively. The resulting 
image was further processed using Subtract Background with a rolling ball radius of 50 
pixels.  5-TAMRA images were then merged with Hoechst 33342 images in order to 
generate composite images.
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  CHAPTER 6: NEURAL STEM CELL MEDIATED DELIVERY OF COBALAMIN 
PHOTOTHERAPEUTICS TO GLIOBLASTOMA 
Section 6.1: Introduction 
 GBM is a death sentence disease with an incidence of approximately 3 in 100,000 
humans per year.[207]  It is the most common neoplasm in the brain and is highly aggressive.  
Median survival with treatment is 14.6 months after diagnosis with 5 year survival rates 
below 5%.[208] Early symptoms are generally nonspecific and characterized by headaches, 
nausea, and personality changes.[209]  Disease progression is rapid and symptoms worsen 
quickly and evolve to include seizures and unconsciousness.[210]  Current treatment for GBM 
consists of surgical resection (when possible) followed by radiation and chemotherapy with 
the alkylating agent temozolomide.[211]  However, recurrent primary tumors and distal 
metastases almost always present themselves after treatment due to the highly diffuse and 
invasive nature of the disease (Figure 6.1).[212] 
Figure 6.1: A MRI of patient diagnosed with GBM immediately after tumor resection (left, 
resection cavity is upper left portion of brain) has recurrence of the primary tumor and 
development of distal metastases (white regions) within 3 (middle) and 4 (right) months of 
treatment.  Reprinted with permission from publisher.[212] 
160 
 
 
 Treatment is complicated by the nature of the tumor (described above) as well as the 
relative difficulty of surgical intervention in highly complex regions of the brain.  In addition, 
there are relatively few chemotherapeutic options for GBM treatment due to the fact that 
many drugs do not cross the BBB and GBMs are generally resistant to many traditional 
chemotherapeutic agents.[213]  
 NSC therapy is a promising route to targeted treatment of GBM due to the fact that 
NSCs have inherent tumor homing capabilities and have been shown to be effective in 
delivering a variety of therapies including enzymes for prodrug activation,[185-186] oncolytic 
viruses,[189] and nanoparticles.[190-191]  However, there is still a need for improvement in 
treatment and small molecule chemotherapeutics still remain the frontline treatment for 
many malignancies.  Therefore, we are collaborating with the Hingtgen lab at UNC to 
combine our cobalamin-based phototherapeutics with their NSC models of GBM treatment.  
Indeed, we have shown that cobalamin phototherapeutics can be loaded onto the 
exterior[166] and interior (publication in preparation) of RBCs to deliver chemotherapeutic and 
Figure 6.2: Outlines an exterior loaded RBC approach to delivery of 
phototherapeutics.  Reprinted with permission from publisher.[166] 
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a variety of other agents to target cells with high temporal precision (Figure 6.2).  Therefore, 
we reasoned that we could extend the approach to NSC mediated treatment of GBM.  
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Section 6.2: Delivery of NSC loaded drug-like phototherapeutics to HeLa cells 
 First, we set out to determine whether or not we could 1) load NSCs with 
phototherapteutics and 2) use light to induce photolysis and subsequent delivery of a drug 
like molecule to target cells.  HB1.F3 NSCs[185-186]  were cultured overnight in the presence 
of Bodipy-cobalamin (Cbl), Bodipy-Cbl-C18, or HO-Cbl-Cy5 (a non-photolyzable analog) 
with Alexa Fluor 488 dextran (as an endosomal loading control).  The cells were extensively 
washed after loading and then placed in co-culture with HeLa cells.  Photolysis of Bodipy 
from Cbl was monitored via widefield microscopy.  It is important to note that, due to the 
nature of Cbl photochemistry, the act of monitoring Bodipy release with 650 nm light induces 
photolysis.  Efficient photolysis, assayed as the transfer of Bodipy fluorescence from the 
loaded NSCs to proximal HeLa cells (Figures 6.3, 6.4, 6.5), was observed.  The non-
photocleavable analog, HO-Cbl-Cy5, was efficiently loaded into NSCs but excitation with 
650 nm light did not induce photolysis and transfer of the fluorophore to neighboring HeLa 
cells (Figure 6.6).  Given that NSC migration to GBM tumors takes time, we wanted to 
assess the retention of Cbl compounds in endosomally loaded NSCs using OH-Cbl-Cy5.  
NSCs retained a significant amount of loaded compound over 4 days and the retention was 
enhanced by the inclusion of Alexa Fluor 488 dextran (Figure 6.7).  It is unclear why 
inclusion of fluorescent dextran enhances OH-Cbl-Cy5 retention.  Perhaps, OH-Cbl-Cy5 
interacts with the dextran and, due to the large size of dextran (10,000 Da), the cells may be 
less efficient at recycling endosomes. 
Section 6.3: Investigation of loading non-photocleavable Cy5-Cbl derivatives with 
different lipid tails 
 Cellular photolysis experiments outlined in section 6.3 revealed that far more Cbl 
compound is loaded onto and released from NSCs using a lipidated Cbl analogue (see 
Figure 6.4) versus its non-lipidated counterpart.  Therefore, we investigated the effects of 
different lipid tails on cellular loading of lipidated, non-photocleavable, Cbl derivatives.  For 
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these experiments, we used Cbl derivatives that contained a triple bond adjacent to the 
carbon cobalt bond.  Alkyl-Cbl compounds do not undergo photolysis when cobalt is bound 
to an sp hybridized carbon.[214] 
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Figure 6.3: NSCs loaded with Bodipy-Cbl (structure at right) were photolysed by imaging 
Bodipy fluorescence with excitation of 650 nm.  The NSCs were loaded by an endosomal 
mechanism (top left) and photolysis resulted in rapid and efficient delivery of Bodipy 
fluorescence to neighboring HeLa cells (bottom left).  Quantification of fluorescence in 
HeLa cells revealed an apparent 6 – 7 fold increase in HeLa cell fluorescence compared 
to t = 0.   
Figure 6.4: NSCs loaded with the lipidated Bodipy-Cbl-C18 derivative (structure at right) 
were photolysed by imaging Bodipy fluorescence with excitation of 650 nm.  The NSCs 
were loaded on the cellular membrane (top left) and photolysis resulted in rapid and 
efficient delivery of Bodipy fluorescence to neighboring HeLa cells (bottom left).  
Quantification of fluorescence in HeLa cells revealed an apparent 30 fold increase in HeLa 
cell fluorescence compared to t = 0.   
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Figure 6.5: A low magnification image of the experiment described in Figure 6.3. 
 
Figure 6.6: NSCs loaded with a non-photocleavable Cbl analog did not transfer Cy5 
fluorescence to neighboring HeLa cells upon excitation with 650 nm light (top left, 
quantification is shown in the bottom left panel).  The structure of OH-Cbl-Cy5 is shown at 
the right. 
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 HeLa cells were loaded with 4 different compounds (DiD = 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine, Cy5-alkynyl-Cbl-ODA1, Cy5-alkynyl-Cbl-ODA2, and 
SulfoCy5-alkynyl-ODA2) overnight at 5 µM in complete media.  Loading was performed in 
the presence or absence of 0.02% Pluronic F127, a surfactant used to enhance membrane 
loading of compounds and disperse hydrophobic aggregates in aqueous solutions.[215]  After 
loading, the cells were washed and media was replaced with imaging media (see Materials 
and Methods).  Cy5 fluorescence was imaged on the confocal microscope to assess loading 
distribution and efficacy.  Fluorescence was detectable in all samples that were loaded 
(Figure 6.8).  For all compounds, except sulfoCy5-alkynyl-Cbl-ODA2, the majority of 
fluorescence was localized to what appear to be intracellular membranes such as 
mitochondria.  SulfoCy5-alkynyl-Cbl-ODA2 was distributed in a punctate pattern reminiscent 
Figure 6.7: NSCs loaded with OH-Cbl-Cy5 retain about 50% of their initial Cy5 
fluorescence when endosomally loaded and allowed to grow in complete media for 4 days.  
Inclusion of Alexa Fluor 488 dextran when loading cells results in an enhanced retention 
of Cy5 fluorescence. 
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of endosomes.  Surprisingly, there is very little fluorescence associated with the cell 
periphery, which was expected to be the initial site of membrane loading.  Given that 
intracellular membrane fluorescence was extremely bright under 24 h loading conditions 
(Figure 6.8) as well as 1 h loading conditions (data not shown), there could be some 
fluorescent contamination in the solution.  Cy5 is a lipophilic cationic species, and lipophilic 
cationic species are known to accumulate in mitochondria in a membrane potential 
dependent manner.[216]  Cell loading conditions employed 1 – 10 µM Cbl derivatives. 
However, even a 1% impurity containing free Cy5, would furnish 10 – 100 nM free 
fluorophore, which is the concentration range generally used to stain mitochondria with 
commercially available fluorescent probes.[165] If this is indeed the case, we hypothesized 
that treating loaded cells with a mitochondrial membrane potential uncoupler such as 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) would reduce intracellular 
fluorescence and reveal subcellular distribution of Cbl compounds.  Indeed, incubation with 
20 µM FCCP resulted in a marked decrease in intracellular membrane fluorescence while 
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revealing both punctate and membrane associated fluorescence (Figure 6.9).  In summary, 
these results suggest that there is a small amount of free Cy5 free in solution during NSC 
Figure 6.8: Fluorescent confocal micrographs of compounds on the right loaded for 24 h 
at 5 µM. 
Figure 6.9: Incubation with mitochondrial membrane decoupler FCCP confirms that a 
proportion of the observed fluorescence in intracellular membranes is due to a membrane 
potential dependent uptake of a small, soluble fluorescent molecule.  The compound on 
the right is the hypothesized species. 
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loading.  Future experiments will seek to determine whether or not the species present is 
free Cy5 by LC/MS.  However, based on the initial Bodipy-Cbl photolysis experiments, it is 
highly likely that Cbl-conjugates are loaded into/onto NSCs, and these results may be 
specific to the Cy5-alkynyl-Cbl compounds.  In addition, cobalt-sp carbon bonds may be 
more sensitive to acidic environments found in endosomes than alkyl cobalamins. 
Section 6.4: Assessing migratory aptitude of NSCs loaded with Cy5-alkynyl-Cbl 
compounds 
 One of the key properties of NSCs as a potential route to GBM treatment is the fact 
that they migrate to, and interact with GBM cells.  In order for our strategy of loading Cbl-
drug conjugates on/into NSCs to be valid, NSCs must retain their migratory potential after 
loading.  Therefore, we loaded RenCell human NSCs with 10 µM Cy5-alkynyl-Cbl, Cy5-
Figure 6.10: RenCells were loaded with 10 µM Cy5-alkynyl-Cbl (top), Cy5-alkynyl-Cbl-
ODA1 (middle) or nothing (bottom) in wells separated by a 100 µm gap.  After cells 
adhered, the wells were removed and cells were allowed to migrate over 5 days.  All groups 
migrated towards the U87 GBM cells. 
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alkynyl-Cbl-ODA1, or unloaded cells and compared their ability to migrate to U87 GBMs 
(Figure 6.10).  We see that both endosomal loading (Cy5-alkynyl-Cbl) and membrane 
loading (Cy5-alkynyl-Cbl-ODA1) does not appear to affect NSC migration to GBM cells in 
culture.  We are currently investigating whether or not NSCs maintain migratory ability in 
vivo.  Given that we observe intracellular membrane fluorescence upon loading NSCs with 
Cy5-alkynyl-Cbl compounds, we also need to determine the amount of intact compound that 
is actually loaded into NSCs by LC/MS.  We will address this concern in ongoing studies. 
 
Section 6.5: Assessment of Cbl cytotoxicity 
 It struck us that Cbl compounds might have their own inherent toxicity independent of 
drug cargo.  Therefore, we decided to perform a series of dose response experiments over 
time to assess the relative toxicity of each potential Cbl core compound that was 
synthesized in an effort to better define loading conditions once we moved into experiments 
where we wanted to deliver actual drugs.  A summer rotation student, Ms. Allison Mercer-
Smith, performed these experiments under my supervision.  She loaded C17 mouse NSCs 
with different concentrations of the various Cy5-alkynyl-Cbl compounds and assayed cell 
viability via an ATP assay over 5 days (Figure 6.11).  Compounds were generally well 
tolerated to a concentration of 1 µM at which point we observed dose dependent decreases 
in cell viability.  The biggest changes were observed in NSCs loaded with lipidated Cbl 
derivatives.  These compounds form macroscopic aggregates at high concentrations and we 
reasoned that decreased cell viability was most likely due to detergent effects from the 
lipidated compounds.  Cy5 itself is also highly hydrophobic, which may enhance our 
proposed lytic effects of lipidated compounds.  It will be interesting to see whether the 
observed cytotoxic effect of high concentrations of lipidated Cbl conjugates is maintained in 
cells loaded with other drug-Cbl compounds. 
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Figure 6.11: Dose response curves to Cy5-alkynyl-Cbl compounds.  Graphs at right 
represent viability over a range of concentrations over 5 days for the compounds drawn on 
the right. 
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Section 6.6: Light mediated release of Colchicine-Cbl in NSCs 
 Given that the act of visualizing a Cbl compound initiates photocleavage of the 
payload, we needed to assess light mediated drug delivery to NSCs in a time point 
dependent manner.  In previous work, we used release of the microtubule depolymerizer 
colchicine (COL) and subsequent loss of microtubules as a readout of photocleavage and 
drug deliver in cells.[166]  Therefore, we reasoned that COL-Cbl treatment followed by tubulin 
staining would be an appropriate assay to determine efficacy of loading and subsequent 
light mediated release of COL in NSCs.  RenCells were incubated with 10 µM COL-Cbl 
overnight.  The excess COL-Cbl was washed away and cells were photolyzed with 525 nm 
light for 1 h and compared to 10 µM free COL, no treatment, or COL-Cbl loaded cells left in 
the dark.  We observed a loss of microtubules in COL-Cbl loaded cells only when they were 
exposed to light (Figure 6.12) indicating that COL was released at an effective 
concentration. 
  
Figure 6.12: RenCells were loaded with COL-Cbl overnight before washing away 
excess compound.  After 1 h photolysis, cells loaded with COL-Cbl had fewer 
microtubules than those left in the dark. 
 
173 
 
Section 6.7: Future directions and discussion 
 The preceding sections of Chapter 6 describe an ongoing project aimed at 
developing a light mediated drug delivery platform for GBM using tumor-homing NSCs 
loaded with Cbl phototherapeutics.  To date, we have shown that 1) NSCs can be loaded 
with Cbl-conjugates in either an endosomal or membrane bound fashion, 2) loaded NSCs 
still retain migratory capacity after loading with Cbl compounds, and 3) we can induce 
photolysis resulting in delivery of small molecule drug-like molecules and drugs to both 
NSCs and neighboring cancer cells.  We are currently in the process of moving these 
experiments into in vivo models of GBM with the Hingtgen group.  While our current efforts 
show great promise for translation in vivo, we are concurrently pursuing a number of 
different strategies for 1) effectively delivering photons in a spatially distinct manner and 2) 
developing viral delivery systems for Cbl-drug delivery.  These approaches will be discussed 
in the following section. 
 NanoLuc mediated photolysis of Cbl-drug compounds.   NanoLuc, an 
engineered ATP independent luciferase, was developed by Promega as a small, highly 
active luciferase for in vitro and in vivo luminescence studies and emits more photons at a 
given substrate concentration than other luciferases currently available.[217]  NanoLuc utilizes 
the engineered substrate furimazine and has a peak emission at 460 nm.  Dr. Amelio and 
colleagues at UNC Chapel Hill have taken advantage of the spectral emission and high 
emission intensity of NanoLuc to develop a series of bioluminescent resonance energy 
transfer (BRET) tools, called Lumifluors.  These Lumifluors are composed of a fluorescent 
protein fused to the NanoLuc such that photons emitted by NanoLuc’s catalytic activity on 
furimazine excite the fluorescent protein to emit longer wavelength photons.[218]  The C17 
NSCs that we use constitutively express a GFP Lumiflour and the NanoLuc-GFP BRET is 
highly efficient resulting in strong emission of photons between 480 – 550 nm.  In addition, 
furimazine is capable of crossing the BBB and is routinely used in intravital imagining to 
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monitor both NSC migration (unpublished data) and tumor progression.[218]  Given the 
difficulties in effectively delivering intense light to deep regions within the brain[219] and the 
fact that Cbl photolyzes readily at wavelengths lower than 560 nm, we reasoned that we 
might be able to take advantage of NSCs expressing GFP-Lumifluor in order to generate 
photons from inside of the brain and subsequently release our drug payloads without 
external light sources (Figure 6.13).   
 In order to determine the efficacy of Lumifluor induced photolysis of Cbl-drug 
conjugates, we turned to the COL microtubule depolymerization assay described in Section 
6.6.  Briefly, 10 µM COL-Cbl was loaded into C17 NSCs expressing Lumifluor overnight and 
photolysis was initiated by either exposure to light (525 nm) or treatment with 40 µM 
furimazine for 1 h. We then performed immunostaining for microtubules to determine the 
effects of COL.  No treatment, 10 µM free COL, 40 µM furimazine alone, and cells loaded 
with COL-Cbl but left in the dark were used as controls (Figure 6.14).  Unfortunately, the 
cells that were loaded with COL-Cbl in the dark also showed a loss of microtubules 
indicating that 1) there was enough free COL in solution to induce microtubule 
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depolymerization, or 2) COL-Cbl is unstable when loaded endosomally.  We are currently 
determining what caused this observation. 
Figure 6.13: BRET emission from the Lumifluor (A) transfers energy to Cbl inducing 
photocleavage of the cobalt-carbon bond releasing drug (left).  A) Outlines the mechanism 
of action of Lumifluor, B) Is a molecular model showing the spatial requirements for 
NanoLuc-GFP BRET.  C) Shows the emission intensity and spectra of both NanoLuc 
(purple) and Lumifluor (green) after treatment with furimazine.  Bottom right shows the 
NanoLuc substrate furimazine. A – C are reprinted with permission from the publisher.[217] 
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Figure 6.14: Lumifluor expressing C17 NSCs were loaded with COL-Cbl (bottom left) for 
24 hs h before the excess compound was washed away.  The cells were then exposed to 
525 nm light (bottom middle image), 40 µM furimazine (bottom right image), or left in the 
dark (bottom left image).  Controls were no treatment (NT, top left image), 10 µM COL (top 
middle image) or 40 µM furimazine alone (top right image).  The COL positive control 
resulted in loss of microtubules relative to no treatment and furimazine alone did not seem 
to effect microtubule morphology.  However, microtubules were gone in all COL-Cbl treated 
groups. 
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 Since microtubule depolymerization was apparent in all COL-Cbl treated groups in 
the overnight loading experiment described above, we reasoned that, as a proof of principle, 
a shorter incubation time and photolysis in the presence of COL-Cbl might reveal Lumifluor 
mediated photolysis of COL-Cbl and subsequent microtubule depolymerization.  Indeed, 
when C17 NSCs expressing Lumifluor were treated with 10 µM COL-Cbl followed 
immediately by photolysis with either 525 nm light or 40 µM furimazine, we observed robust 
microtubule depolymerization relative to controls (Figure 6.15). 
 These were exciting results, and we are currently following up on this approach for 
internally generating photons for photocleavage of Cbl-drugs.  Endosomal loading may 
result in unstable Cbl-drug conjugates due to the pH change associated with endocytosis.  
Therefore, we will investigate whether membrane loading of NSCs with lipidated COL-Cbl 
derivatives decreases the off-target effects of incubating COL-Cbl with NSCs for extended 
periods of time.  We are also investigating whether or not we can modify the system to work 
with NanoLuc-conjugated antibodies to remove the need for all components to be contained 
in NSCs alone.   
 Positron emission as a source of photons for photocleavage of Cbl-drugs. 
Positron Emission Tomography (PET) is an imaging method used to monitor tumor location 
and size in GBM.[220]  PET imagining takes advantage of the fact that positron emission from 
a radionuclide results in matter-antimatter annihilation over a short distance (0.2 – 1.5 mm) 
Figure 6.15: Treatment with COL-Cbl followed by immediate photolysis with 525 nm light 
or addition of furimazine for 1 h (in the presence of COL-Cbl) resulted in marked 
microtubule depolymerization in C17 NSCs expressing Lumifluor relative to no treat or 
COL-Cbl dark controls. 
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when the positron interacts with an electron.  The annihilation event results in the production 
of a pair of photons that are emitted in opposite directions (Figure 6.16 top panel).  Patients 
are placed in a detector ring after injection with a given radioisotope and, when the detector 
counts two photons at 180º from each other, assign a line connecting the two thus 
pinpointing the location of emission.[220]  A variety of radioisotopes are used in PET imaging.  
All isotopes that are used have short half-lives (2 min – 12.7 h) so they are amenable to 
short term imaging experiments.[221] In GBM, the primary radionuclide in use is 2-[18F]-fluoro-
2-deoxy-D-glucose (FDG).[220]  Tumors are characterized metabolically as being highly 
glycolytic.[222]  Therefore, FDG is rapidly taken up in tumors relative to healthy tissue.  This 
fact results in a higher relative concentration of FDG in tumors and acts to enhance contrast 
of tumors in PET imaging.  In addition, positron emission results in two other mechanisms of 
photon emission.  First, when a positron is traveling faster than the phase velocity of light in 
a given media (Cherenkov Radiation), photons are emitted at an angle dependent on the 
inverse of a given material’s refractive index (Figure 6.16).[223]  The number of photons that 
are emitted is dependent upon the energy of the particle and radioisotope.  A second 
alternative mechanism of photon emission from positron decay is known as Bremsstrahlung, 
or “braking radiation”.[224]  Bremsstrahlung occurs when a charged particle (positron) travels 
close to the nucleus of another atom.  The nuclear forces that the nucleus exerts on the 
charged particle can slow the particle and change its vector resulting in a loss of velocity 
and energy.  In order to conform to the Law of Energy Conservation, photons are emitted 
from the passing charged particle equal to the difference in energy for the two vectors.[225]   
 Since positron emission is in use in the clinic and produces photons via a number of 
different mechanisms, it may be a useful route to tumor specific photolysis of Cbl-drug 
conjugates.  Indeed, there is a single report in literature that claims to have used Cherenkov 
radiation to uncage nitrobenzyl compounds.[226]  In addition, Bremsstrahlung has been used 
to increase the efficiency in photodynamic therapies.[227]  Positrons are highly energetic 
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species (mean energy FDG positron = 250 keV[228]) providing an additional potential 
mechanism for cleavage of the cobalt-carbon bond by kinetic energy.  Therefore, we set out 
to collaborate with Dr. Matthew Parrot, a PET tool developer, to investigate if we could 
detect photolysis of Cbl-drugs after exposure to FDG.  Our initial experiment was performed 
in vitro.  We incubated 10 µM Paclitaxel-Cbl (PTX-Cbl) or Cy5-Cbl with a range of 
concentrations of FDG (3.75 – 0.006 µCi/µl) and allowed the samples to sit until the FDG 
decayed to undetectable levels.  We then quantified photolysis by LC/MS.  At the highest 
concentrations of FDG we observed photolysis of both PTX-Cbl (Figure 6.17) and Cy5-Cbl 
(data not shown) indicating that some form of energy released from FDG decay is capable 
of breaking the cobalt-carbon bond.  This is ongoing work and we plan to transition to cell 
based assays in the near future as we expect the effect to be enhanced due to the fact that 
cells will concentrate FDG in space relative to the drug-Cbl conjugates. 
 
  
Figure 6.16: Descriptions of the different modes of photon emission for positron (β+) decay. 
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 Viral delivery of lipidated Cbl-drugs.  Viral particles are an appealing strategy for 
drug delivery.  Viruses display inherent tropism (preference for infecting specific tissues), 
can be generated in high numbers, and are highly efficient at cell fusion and gene delivery.  
Viruses have garnered great interest in the biomedical community as routes to treatment of 
a variety of diseases including glioblastoma,[229] color blindness,[230] and a variety of other 
genetic disorders.[231]   Many viruses have a lipid-bilayer envelope that surrounds their 
proteinaceous capsid.  Given that viruses 1) have highly specific tropism and 2) may be 
enveloped, we reasoned that we might be able to utilize enveloped viral particles to load and 
effectively deliver lipidated Cbl-drugs to sites of disease.   
 This work is in collaboration with Dr. Nathaniel Moorman, a cytomegalovirus (CMV) 
researcher at UNC Chapel Hill.  CMV is a member of the herpes virus family and is 
enveloped.  We were concerned that viral particles do not afford adequate surface area for 
Figure 6.17: PTX-Cbl (notated Cbl-PTX in figure) was incubated with increasing 
concentrations of FDG over the weekend to allow FDG to decay to safe working levels.  
PTX-Cbl cleavage was quantified by LC/MS monitoring the appearance of OH-Cbl 
because PTX does not absorb strongly at an amenable wavelength but OH-Cbl has strong 
absorbance at 350 nm.  The top left panel shows the LC trace from PTX-Cbl without FDG 
treatment and the bottom left panel shows the trace for PTX-Cbl incubated with the highest 
concentration of FDG (3.75 µCi/µl).  Notice the appearance of OH-Cbl photolysis product 
in the bottom trace.  The proposed reaction is shown on the right. 
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loading therapeutic levels of Cbl-drug compounds.  However, some simple math put our 
worries to rest.  Human CMV (hCMV) particles have diameters between 150 – 200 nm.[232]  
If we treat the viral particle as a sphere, the total surface area for a 150 nm viral particle is 
70685.83 nm2 (surface area of a sphere = 4πr2 and r = 75 nm for a 150 nm particle).  For 
gene therapy viral doses of 107 – 1011 viral particles is common.[233]  Therefore, a 150 nm 
hCMV particle delivered at a dose of 107 – 1011 particles would yield a total surface area of 
706.85 – 7.0685 x 106 m2 of surface area.  The upper limit of surface area is on the order of  
7 km2 or about 2 times the size of London, England.[234]  Rough calculations on the cross-
sectional area of cobalamin’s corrin ring reveal that the area for a single cobalamin molecule 
is about 2.1 nm2.  This area was calculated by determining the distance between primary 
amides on opposite sides of the corrin ring (distance = 1.633 nm, r = 0.8165 nm) and 
treating it as a circle.  If the entire surface of an hCMV virion envelope is available for Cbl 
loading, then the maximum number of Cbl molecules per virion is 33,756.  There are 
membrane proteins associated with the hCMV envelope so the actual number of Cbl 
molecules per virion will be lower.  However, the potential number of Cbl-drug conjugates 
per virion is four orders of magnitude greater than the average number of drug molecules 
conjugated to an antibody for ADC (2 – 6 molecules / antibody).[235]   Therefore, it is clear 
that hCMV provides more than adequate surface area for loading of Cbl-drug compounds 
and a potentially large loading capacity per delivery unit relative to ADC.   
 First, we wanted to determine whether or not lipidated Cbl compounds could be 
loaded onto hCMV particles.  While hCMV particles are near the diffraction limit of light and 
difficult to visualize as individual particles via light microscopy, fluorophores emit light upon 
excitation independent of the diffraction limit of light.  Therefore, we reasoned that, if hCMV 
particles were successfully loaded with nonphotocleavable Cy5-alkynyl-Cbl-ODA1, then we 
should be able to observe Cy5 fluorescent puncta under the microscope.  we incubated 1 ml 
viral supernatant with 1 µM Cy5-alkynyl-Cbl-ODA1 for 1 h at room temperature and plated a 
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small aliquot on a glass slide and covered it with a glass coverslip.  Upon imaging for Cy5 
fluorescence, we observed a greater number of puncta when both hCMV and Cy5-alkynyl-
Cbl-ODA1 were present compared to Cy5-alkynyl-Cbl-ODA1 without virus (Figure 6.18) 
indicating that the Cbl compound was, in fact, associating with hCMV particles. 
 We then wanted to test whether these Cbl-loaded hCMV particles could 1) still infect 
host cells and 2) transfer the Cbl cargo to host cells.  We loaded viral supernatants 
containing hCMV that encoded GFP as a reporter of infection as described above and 
pelleted the loaded viral particles by ultracentrifugation to remove excess Cy5-alkynyl-Cbl-
ODA1 in solution (Figure 6.19 top left).  Indeed, pellets loaded with either Cy5-alkynyl-Cbl-
ODA1 or the membrane loading control DiD were blue indicating association of cyanine 
fluorophore with viral particles.  The viral pellets were resuspended in 500 µL complete 
media and incubated with human primary fibroblasts for 1 h before excess virus was 
washed away.  The infected cells were incubated overnight and the following day, we 
imaged the cells for 1) GFP expression indicating viral infection and 2) Cy5 fluorescence 
indicating transfer of Cy5-alkynyl-Cbl-ODA1 to the host cells.  We observed robust GFP 
expression and Cy5 fluorescence in all cells treated with DiD or Cy5-alkynyl-Cbl-ODA1 
loaded hCMV.  GFP fluorescence was apparent in unloaded hCMV but there was no Cy5 
fluorescence associated with infected cells, as expected (Figure 6.19). 
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Figure 6.18: hCMV particles were loaded for 1 h with DiD or Cy5-alkynyl-Cbl-ODA1 
and imaged via widefield microscopy for the presence of fluorescent puncta indicative 
of compound association with viral particles.  Copounds in the absence of hCMV were 
used as controls.  More fluorescent puncta are present when hCMV was present 
indicating that the compounds associate with viral particles. 
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Figure 6.19: Blue viral pellets (top left) indicate that Cy5-alkynyl-Cbl-ODA1 (1) and 
DiD (2) load onto hCMV particles.  Unloaded particles (3) are not blue.  Human 
fibroblasts infected with Cy5-alkynyl-Cbl-ODA1 (middle) or DiD (bottom) loaded 
hCMV particles express GFP and show intracellular Cy5 fluorescence indicating 
successful viral infection and transfect of fluorescent cargo.  Unloaded hCMV 
particles (top right) induce GFP expression but no Cy5 fluorescence is associated 
with these cells indicating that Cy5 fluorescence is a result of hCMV cargo in loaded 
particles. 
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 Our initial results are promising.  However, we need to ensure that the Cbl 
compounds are actually loaded onto the viral particles themselves and not simply 
aggregating.  We will do a band purification experiment in order to rule out the unlikely 
possibility that the blue color is simply due to Cbl aggregates.  In short, loaded virions will be 
spun over a sucrose gradient to separate heavy and light particles and produce a specific 
band associated with mature viral particles.  If the Cbl compounds are loaded onto the viral 
particles, then we expect to see Cy5 fluorescence associate with the viral band.  Once we 
confirm that the viral particles are actually loaded with Cbl compounds, we will attempt to 
deliver actual drugs with either hCMV or another enveloped virus.  For example HIV 
expresses tropism for CD4+ T-cells.[236]  Therefore, we can load HIV particles with a 
cytotoxic Cbl-drug conjugate.  We can then mix the loaded HIV particles with human blood 
and, after an appropriate period of time, induce drug release by photolysis.  We expect to 
observe selective ablation of CD4+ T-cells in photolyzed samples.  Photolysis of Cbl-drug 
conjugates will serve as a useful proof of principle.  Acid or enzyme labile linkers between 
the lipid and drug may provide a more effective route to delivery of viral loaded therapeutics.  
However, both of these approaches can result in unstable conjugates in plasma.[149]  
Photolytic cleavage provides a release route that is completely orthogonal to biology and 
may be more effective. 
 Viral gene therapy is an exciting and active area of research.  Our approach to using 
viral particles as delivery system for phototherapeutics may act synergistically with current 
viral therapy approaches.  For example, viral particles for therapeutic purposes generally are 
replication deficient.  That is to say that the genomic regions necessary for replication have 
been removed.  Therefore, there is extra space in the viral genome that could house 
cytotoxic genes[237] or small interfering RNAs (siRNA).[238]  Viral genomes encoding either of 
these species have been shown to be effective in treating cancers in animal models.[237-238]  
We could conceivably include Cbl phototherapeutics in order to add a 1 – 2 knockout punch 
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to cancerous cells.  In addition, we may be able to combine viruses that encode NanoLuc or 
Lumiflours with our Cbl phototherapeutics to alleviate the need for external light sources to 
induce drug release.  It will be exciting to see how this project progresses over the next few 
months. 
 Closing remarks.  In conclusion, the second half of my thesis described a number 
of approaches for spatial and temporal delivery of phototherapeutics.  Chapter 5 describes a 
publication in Angewandte Chemie that used RBC membranes as a pool and protecting 
group for peptide phototherapeutics.  Chapter 6 describes the use of Cbl-drug conjugates 
and cellular or viral carriers towards developing treatments for GBM and other diseases.  
Taken together, Chapters 5 and 6 represent one half of my thesis work directed at 
developing light-mediated drug delivery platforms. 
Section 6.8: Materials and Methods 
Cbl compounds 
We would like to thank Dr’s Qunzhao Wang, Song Ding, Weston Smith, Zackary 
Rodgers, David Friedman, and Thomas Shell for the synthesis and characterization of all 
Cbl compounds used in Chapter 6. 
Cell Culture 
HB1.F3, RenCells, and C17 NSCs were provided as gifts from Dr. Shawn Hingtgen.  
Human fibroblasts were provided by Dr. Nathanial Moorman. HB1.F3, C17, and human 
fibroblast cells were cultured in DMEM + 10% FBS + 1X GlutaMAX + 1X PenStrep (all from 
Gibco, except FBS which was HyClone).  For long term studies with C17 cells, 1% FBS was 
used to inhibit cell growth.  RenCells were cultured in RenCell media with EGF and bFGF 
supplements (EMD Millipore). 
Bodipy release experiments 
HB1.F3 NSCs were loaded overnight with 10 µM Bodipy-Cbl compounds and 1 µM 
Alexa Fluor 488 dextran (Molecular Probes).  The following day, NSCs were washed 3X with 
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media and dissociated from plates with Accutase (Life Technologies).  NSCs were then 
plated onto HeLa cell cultures stained with 1 µg/ml Hoechst 33342 (Molecular Probes) in 
complete media and allowed to attach for 3 h before media exchange to imaging media 
(Lebowitz L-15 + 10% FBS, Gibco).  Cells were placed in a humidified heated incubator on 
our widefield microscope (see materials and methods in previous chapters) for at least an h 
to equilibrate.  Imaging was performed at 60X by taking 100 ms frames with the Cy5 cube 
every 30 s over 15 min.  Alexa Fluor 488 fluorescence was imaged with an exposure of 100 
ms using the FITC filter cube and Hoechst 33342 fluorescence was imaged with the DAPI 
filter cube and 500 ms exposure time.  Data analysis was performed by measuring ROIs 
within both NSCs and the adjacent HeLa cells.  Background was subtracted and the raw 
values were converted into either fold change in fluorescence (Fn/F0) or normalized between 
0 and 1.  The same protocol was used for imaging studies with OH-Cbl-Cy5. 
OH-Cbl-Cy5 retention studies 
HB1.F3 cells were loaded with 10 µM OH-Cbl-Cy5 +/- 1 µM Alexa Fluor 488 dextran 
overnight and thoroughly washed.  Cells were imaged for Cy5 and Alexa Fluor 488 
fluorescence using the Cy5 and FITC filter cubes respectively on day 1 and 4 at 60X.  
Exposure times for both days was 100 ms Cy5 and 100 ms FITC.  Fluorescence intensities 
minus background were determined for quantitative analysis. 
Cy5-alkynyl-Cbl loading and cellular distribution experiments 
HeLa cells (ATCC) were loaded with 5 µM Cy5-alkynyl-Cbl compounds or DiD 
overnight and thoroughly washed to remove excess compound.  Imaging was performed on 
our confocal microscope (see previous chapters for description) at 60X and 1024 x 1024 
resolution.  For determining the role of mitochondrial membrane potential in cellular 
distribution of fluorescence, C17 cells were loaded with Cy5-alkynyl-Cbl-ODA1 as described 
above and then incubated with 20 µM FCCP (Sigma) after initial imaging.  Imaging after 
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FCCP treatment occurred 1 h after addition of FCCP and used the same settings as initial 
imaging. 
NSC migration 
RenCells were loaded with 10 µM Cy5-alkynyl-Cbl or Cy5-alkynyl-Cbl-ODA1 
overnight as described above.  Loaded cells were dissociated from plates and placed in 
separation wells adjacent to wells containing U87 GBM cells (a gift from Dr. Hingtgen).  After 
3 h the cells had adhered to the plate and the wells were removed.  Adherent cells were 
washed 3X with media to remove any non-adherent cells.  Imaging was performed at 4X on 
our widefield microscope in the morning and afternoon over 5 days.  The Cy5 cube was 
used to image loaded NSCs and the FITC cube was used to image the GFP expressing U87 
GBMs. 
Cbl compound loading toxicity studies 
C17 NSCs were plated in 96 well plates and loaded with the indicated concentration 
of each compound listed overnight.  The cells were then washed at least 3X with media and 
fresh complete media was added to each well.  Each day after loading for a total of 5 days 
we performed Promega’s CellTiterglo 2.0 assay to determine cell viability relative to 
untreated controls.  Data is presented as % viability relative to untreated controls. 
COL-Cbl photolysis experiments 
RenCells were plated on 35 mm glass bottom dishes (Mattek) and grown overnight 
in complete media.  The following day, cells were loaded with 10 µM COL-Cbl overnight and 
then subsequently washed to remove excess compound in solution.  Cells were either kept 
in the dark or irradiated with 525 nm LED light for 1 h.  Controls were treated with nothing or 
treated with 10 µM free colchicine (Sigma) for 1 h.  Cells were fixed in 4% PFA/PBS and 
blocked in blocking buffer for 1 h at room temperature.  Cells were stained with primary 
antibody overnight at 4 ºC (Rb anti-alpha tubulin, 1:100, Cell Signaling Technologies) and 
secondary antibody (anti-rabbit Alexa Fluor 488, 1:1000, Molecular Probes) for 1 h at room 
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temperature.  Cells were imaged at 60X on the widefield microscope using the FITC filter 
cube to detect Alexa Fluor 488 fluorescence. 
NanoLuc photolysis experiments 
C17 NSCs expressing Lumifluor (cells were a gift from Dr. Hingtgen) were plated on 
35 mm glass bottom dishes (Mattek) and allowed to grown overnight.  The following day, 
cells were incubated with 10 µM COL-Cbl for 24 h.  The following day, the cells were 
washed to remove excess COL-Cbl in solution and treated with 40 µM furimazine 
(Promega), exposed to 525 nm LED light, or treated with 10 µM colchicine for 1 h.  Cells 
were fixed and imaged for microtubules as described above. 
For short term experiments, cells were plated and allowed to grow overnight.  The following 
day, 10 µM COL-Cbl was added to experimental wells and 40 µM furimazine was 
immediately added to appropriate plates or cells were exposed to 525 nm light.  The cells 
were fixed and stained as described previously. 
Positron mediated photolysis 
Fresh solutions of FDG were acquired by Dr. Matthew Parrot.  A series of dilutions 
were prepared in 600 µl PBS to contain 5800, 1940, 968, 480, 236, 117, 57, 28.6, 14.4, 7.2, 
3.6, or 0 µCi total radiation.  Cy5-Cbl or PTX-Cbl was added to a final concentration of 10 
µM in the dark and tubes were stored in individual lead containers around the lab for 24 hs.  
The tubes were then placed at 4 ºC for 48 hs in order to allow decay of the radioisotope.  
The samples were then run by Dr. Qunzhao Wang or Dr. Song Ding on LC/MS to determine 
the amount of photolysis. 
Initial viral loading with Cy5-alkynyl-Cbl-ODA1 
Supernatants containing hCMV (a gift from Dr. Moorman) were thawed on ice.  A 
final concentration of 10 µM Cy5-alkynyl-Cbl-ODA1 or DiD was added to 1 ml viral 
supernatant or 1 ml DMEM and allowed to incubate at room temperature with rotation for 1 
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h.  5 µl from each sample was placed on a glass slide and covered with a coverslip.  The 
slides were imaged at 60X on the widefield microscope using a Cy5 filter cube for 500 ms. 
Viral loading and delivery to human fibroblasts 
10 ml of hCMV (containing a gene expressing GFP) solution was incubated with 
rotation for 1 h at room temperature with 10 µM Cy5-alkynyl-Cbl-ODA1, DiD, or nothing.  
The viral solutions were then placed in ultracentrifuge tubes.  A 7 ml layer of 20% sorbitol in 
PBS was laid underneath the supernatants. The tubes were balanced, and spun at 20,000 
rpm in a Beckman Coulter SW Ti32 ultracentrifuge rotor for 1.5 h.  The supernatants were 
aspirated and pellets resuspended in 500 µl DMEM.  Human fibroblasts (maintained by 
Heather Valentine, a member of Dr. Moorman’s group) were treated with the entire 500 µl 
viral suspension for 1 h before being thoroughly washed to remove excess virus.  The 
infected cells were incubated overnight at 37 ºC.  The cells were then imaged on the 
widefield microscope at 60X using the FITC and Cy5 filter cubes to image GFP expression 
and transferred Cbl or DiD compounds respectively.   
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